{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Introduction\n",
    "\n",
    "This notedbook loads and processed the source data to make it ready for RAG system. I am experimenting with publicly available \n",
    "- [Patient-level Clinical Drug Trial Data](https://www.kaggle.com/datasets/dillonmyrick/bells-palsy-clinical-trial)\n",
    "- [COVID-19 Clinical Trials dataset](https://www.kaggle.com/datasets/parulpandey/covid19-clinical-trials-dataset)\n",
    "\n",
    "datasets from Kaggle. The two datasets are fundamentally different. The former has more int or bool data fields, while the latter is semi-structured that has fields like trial title and outcome measures. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Data Processing \n",
    "\n",
    "The input data is the [COVID-19 Clinical Trials dataset]('https://www.kaggle.com/datasets/parulpandey/covid19-clinical-trials-dataset') a data set in csv format from Kaggle. Using __pandas__ package, I am loading the data into a data frame and getting some descriptive statistics using the *Describe*. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>NCT Number</th>\n",
       "      <th>Title</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Status</th>\n",
       "      <th>Study Results</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Outcome Measures</th>\n",
       "      <th>Sponsor/Collaborators</th>\n",
       "      <th>...</th>\n",
       "      <th>Other IDs</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Completion Date</th>\n",
       "      <th>First Posted</th>\n",
       "      <th>Results First Posted</th>\n",
       "      <th>Last Update Posted</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Study Documents</th>\n",
       "      <th>URL</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>NCT04785898</td>\n",
       "      <td>Diagnostic Performance of the ID Now™ COVID-19...</td>\n",
       "      <td>COVID-IDNow</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Covid19</td>\n",
       "      <td>Diagnostic Test: ID Now™ COVID-19 Screening Test</td>\n",
       "      <td>Evaluate the diagnostic performance of the ID ...</td>\n",
       "      <td>Groupe Hospitalier Paris Saint Joseph</td>\n",
       "      <td>...</td>\n",
       "      <td>COVID-IDNow</td>\n",
       "      <td>November 9, 2020</td>\n",
       "      <td>December 22, 2020</td>\n",
       "      <td>April 30, 2021</td>\n",
       "      <td>March 8, 2021</td>\n",
       "      <td>NaN</td>\n",
       "      <td>March 8, 2021</td>\n",
       "      <td>Groupe Hospitalier Paris Saint-Joseph, Paris, ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04785898</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>NCT04595136</td>\n",
       "      <td>Study to Evaluate the Efficacy of COVID19-0001...</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>SARS-CoV-2 Infection</td>\n",
       "      <td>Drug: Drug COVID19-0001-USR|Drug: normal saline</td>\n",
       "      <td>Change on viral load results from baseline aft...</td>\n",
       "      <td>United Medical Specialties</td>\n",
       "      <td>...</td>\n",
       "      <td>COVID19-0001-USR</td>\n",
       "      <td>November 2, 2020</td>\n",
       "      <td>December 15, 2020</td>\n",
       "      <td>January 29, 2021</td>\n",
       "      <td>October 20, 2020</td>\n",
       "      <td>NaN</td>\n",
       "      <td>October 20, 2020</td>\n",
       "      <td>Cimedical, Barranquilla, Atlantico, Colombia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04595136</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>NCT04395482</td>\n",
       "      <td>Lung CT Scan Analysis of SARS-CoV2 Induced Lun...</td>\n",
       "      <td>TAC-COVID19</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>covid19</td>\n",
       "      <td>Other: Lung CT scan analysis in COVID-19 patients</td>\n",
       "      <td>A qualitative analysis of parenchymal lung dam...</td>\n",
       "      <td>University of Milano Bicocca</td>\n",
       "      <td>...</td>\n",
       "      <td>TAC-COVID19</td>\n",
       "      <td>May 7, 2020</td>\n",
       "      <td>June 15, 2021</td>\n",
       "      <td>June 15, 2021</td>\n",
       "      <td>May 20, 2020</td>\n",
       "      <td>NaN</td>\n",
       "      <td>November 9, 2020</td>\n",
       "      <td>Ospedale Papa Giovanni XXIII, Bergamo, Italy|P...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04395482</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>NCT04416061</td>\n",
       "      <td>The Role of a Private Hospital in Hong Kong Am...</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>COVID</td>\n",
       "      <td>Diagnostic Test: COVID 19 Diagnostic Test</td>\n",
       "      <td>Proportion of asymptomatic subjects|Proportion...</td>\n",
       "      <td>Hong Kong Sanatorium &amp; Hospital</td>\n",
       "      <td>...</td>\n",
       "      <td>RC-2020-08</td>\n",
       "      <td>May 25, 2020</td>\n",
       "      <td>July 31, 2020</td>\n",
       "      <td>August 31, 2020</td>\n",
       "      <td>June 4, 2020</td>\n",
       "      <td>NaN</td>\n",
       "      <td>June 4, 2020</td>\n",
       "      <td>Hong Kong Sanatorium &amp; Hospital, Hong Kong, Ho...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04416061</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>NCT04395924</td>\n",
       "      <td>Maternal-foetal Transmission of SARS-Cov-2</td>\n",
       "      <td>TMF-COVID-19</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>No Results Available</td>\n",
       "      <td>Maternal Fetal Infection Transmission|COVID-19...</td>\n",
       "      <td>Diagnostic Test: Diagnosis of SARS-Cov2 by RT-...</td>\n",
       "      <td>COVID-19 by positive PCR in cord blood and / o...</td>\n",
       "      <td>Centre Hospitalier Régional d'Orléans|Centre d...</td>\n",
       "      <td>...</td>\n",
       "      <td>CHRO-2020-10</td>\n",
       "      <td>May 5, 2020</td>\n",
       "      <td>May 2021</td>\n",
       "      <td>May 2021</td>\n",
       "      <td>May 20, 2020</td>\n",
       "      <td>NaN</td>\n",
       "      <td>June 4, 2020</td>\n",
       "      <td>CHR Orléans, Orléans, France</td>\n",
       "      <td>NaN</td>\n",
       "      <td>https://ClinicalTrials.gov/show/NCT04395924</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows × 27 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Rank   NCT Number                                              Title  \\\n",
       "0     1  NCT04785898  Diagnostic Performance of the ID Now™ COVID-19...   \n",
       "1     2  NCT04595136  Study to Evaluate the Efficacy of COVID19-0001...   \n",
       "2     3  NCT04395482  Lung CT Scan Analysis of SARS-CoV2 Induced Lun...   \n",
       "3     4  NCT04416061  The Role of a Private Hospital in Hong Kong Am...   \n",
       "4     5  NCT04395924         Maternal-foetal Transmission of SARS-Cov-2   \n",
       "\n",
       "        Acronym                  Status         Study Results  \\\n",
       "0   COVID-IDNow  Active, not recruiting  No Results Available   \n",
       "1      COVID-19      Not yet recruiting  No Results Available   \n",
       "2   TAC-COVID19              Recruiting  No Results Available   \n",
       "3      COVID-19  Active, not recruiting  No Results Available   \n",
       "4  TMF-COVID-19              Recruiting  No Results Available   \n",
       "\n",
       "                                          Conditions  \\\n",
       "0                                            Covid19   \n",
       "1                               SARS-CoV-2 Infection   \n",
       "2                                            covid19   \n",
       "3                                              COVID   \n",
       "4  Maternal Fetal Infection Transmission|COVID-19...   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0   Diagnostic Test: ID Now™ COVID-19 Screening Test   \n",
       "1    Drug: Drug COVID19-0001-USR|Drug: normal saline   \n",
       "2  Other: Lung CT scan analysis in COVID-19 patients   \n",
       "3          Diagnostic Test: COVID 19 Diagnostic Test   \n",
       "4  Diagnostic Test: Diagnosis of SARS-Cov2 by RT-...   \n",
       "\n",
       "                                    Outcome Measures  \\\n",
       "0  Evaluate the diagnostic performance of the ID ...   \n",
       "1  Change on viral load results from baseline aft...   \n",
       "2  A qualitative analysis of parenchymal lung dam...   \n",
       "3  Proportion of asymptomatic subjects|Proportion...   \n",
       "4  COVID-19 by positive PCR in cord blood and / o...   \n",
       "\n",
       "                               Sponsor/Collaborators  ...         Other IDs  \\\n",
       "0              Groupe Hospitalier Paris Saint Joseph  ...       COVID-IDNow   \n",
       "1                         United Medical Specialties  ...  COVID19-0001-USR   \n",
       "2                       University of Milano Bicocca  ...       TAC-COVID19   \n",
       "3                    Hong Kong Sanatorium & Hospital  ...        RC-2020-08   \n",
       "4  Centre Hospitalier Régional d'Orléans|Centre d...  ...      CHRO-2020-10   \n",
       "\n",
       "         Start Date Primary Completion Date   Completion Date  \\\n",
       "0  November 9, 2020       December 22, 2020    April 30, 2021   \n",
       "1  November 2, 2020       December 15, 2020  January 29, 2021   \n",
       "2       May 7, 2020           June 15, 2021     June 15, 2021   \n",
       "3      May 25, 2020           July 31, 2020   August 31, 2020   \n",
       "4       May 5, 2020                May 2021          May 2021   \n",
       "\n",
       "       First Posted Results First Posted Last Update Posted  \\\n",
       "0     March 8, 2021                  NaN      March 8, 2021   \n",
       "1  October 20, 2020                  NaN   October 20, 2020   \n",
       "2      May 20, 2020                  NaN   November 9, 2020   \n",
       "3      June 4, 2020                  NaN       June 4, 2020   \n",
       "4      May 20, 2020                  NaN       June 4, 2020   \n",
       "\n",
       "                                           Locations Study Documents  \\\n",
       "0  Groupe Hospitalier Paris Saint-Joseph, Paris, ...             NaN   \n",
       "1       Cimedical, Barranquilla, Atlantico, Colombia             NaN   \n",
       "2  Ospedale Papa Giovanni XXIII, Bergamo, Italy|P...             NaN   \n",
       "3  Hong Kong Sanatorium & Hospital, Hong Kong, Ho...             NaN   \n",
       "4                       CHR Orléans, Orléans, France             NaN   \n",
       "\n",
       "                                           URL  \n",
       "0  https://ClinicalTrials.gov/show/NCT04785898  \n",
       "1  https://ClinicalTrials.gov/show/NCT04595136  \n",
       "2  https://ClinicalTrials.gov/show/NCT04395482  \n",
       "3  https://ClinicalTrials.gov/show/NCT04416061  \n",
       "4  https://ClinicalTrials.gov/show/NCT04395924  \n",
       "\n",
       "[5 rows x 27 columns]"
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## load the clinical trial data from file to dataframe for analysis\n",
    "df_CT_cancer = pd.read_csv('./data/COVID_clinical_trials.csv')\n",
    "df_CT_cancer.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>Enrollment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>5783.000000</td>\n",
       "      <td>5.749000e+03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>2892.000000</td>\n",
       "      <td>1.831949e+04</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1669.552635</td>\n",
       "      <td>4.045437e+05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>0.000000e+00</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>1446.500000</td>\n",
       "      <td>6.000000e+01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>2892.000000</td>\n",
       "      <td>1.700000e+02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>4337.500000</td>\n",
       "      <td>5.600000e+02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>5783.000000</td>\n",
       "      <td>2.000000e+07</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              Rank    Enrollment\n",
       "count  5783.000000  5.749000e+03\n",
       "mean   2892.000000  1.831949e+04\n",
       "std    1669.552635  4.045437e+05\n",
       "min       1.000000  0.000000e+00\n",
       "25%    1446.500000  6.000000e+01\n",
       "50%    2892.000000  1.700000e+02\n",
       "75%    4337.500000  5.600000e+02\n",
       "max    5783.000000  2.000000e+07"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## Dataset statistics like total acount & data distribution values (mean / std )\n",
    "df_CT_cancer.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Rank</th>\n",
       "      <th>Enrollment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>182.000000</td>\n",
       "      <td>179.00000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>3158.406593</td>\n",
       "      <td>10216.96648</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>1821.715884</td>\n",
       "      <td>82183.01819</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>20.000000</td>\n",
       "      <td>1.00000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>1579.250000</td>\n",
       "      <td>50.00000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>3057.500000</td>\n",
       "      <td>200.00000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>5017.000000</td>\n",
       "      <td>880.00000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>5771.000000</td>\n",
       "      <td>1000000.00000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "              Rank     Enrollment\n",
       "count   182.000000      179.00000\n",
       "mean   3158.406593    10216.96648\n",
       "std    1821.715884    82183.01819\n",
       "min      20.000000        1.00000\n",
       "25%    1579.250000       50.00000\n",
       "50%    3057.500000      200.00000\n",
       "75%    5017.000000      880.00000\n",
       "max    5771.000000  1000000.00000"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# remove empty values \n",
    "df_CT_cancer = df_CT_cancer[df_CT_cancer['Title'].notna()]\n",
    "df_CT_cancer = df_CT_cancer[df_CT_cancer['Study Documents'].notna()]\n",
    "\n",
    "df_CT_cancer.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'Rank': 20,\n",
       "  'NCT Number': 'NCT04407585',\n",
       "  'Title': 'Testing the Accuracy of a Digital Test to Diagnose Covid-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid-19',\n",
       "  'Interventions': 'Diagnostic Test: Covid-19 swab PCR test',\n",
       "  'Outcome Measures': 'SARS-CoV-2 infection',\n",
       "  'Sponsor/Collaborators': \"King's College London|Zoe Global Limited|Department of Health, United Kingdom\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 1000000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'Covid-19 Validation Study',\n",
       "  'Start Date': 'June 1, 2020',\n",
       "  'Primary Completion Date': 'May 10, 2021',\n",
       "  'Completion Date': 'May 10, 2021',\n",
       "  'First Posted': 'May 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 24, 2020',\n",
       "  'Locations': \"King's College London, London, United Kingdom\",\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04407585/SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04407585'},\n",
       " {'Rank': 71,\n",
       "  'NCT Number': 'NCT04674644',\n",
       "  'Title': 'Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19 Pandemic',\n",
       "  'Interventions': 'Behavioral: The psychosocial effects of COVID-19 pandemic on dental professionals',\n",
       "  'Outcome Measures': 'The Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 Scale|The Psychosocial Effects of COVID-19 Pandemic Using the Turkish Version of the Coronavirus Anxiety Scale',\n",
       "  'Sponsor/Collaborators': 'Suleyman Demirel University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '23 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 850.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other',\n",
       "  'Other IDs': '355',\n",
       "  'Start Date': 'October 16, 2020',\n",
       "  'Primary Completion Date': 'October 23, 2020',\n",
       "  'Completion Date': 'October 23, 2020',\n",
       "  'First Posted': 'December 19, 2020',\n",
       "  'Results First Posted': 'January 29, 2021',\n",
       "  'Last Update Posted': 'February 2, 2021',\n",
       "  'Locations': 'Suleyman Demirel University Faculty of Dentistry Pediatric Dentistry Department, Isparta, Turkey',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04674644/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04674644'},\n",
       " {'Rank': 84,\n",
       "  'NCT Number': 'NCT04816318',\n",
       "  'Title': 'Policy Responses Against the COVID-19 Pandemic in Latin America',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Infectious Disease|Death|SARS-CoV Infection',\n",
       "  'Interventions': 'Other: Social and public health measures against COVID-19|Other: Control',\n",
       "  'Outcome Measures': '7-day moving average of daily confirmed cases of COVID-19/SARS-CoV-2|Time-varying reproductive number of confirmed cases of COVID-19/SARS-CoV-2|7-day moving average of daily confirmed deaths of COVID-19/SARS-CoV-2',\n",
       "  'Sponsor/Collaborators': 'University of Chile',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 10000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Ecologic or Community|Time Perspective: Prospective',\n",
       "  'Other IDs': 'ANID-COVID 0960',\n",
       "  'Start Date': 'March 22, 2021',\n",
       "  'Primary Completion Date': 'May 31, 2021',\n",
       "  'Completion Date': 'May 31, 2021',\n",
       "  'First Posted': 'March 25, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 29, 2021',\n",
       "  'Locations': 'Escuela de Salud Pública, Santiago, Región Metropolitana, Chile',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/18/NCT04816318/SAP_000.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/18/NCT04816318/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04816318'},\n",
       " {'Rank': 87,\n",
       "  'NCT Number': 'NCT04474496',\n",
       "  'Title': 'Impact of COVID-19 on Marshallese Communities in the U.S.',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Other: Assessing the impact of COVID-19',\n",
       "  'Outcome Measures': 'Personal Preventative Behaviors to Decrease Risk of COVID-19 Exposure|Workplace Preventative Actions to Decrease Risk of COVID-19 Exposure|Effects of COVID-19 on General Health Status|Effects of COVID-19 on Access to Healthcare Services|Effects of COVID-19 on Dietary Habits|Effects of COVID-19 on Physical Activity Behaviors (Not Specifically for Exercise)|Effects of COVID-19 on Physical Activity Behaviors (Specifically for Exercise)|Effects of COVID-19 on Weight|Effects of COVID-19 on HbA1c (Glycated Hemoglobin)|Barriers to Type 2 Diabetes Management Due to COVID-19|COVID-19 Screening|COVID-19 Testing|COVID-19 Vaccine Willingness/Hesitancy|Trusted Sources of COVID-19 Information|Effects of COVID-19 on Housing|Effects of COVID-19 on Employment|Effects of COVID-19 on Income|Sources of Stress During COVID-19',\n",
       "  'Sponsor/Collaborators': 'University of Arkansas|Patient-Centered Outcomes Research Institute',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 120.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Other|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': '261131',\n",
       "  'Start Date': 'July 27, 2020',\n",
       "  'Primary Completion Date': 'November 30, 2020',\n",
       "  'Completion Date': 'November 30, 2020',\n",
       "  'First Posted': 'July 16, 2020',\n",
       "  'Results First Posted': 'April 5, 2021',\n",
       "  'Last Update Posted': 'April 5, 2021',\n",
       "  'Locations': 'University of Arkansas for Medical Sciences Northwest, Fayetteville, Arkansas, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/96/NCT04474496/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04474496'},\n",
       " {'Rank': 112,\n",
       "  'NCT Number': 'NCT04713163',\n",
       "  'Title': 'COVID-19 Vaccine Induced Immunity',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': 'Drug: covid19 vaccine',\n",
       "  'Outcome Measures': 'Nasal T cell responses|Systemic T cell responses|Systemic and nasal antibody responses',\n",
       "  'Sponsor/Collaborators': 'University of Manitoba|Public Health Agency of Canada (PHAC)|Cadham Provincial Lab',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 200.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'B2021:008',\n",
       "  'Start Date': 'January 2021',\n",
       "  'Primary Completion Date': 'April 2021',\n",
       "  'Completion Date': 'December 2021',\n",
       "  'First Posted': 'January 19, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 19, 2021',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/63/NCT04713163/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04713163'},\n",
       " {'Rank': 114,\n",
       "  'NCT Number': 'NCT04780126',\n",
       "  'Title': 'Sarco-COVID Study: Measuring the Loss of Skeletal Muscle Mass in the Hospitalized Patient With the Diagnosis of COVID-19',\n",
       "  'Acronym': 'SARCO-COVID',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Sarcopenia|Covid19',\n",
       "  'Interventions': 'Other: Sarcopenia diagnosis',\n",
       "  'Outcome Measures': 'Loss of muscle mass|Prevalence of sarcopenia|Normal values of muscle ultrasound thickness|C reactive protein (CRP) correlated to the presence of sarcopenia|Therapy with corticosteroids impact on muscle thickness|Normal values of medial gastrocnemius pennation angle in all patients|Ferritin correlated to the presence of sarcopenia|Fibrinogen correlated to the presence of sarcopenia',\n",
       "  'Sponsor/Collaborators': 'Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 64.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Ecologic or Community|Time Perspective: Prospective',\n",
       "  'Other IDs': '21/090-E_COVID',\n",
       "  'Start Date': 'February 26, 2021',\n",
       "  'Primary Completion Date': 'April 30, 2021',\n",
       "  'Completion Date': 'May 31, 2021',\n",
       "  'First Posted': 'March 3, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 3, 2021',\n",
       "  'Locations': 'Hospital de Emergencias Isabel Zendal, Madrid, Spain',\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04780126/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04780126'},\n",
       " {'Rank': 126,\n",
       "  'NCT Number': 'NCT04410549',\n",
       "  'Title': 'Pulmonary Optical Coherence Tomography in COVID-19 Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Pulmonary Embolism',\n",
       "  'Interventions': 'Diagnostic Test: Optical Coherence Tomography (OCT)',\n",
       "  'Outcome Measures': 'optical coherence tomography pulmonary microthrombosis assessment in COVID-19 pneumonia patients|Pulmonary artery vessel anatomy characterization|Correlation between TTE pulmonary hypertension and right ventricular disfunction|Correlations with standard inflammatory, coagulation and tissue damage',\n",
       "  'Sponsor/Collaborators': 'IRCCS San Raffaele',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 10.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic',\n",
       "  'Other IDs': 'OCT COVID',\n",
       "  'Start Date': 'June 1, 2020',\n",
       "  'Primary Completion Date': 'December 31, 2021',\n",
       "  'Completion Date': 'December 31, 2021',\n",
       "  'First Posted': 'June 1, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 25, 2021',\n",
       "  'Locations': 'Incor - Heart Institute - University of Sao Paulo, São Paulo, Brazil|IRCCS San Raffaele, Milano, Italy',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04410549/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04410549'},\n",
       " {'Rank': 251,\n",
       "  'NCT Number': 'NCT04341441',\n",
       "  'Title': 'Will Hydroxychloroquine Impede or Prevent COVID-19',\n",
       "  'Acronym': 'WHIP COVID-19',\n",
       "  'Status': 'Terminated',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment',\n",
       "  'Outcome Measures': 'To determine if the use of hydroxychloroquine as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in Study Participants for each randomized treatment arm as compared to placebo.|Determine the effect of hydroxychloroquine dose in the prevention of COVID-19 viremia and disease.|Assess the impact of chronic weight-based dosing of HCQ for COVID-19 prevention.|Comparison of the rate of SARS-CoV 2 infections as measured by IgM/IgG seroconversion in study participants receiving randomized HCQ versus placebo.|Compare the seroprevalence of SARS-CoV 2 IgM/IgG positive samples at study entry and study conclusion in all participants receiving HCQ compared to those receiving placebo.|Comparison of the emergence of clinical symptoms or COVID-19 diagnosis in participants presenting asymptomatically at study entry but identified as seropositive by serology at entry between the randomized treatment arms and comparator arm.|To examine the level of care needed by participants in each arm developing COVID19 as measured as requiring emergency room visit, hospitalization or able to stay home without hospital care.|Determine the safety and tolerability of HCQ dosing for preventive strategy against COVID-19 as measured by adverse events and serious adverse events.|To examine other clinical determinants contributing to the risk of SARS-CoV 2 infection in healthcare workers and first responders.|Examine the association between HCQ drug levels and development of COVID-19 symptoms or positive test results.|identify immunologic, serological and inflammatory markers associated with acquisition and response to COVID-19 in both HCQ and placebo Participants developing laboratory or clinical confirmed disease.',\n",
       "  'Sponsor/Collaborators': 'Henry Ford Health System',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 75 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 624.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '1410401',\n",
       "  'Start Date': 'April 7, 2020',\n",
       "  'Primary Completion Date': 'December 15, 2020',\n",
       "  'Completion Date': 'December 15, 2020',\n",
       "  'First Posted': 'April 10, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 21, 2020',\n",
       "  'Locations': 'Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04341441'},\n",
       " {'Rank': 281,\n",
       "  'NCT Number': 'NCT04468256',\n",
       "  'Title': 'The Heart Hive COVID-19 Study',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19|Cardiomyopathies',\n",
       "  'Interventions': 'Other: COVID-19 experience surveys',\n",
       "  'Outcome Measures': 'Qualitative measures of exposure, perception of risk, behaviour, and experience during the COVID-19 pandemic.|Health Outcomes',\n",
       "  'Sponsor/Collaborators': 'Imperial College London',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 1000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Control|Time Perspective: Prospective',\n",
       "  'Other IDs': '20IC6036',\n",
       "  'Start Date': 'July 26, 2020',\n",
       "  'Primary Completion Date': 'July 2022',\n",
       "  'Completion Date': 'July 2022',\n",
       "  'First Posted': 'July 13, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'September 2, 2020',\n",
       "  'Locations': 'Imperial College London, London, United Kingdom',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04468256/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04468256'},\n",
       " {'Rank': 284,\n",
       "  'NCT Number': 'NCT04382781',\n",
       "  'Title': 'Immunosupressive Treatment in COVID-19 Patients',\n",
       "  'Acronym': 'SAM-COVID',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19 Infection',\n",
       "  'Interventions': 'Drug: NO-Immunosuppressive|Drug: Immunosuppressive|Drug: Immunoglubulins',\n",
       "  'Outcome Measures': 'Invasive ventilation or death|Ventilation|Death|Secondary infections|Digestive tract hemorrhage|Change in 7 points scale',\n",
       "  'Sponsor/Collaborators': 'Spanish Network for Research in Infectious Diseases|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 500.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Retrospective',\n",
       "  'Other IDs': 'FIS-INM-2020-03',\n",
       "  'Start Date': 'May 2020',\n",
       "  'Primary Completion Date': 'May 2020',\n",
       "  'Completion Date': 'May 2020',\n",
       "  'First Posted': 'May 11, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'May 12, 2020',\n",
       "  'Locations': 'Hospital Virgen Macarena, Sevilla, Spain',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04382781/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04382781'},\n",
       " {'Rank': 452,\n",
       "  'NCT Number': 'NCT04568356',\n",
       "  'Title': 'A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'SARS CoV-2',\n",
       "  'Interventions': 'Diagnostic Test: Direct Antigen Tests for COVID-19',\n",
       "  'Outcome Measures': 'Percent Positive Agreement and Negative Percent Agreement',\n",
       "  'Sponsor/Collaborators': 'E25Bio, Inc.|SCRI Development Innovations, LLC',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 200.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic',\n",
       "  'Other IDs': 'E25001_NEU2012',\n",
       "  'Start Date': 'April 24, 2020',\n",
       "  'Primary Completion Date': 'June 12, 2020',\n",
       "  'Completion Date': 'September 24, 2020',\n",
       "  'First Posted': 'September 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 19, 2020',\n",
       "  'Locations': 'JFK Medical Center, Miami, Florida, United States|Kendall Regional, Miami, Florida, United States|Aventura Hospital and Medical Center, Miami, Florida, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04568356/ICF_000.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/56/NCT04568356/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04568356'},\n",
       " {'Rank': 462,\n",
       "  'NCT Number': 'NCT04321811',\n",
       "  'Title': 'Behavior, Environment And Treatments for Covid-19',\n",
       "  'Acronym': 'BEAT19',\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus',\n",
       "  'Interventions': 'Other: Observation of patients with known, suspected, or at risk for COVID-19 infection',\n",
       "  'Outcome Measures': 'Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery',\n",
       "  'Sponsor/Collaborators': 'xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 100000.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'XC-PCOR-COVID19',\n",
       "  'Start Date': 'March 21, 2020',\n",
       "  'Primary Completion Date': 'February 9, 2021',\n",
       "  'Completion Date': 'March 20, 2022',\n",
       "  'First Posted': 'March 25, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 10, 2021',\n",
       "  'Locations': 'BEAT19.org, San Francisco, California, United States',\n",
       "  'Study Documents': '\"Study Protocol and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04321811'},\n",
       " {'Rank': 491,\n",
       "  'NCT Number': 'NCT04386239',\n",
       "  'Title': 'Study on the Use of Sarilumab in Patients With COVID-19 Infection',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID19',\n",
       "  'Interventions': 'Drug: Sarilumab Prefilled Syringe',\n",
       "  'Outcome Measures': 'Proportion of patients who show an improvement of the respiratory function|Evaluation of the time to resolution of fever|Evaluation of the viral load on blood and sputum for COVID-19|Evaluation of the plasma concentration of GM-CSF|Evaluation of the plasma concentration of Il-6|Evaluation of the plasma concentration of TNF-α|Evaluation of the rate of progression of White Blood Cell (WBC) fraction',\n",
       "  'Sponsor/Collaborators': 'ASST Fatebenefratelli Sacco',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 84 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Early Phase 1',\n",
       "  'Enrollment': 40.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'COVID-SARI-001',\n",
       "  'Start Date': 'January 2021',\n",
       "  'Primary Completion Date': 'January 2021',\n",
       "  'Completion Date': 'December 2021',\n",
       "  'First Posted': 'May 13, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 20, 2021',\n",
       "  'Locations': 'Divisione Clinicizzata di Malattie Infettive, ASST FBF-Sacco, Milano, MI, Italy',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04386239/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04386239'},\n",
       " {'Rank': 589,\n",
       "  'NCT Number': 'NCT04420988',\n",
       "  'Title': 'Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Available',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19|SARS-CoV 2|SARS-CoV Infection',\n",
       "  'Interventions': 'Biological: COVID-19 Convalescent Plasma',\n",
       "  'Outcome Measures': nan,\n",
       "  'Sponsor/Collaborators': 'Rutgers, The State University of New Jersey|University Hospital - Newark, NJ',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': nan,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Expanded Access:Individual Patients|Intermediate-size Population',\n",
       "  'Study Designs': nan,\n",
       "  'Other IDs': 'Pro2020000746, Pro2020000911',\n",
       "  'Start Date': nan,\n",
       "  'Primary Completion Date': nan,\n",
       "  'Completion Date': nan,\n",
       "  'First Posted': 'June 9, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 9, 2020',\n",
       "  'Locations': 'Rutgers New Jersey Medical School, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04420988/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04420988'},\n",
       " {'Rank': 615,\n",
       "  'NCT Number': 'NCT04659941',\n",
       "  'Title': 'Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers',\n",
       "  'Acronym': 'ProBCG',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID 19 Vaccine',\n",
       "  'Interventions': 'Biological: BCG vaccine',\n",
       "  'Outcome Measures': 'Compare the cumulative incidence of SARS-CoV-2 infection|Compare the cumulative incidence of severe forms of COVID-19|Assess the BCG vaccine-mediated immune response in health care workers',\n",
       "  'Sponsor/Collaborators': 'Universidade Federal do Rio de Janeiro|Ministry of Science and Technology, Brazil',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 1000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '31942220.8.1001.5257',\n",
       "  'Start Date': 'October 1, 2020',\n",
       "  'Primary Completion Date': 'October 1, 2021',\n",
       "  'Completion Date': 'October 1, 2022',\n",
       "  'First Posted': 'December 9, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 9, 2020',\n",
       "  'Locations': 'Universidade Federal do Rio de Janeiro, Rio De Janeiro, RJ, Brazil',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04659941/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04659941'},\n",
       " {'Rank': 627,\n",
       "  'NCT Number': 'NCT04343261',\n",
       "  'Title': 'Convalescent Plasma in the Treatment of COVID 19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|COVID|Coronavirus',\n",
       "  'Interventions': 'Biological: Convalescent Plasma',\n",
       "  'Outcome Measures': 'Mortality|Viral Load|Serum Antibody Titers',\n",
       "  'Sponsor/Collaborators': 'Saint Francis Care',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 90 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 48.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'SFH-20-23',\n",
       "  'Start Date': 'April 10, 2020',\n",
       "  'Primary Completion Date': 'July 23, 2020',\n",
       "  'Completion Date': 'August 13, 2020',\n",
       "  'First Posted': 'April 13, 2020',\n",
       "  'Results First Posted': 'September 17, 2020',\n",
       "  'Last Update Posted': 'September 24, 2020',\n",
       "  'Locations': 'Trinity Health Of New England, Hartford, Connecticut, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/Prot_SAP_000.pdf|\"Informed Consent Form: Donor Consent\", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/ICF_001.pdf|\"Informed Consent Form: Patient Consent\", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04343261/ICF_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04343261'},\n",
       " {'Rank': 638,\n",
       "  'NCT Number': 'NCT04568421',\n",
       "  'Title': 'Argentinian Registry of Patients With Rheumatic Diseases and COVID-19 Infection',\n",
       "  'Acronym': 'SAR-COVID',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Rheumatic Diseases',\n",
       "  'Interventions': 'Drug: Immunosuppressive Agents',\n",
       "  'Outcome Measures': 'Mortality|Hospitalization|SARS-CoV-2 infection presentation|Admission at the intensive care unit|Invasive mechanical ventilation|COVID-19 Complications|Recovery rate',\n",
       "  'Sponsor/Collaborators': 'Sociedad Argentina de Reumatologia',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 100 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 3000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '01',\n",
       "  'Start Date': 'August 18, 2020',\n",
       "  'Primary Completion Date': 'December 31, 2021',\n",
       "  'Completion Date': 'December 31, 2021',\n",
       "  'First Posted': 'September 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'September 29, 2020',\n",
       "  'Locations': 'Sociedad Argentina de Reumatología, Ciudad Autónoma de Buenos Aires, Caba, Argentina',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/21/NCT04568421/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04568421'},\n",
       " {'Rank': 668,\n",
       "  'NCT Number': 'NCT04491240',\n",
       "  'Title': 'Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.',\n",
       "  'Acronym': 'COVID-19EXO',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Covid19|SARS-CoV-2 PNEUMONIA|COVID-19',\n",
       "  'Interventions': 'Drug: EXO 1 inhalation|Drug: EXO 2 inhalation|Drug: Placebo inhalation',\n",
       "  'Outcome Measures': 'Number of Participants With Non-serious and Serious Adverse Events During Trial|Number of Participants With Non-serious and Serious Adverse During Inhalation Procedure|Time to Clinical Recovery (TTCR)|SpO2 Concentration|C-reactive Protein|Lactic Acid Dehydrogenase (LDH)',\n",
       "  'Sponsor/Collaborators': 'State-Financed Health Facility \"Samara Regional Medical Center Dinasty\"|Clinics of the Federal State Budgetary Educational Institution SSMU|Samara Regional Clinical Hospital V.D. Seredavin',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 65 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 1|Phase 2',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other',\n",
       "  'Other IDs': 'COVID-19 EXO',\n",
       "  'Start Date': 'July 20, 2020',\n",
       "  'Primary Completion Date': 'October 1, 2020',\n",
       "  'Completion Date': 'October 20, 2020',\n",
       "  'First Posted': 'July 29, 2020',\n",
       "  'Results First Posted': 'November 4, 2020',\n",
       "  'Last Update Posted': 'November 4, 2020',\n",
       "  'Locations': 'Medical Centre Dinasty, Samara, Russian Federation',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/40/NCT04491240/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04491240'},\n",
       " {'Rank': 687,\n",
       "  'NCT Number': 'NCT04542044',\n",
       "  'Title': 'Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia',\n",
       "  'Acronym': 'PneumoCoV-Ambu',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Pneumonia',\n",
       "  'Interventions': 'Other: management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia',\n",
       "  'Outcome Measures': 'Secondary hospitalization(s) or death COVID-19 related|severity of COVID-19 disease|patient satisfaction with management strategies|Saved costs',\n",
       "  'Sponsor/Collaborators': 'University Hospital, Geneva',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 99 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 40.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'CCER2020-01518',\n",
       "  'Start Date': 'April 2, 2020',\n",
       "  'Primary Completion Date': 'May 5, 2020',\n",
       "  'Completion Date': 'June 30, 2020',\n",
       "  'First Posted': 'September 9, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'September 9, 2020',\n",
       "  'Locations': 'Geneva University Hospital, Geneva, Switzerland',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04542044/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04542044'},\n",
       " {'Rank': 694,\n",
       "  'NCT Number': 'NCT04824365',\n",
       "  'Title': 'Sodium Pyruvate Nasal Spray Treatment of COVID-19 and Influenza Infections',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Influenza',\n",
       "  'Interventions': 'Drug: Sodium Pyruvate|Other: Saline',\n",
       "  'Outcome Measures': 'Evaluate the ability of inhaled nasal sodium pyruvate to change COVID-19 or influenza viral titers.|Evaluate the ability of inhaled nasal sodium pyruvate to change the symptoms of COVID-19 or influenza.',\n",
       "  'Sponsor/Collaborators': 'Cellular Sciences, inc.|Missouri State University|Dynamic DNA Labs|Trinity Health Care',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 40 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Phase 2|Phase 3',\n",
       "  'Enrollment': 60.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'CSI-COVID-19_007',\n",
       "  'Start Date': 'April 3, 2021',\n",
       "  'Primary Completion Date': 'May 2022',\n",
       "  'Completion Date': 'June 2022',\n",
       "  'First Posted': 'April 1, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 8, 2021',\n",
       "  'Locations': 'Missouri State University, Springfield, Missouri, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/65/NCT04824365/Prot_SAP_001.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/65/NCT04824365/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04824365'},\n",
       " {'Rank': 761,\n",
       "  'NCT Number': 'NCT04323514',\n",
       "  'Title': 'Use of Ascorbic Acid in Patients With COVID 19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Hospitalized Patients With Covid-19 Pneumonia',\n",
       "  'Interventions': 'Dietary Supplement: Vitamin C',\n",
       "  'Outcome Measures': 'In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging',\n",
       "  'Sponsor/Collaborators': 'University of Palermo',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 500.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '3143',\n",
       "  'Start Date': 'March 13, 2020',\n",
       "  'Primary Completion Date': 'March 13, 2021',\n",
       "  'Completion Date': 'March 13, 2021',\n",
       "  'First Posted': 'March 26, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 26, 2020',\n",
       "  'Locations': 'A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy',\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04323514'},\n",
       " {'Rank': 763,\n",
       "  'NCT Number': 'NCT04501822',\n",
       "  'Title': 'One-year Cardiac Follow-up of Patients With COVID-19 Pneumonia',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Cardiac Complication',\n",
       "  'Interventions': 'Diagnostic Test: Evaluation of clinical, instrumental and laboratory diagnostics tests',\n",
       "  'Outcome Measures': 'Echocardiographic assessment of cardiac function|МАССЕ|Quantitative analysis of parenchymal lung damage|Functional exercises capacity assessment|Evaluation of renal function|Evaluation of inflammation|Evaluation of coagulation abnormality|Evaluation of quality of life in first year after discharge',\n",
       "  'Sponsor/Collaborators': 'Tomsk National Research Medical Center of the Russian Academy of Sciences',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 380.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'TCRC-COVID',\n",
       "  'Start Date': 'July 19, 2020',\n",
       "  'Primary Completion Date': 'July 19, 2021',\n",
       "  'Completion Date': 'December 31, 2021',\n",
       "  'First Posted': 'August 6, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 6, 2020',\n",
       "  'Locations': 'Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science, Tyumen, Russian Federation',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04501822/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04501822'},\n",
       " {'Rank': 765,\n",
       "  'NCT Number': 'NCT04716426',\n",
       "  'Title': 'APT™ T3X on the COVID-19 Contamination Rate',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Tetracycline hydrochloride 3%|Drug: Placebo',\n",
       "  'Outcome Measures': 'COVID-19 Contamination Rate.|Number of Participants With Adverse Events|Average Number of Adverse Events|Days Over Which an Adverse Event Was Reported|Other Virus or Bacteria Contamination Rate.',\n",
       "  'Sponsor/Collaborators': 'University of Nove de Julho|Santa Casa de Misericórdia de Porto Alegre',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 100.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '4.485.847',\n",
       "  'Start Date': 'January 28, 2021',\n",
       "  'Primary Completion Date': 'March 25, 2021',\n",
       "  'Completion Date': 'March 25, 2021',\n",
       "  'First Posted': 'January 20, 2021',\n",
       "  'Results First Posted': 'April 8, 2021',\n",
       "  'Last Update Posted': 'April 8, 2021',\n",
       "  'Locations': 'Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04716426/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04716426'},\n",
       " {'Rank': 766,\n",
       "  'NCT Number': 'NCT04491994',\n",
       "  'Title': 'Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression',\n",
       "  'Acronym': 'COVID-19',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Covid19|Progression',\n",
       "  'Interventions': 'Drug: HCQ',\n",
       "  'Outcome Measures': 'Number of Participants With Progression|Viral Clearance',\n",
       "  'Sponsor/Collaborators': 'UNICEF|Pak Emirates Military Hospital Rawalpindi, Pakistan',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 80 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 540.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'Sultan Mehmood Kamran 2',\n",
       "  'Start Date': 'April 10, 2020',\n",
       "  'Primary Completion Date': 'May 31, 2020',\n",
       "  'Completion Date': 'May 31, 2020',\n",
       "  'First Posted': 'July 30, 2020',\n",
       "  'Results First Posted': 'August 21, 2020',\n",
       "  'Last Update Posted': 'August 21, 2020',\n",
       "  'Locations': 'Pak Emirates Military Hospital, Rawalpindi, Punjab, Pakistan',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04491994/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04491994'},\n",
       " {'Rank': 784,\n",
       "  'NCT Number': 'NCT04521309',\n",
       "  'Title': 'SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Biological: SARS-CoV-2 antibody based IVIG therapy',\n",
       "  'Outcome Measures': '28 Days mortality|Requirement of supplemental oxygen support|Number of days on assisted ventilation|Days to step down|Days to Hospital Discharge|Adverse events during hospital stay|Change in C-Reactive Protein (CRP) levels|Change in neutrophil lymphocyte ratio|Change in Ferritin levels|Change in lactate dehydrogenase (LDH) levels|Change in radiological (X-ray) findings|Days to negative SARS-CoV-2 Polymerase Chain Reaction (PCR) test|Anti-SARS-CoV-2 Antibody|Change in fever|Change in Sodium levels|Change in Potassium levels|Change in Chloride levels|Change in Bicarbonate levels',\n",
       "  'Sponsor/Collaborators': 'Dow University of Health Sciences|Higher Education Commission (Pakistan)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 1|Phase 2',\n",
       "  'Enrollment': 50.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'biotech001',\n",
       "  'Start Date': 'June 19, 2020',\n",
       "  'Primary Completion Date': 'January 26, 2021',\n",
       "  'Completion Date': 'February 8, 2021',\n",
       "  'First Posted': 'August 20, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 24, 2021',\n",
       "  'Locations': 'Dow University of Health Sciences, Karachi, Sindh, Pakistan',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04521309/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04521309'},\n",
       " {'Rank': 802,\n",
       "  'NCT Number': 'NCT04427098',\n",
       "  'Title': 'Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients',\n",
       "  'Acronym': 'INHIXACOV19',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution|Drug: Enoxaparin',\n",
       "  'Outcome Measures': 'To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.|To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19.|To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19.',\n",
       "  'Sponsor/Collaborators': 'IRCCS Azienda Ospedaliero-Universitaria di Bologna',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 90 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 300.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '2020-001308-40',\n",
       "  'Start Date': 'May 22, 2020',\n",
       "  'Primary Completion Date': 'October 30, 2020',\n",
       "  'Completion Date': 'October 30, 2020',\n",
       "  'First Posted': 'June 11, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 17, 2020',\n",
       "  'Locations': 'Policlinico S. Orsola Malpighi Dipartimento Malattie Infettive, Bologna, Emilia Romagna, Italy|Azienda Ospedaliero-Universitaria di Parma Anestesia e Rianimazione Dipartimento di Medicina e Chirurgia, Parma, Emilia Romagna, Italy|I.R.C.C.S. \"Casa Sollievo della Sofferenza\", San Giovanni Rotondo (FG) UOVD Emostasi e trombosi- Poliambulatorio Giovanni Paolo II Viale Padre Pio n.7 San Giovanni Rotondo (FG), San Giovanni Rotondo, Foggia, Italy|Fondazione Poliambulanza Chirurgia Vascolare, Brescia, Italy|Piazzale Spedali Civili, 1, 25123 Brescia BS Medicina Interna UniBS 2° Medicina ASST Spedali Civili, Brescia, Italy|Azienda Ospedaliero-Universitaria \"Policlinico - V. Emanuele\", Catania Anestesia e Rianimazione UO Malattie Infettive, Catania, Italy|ASST Cremona Unità Operativa di Chirurgia Vascolare Dipartimento di Medicina di Laboratorio e di Radiologia- Centro Emostasi e Trombosi, Cremona, Italy|Ospedale Morgagni Pierantoni U.O.C. Malattie Infettive, Forlì, Italy|Ospedale Carlo Poma di Mantova MALATTIE INFETTIVE Padiglione 37 Str. Lago Paiolo, 10, 46100 Mantova, Mantova, Italy|AZIENDA OSPEDALIERA Regionale S CARLO POTENZA Struttura Complessa Interaziendale \"Malattie Infettive\", Matera, Italy|Ospedale San Raffaele Unità Funzionale dell\\'Unità Operativa di Malattie Infettive Osp. San Raffaele, Milano, Italy|Ospedale Amedeo di Savoia Torino Università di Torino Malattie Infettive, Torino, Italy|Azienda Ospedaliera Universitaria Integrata Verona UOC Malattie Infettive e Tropicali, Verona, Italy',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04427098/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04427098'},\n",
       " {'Rank': 837,\n",
       "  'NCT Number': 'NCT04523831',\n",
       "  'Title': 'Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': 'Drug: Ivermectin and Doxycycline|Drug: Standard of care',\n",
       "  'Outcome Measures': 'Number of Patients With Early Clinical Improvement|Number of Participants With Late Clinical Recovery|Number of Patients Having Clinical Deterioration.|Number of Patients Remain Persistently Positive for RT-PCR of Covid-19',\n",
       "  'Sponsor/Collaborators': 'Dhaka Medical College',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 400.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'ERC-DMC/ECC/2020/117',\n",
       "  'Start Date': 'June 1, 2020',\n",
       "  'Primary Completion Date': 'August 22, 2020',\n",
       "  'Completion Date': 'September 10, 2020',\n",
       "  'First Posted': 'August 24, 2020',\n",
       "  'Results First Posted': 'October 9, 2020',\n",
       "  'Last Update Posted': 'October 9, 2020',\n",
       "  'Locations': 'Dhaka Medical College, Dhaka, Bangladesh',\n",
       "  'Study Documents': '\"Study Protocol and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04523831/Prot_ICF_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04523831/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04523831'},\n",
       " {'Rank': 930,\n",
       "  'NCT Number': 'NCT04783025',\n",
       "  'Title': 'A Blended Gaming COVID-19 Training System (BGCTS) With WHO Guidelines for Staff in Residential Care Homes',\n",
       "  'Acronym': 'BGCTS',\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Infection Control|COVID-19',\n",
       "  'Interventions': 'Behavioral: Blended Gaming COVID-19 Training System (BGCTS)|Behavioral: Usual care, infection control briefing',\n",
       "  'Outcome Measures': 'Changes in unobtrusive observational-based compliance rate of infection control practices|Knowledge and attitudes towards respiratory infection (KARI)|Self-reported Infection Control Practice (SICP)|Demographic data|Data on experience',\n",
       "  'Sponsor/Collaborators': 'The Hong Kong Polytechnic University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 65 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 188.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research',\n",
       "  'Other IDs': 'HSEARS20200903007',\n",
       "  'Start Date': 'March 1, 2021',\n",
       "  'Primary Completion Date': 'December 31, 2021',\n",
       "  'Completion Date': 'March 1, 2022',\n",
       "  'First Posted': 'March 4, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 4, 2021',\n",
       "  'Locations': 'The Hong Kong Polytechnic University, Hong Kong, Hong Kong',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/25/NCT04783025/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04783025'},\n",
       " {'Rank': 1017,\n",
       "  'NCT Number': 'NCT04367207',\n",
       "  'Title': 'African Covid-19 Critical Care Outcomes Study',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Severe Acute Respiratory Syndrome Coronavirus 2',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'In-hospital mortality|Risk factors (resources, comorbidities and interventions) associated with mortality',\n",
       "  'Sponsor/Collaborators': 'University of Cape Town|University of KwaZulu',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 2000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'ACCCOS',\n",
       "  'Start Date': 'May 1, 2020',\n",
       "  'Primary Completion Date': 'December 1, 2020',\n",
       "  'Completion Date': 'December 31, 2020',\n",
       "  'First Posted': 'April 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'September 10, 2020',\n",
       "  'Locations': 'Groote Schuur Hospital, Cape Town, Western Cape, South Africa',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04367207/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04367207'},\n",
       " {'Rank': 1085,\n",
       "  'NCT Number': 'NCT04456413',\n",
       "  'Title': 'Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Biological: Convalescent Plasma|Other: Best Supportive Care',\n",
       "  'Outcome Measures': \"Hospitalization Rate|Time to symptoms resolution|Overall survival|Rate of virologic clearance by nasopharyngeal swab at 2 and 4 weeks|Rate of nasopharyngeal swab positivity in donors|Rate of donor titers level|Impact of donor titers level on efficacy|Patients' anti-SARS-CoV2 titer assessment pre-infusion for the Treatment group, at 2 weeks , 4 weeks and 2 months.\",\n",
       "  'Sponsor/Collaborators': 'Hackensack Meridian Health|United States Department of Defense',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 306.0,\n",
       "  'Funded Bys': 'Other|U.S. Fed',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'Pro2020-0542',\n",
       "  'Start Date': 'November 6, 2020',\n",
       "  'Primary Completion Date': 'November 2021',\n",
       "  'Completion Date': 'November 2021',\n",
       "  'First Posted': 'July 2, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 1, 2021',\n",
       "  'Locations': 'Hackensack University Medical Center, Hackensack, New Jersey, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04456413/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04456413'},\n",
       " {'Rank': 1144,\n",
       "  'NCT Number': 'NCT04377464',\n",
       "  'Title': 'COVID-19 - Quality of Life After Infection',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19|Quality of Life',\n",
       "  'Interventions': 'Other: SF12, EQ-5D-5L and work status standardized quantitative assessments',\n",
       "  'Outcome Measures': 'Six-month SF-12v2(HK) Scores|Six-month EQ-5D-5L Scores|One-month SF-12v2(HK)|One-month EQ-5D-5L Scores|Three-month SF-12v2(HK) Scores|Three-month EQ-5D-5L Scores|One, Three and Six-month Return to Work Status',\n",
       "  'Sponsor/Collaborators': 'Chinese University of Hong Kong',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 200.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'NTEC-2020-0227',\n",
       "  'Start Date': 'May 5, 2020',\n",
       "  'Primary Completion Date': 'April 30, 2021',\n",
       "  'Completion Date': 'April 30, 2022',\n",
       "  'First Posted': 'May 6, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'May 6, 2020',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/ICF_000.pdf|\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04377464/Prot_SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04377464'},\n",
       " {'Rank': 1170,\n",
       "  'NCT Number': 'NCT04354519',\n",
       "  'Title': 'The United Kingdom Multiple Sclerosis Register Covid-19 Substudy',\n",
       "  'Acronym': 'UKMSRCV19',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Multiple Sclerosis|COVID-19',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Incidence of COVID-19 Infections within an MS Cohort in the UK|Hospitalisations in MS Patients with COVID-19|Mortality|Patient Reported Expanded Disability Status Score|Hospital Anxiety and Depression Scale|Multiple Sclerosis Impact Scale 29 V2|Multiple Sclerosis Walking Scale 12 V2|Fatigue Severity Scale|EuroQol 5D (3l)',\n",
       "  'Sponsor/Collaborators': 'Swansea University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 3000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '16SW0194',\n",
       "  'Start Date': 'March 14, 2020',\n",
       "  'Primary Completion Date': 'July 14, 2021',\n",
       "  'Completion Date': 'July 14, 2022',\n",
       "  'First Posted': 'April 21, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 22, 2020',\n",
       "  'Locations': 'Swansea Univeristy, Swansea, United Kingdom',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04354519/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04354519'},\n",
       " {'Rank': 1187,\n",
       "  'NCT Number': 'NCT04665193',\n",
       "  'Title': 'An Approach to Screening for COVID-19 at Vancouver Airport',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Asymptomatic Condition|Healthy',\n",
       "  'Interventions': 'Diagnostic Test: Rapid Antigen Test',\n",
       "  'Outcome Measures': 'COVID-19 status',\n",
       "  'Sponsor/Collaborators': 'University of British Columbia|Vancouver Airport Authority|WestJet Airlines|Providence Health & Services',\n",
       "  'Gender': 'All',\n",
       "  'Age': '19 Years to 80 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 900.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening',\n",
       "  'Other IDs': 'H20-03225',\n",
       "  'Start Date': 'November 23, 2020',\n",
       "  'Primary Completion Date': 'April 30, 2021',\n",
       "  'Completion Date': 'April 30, 2021',\n",
       "  'First Posted': 'December 11, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 11, 2020',\n",
       "  'Locations': 'Vancouver International Airport, WestJet Domestic Terminal, Level 3, Richmond, British Columbia, Canada',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04665193/Prot_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04665193/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04665193'},\n",
       " {'Rank': 1268,\n",
       "  'NCT Number': 'NCT04542213',\n",
       "  'Title': 'Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19',\n",
       "  'Acronym': 'Covid19DPP4i',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Hyperglycemia|Covid19',\n",
       "  'Interventions': 'Drug: Linagliptin tablet|Drug: Insulin',\n",
       "  'Outcome Measures': 'Glucose levels|Number of patients who achieve metabolic control|Number of patients who die or need mechanical ventilation|C reactive protein levels',\n",
       "  'Sponsor/Collaborators': 'Hospital Regional de Alta Especialidad del Bajio',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 75 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 70.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'CEI-22-2020',\n",
       "  'Start Date': 'August 1, 2020',\n",
       "  'Primary Completion Date': 'February 28, 2021',\n",
       "  'Completion Date': 'February 28, 2021',\n",
       "  'First Posted': 'September 9, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 23, 2021',\n",
       "  'Locations': 'Hospital Regional de Alta Especialidad del Bajìo, Leòn, Guanajuato, Mexico',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04542213/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04542213'},\n",
       " {'Rank': 1270,\n",
       "  'NCT Number': 'NCT04780594',\n",
       "  'Title': 'Impact of the COVID-19 Pandemic on the Surgical Activity of Bellvitge University Hospital',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Surgery--Complications|Nosocomial Infection',\n",
       "  'Interventions': 'Procedure: The study evaluates all surgical patients operated, both elective scheduled and emergent cases',\n",
       "  'Outcome Measures': 'Register the post-surgical complications|Register the rate of surgical reintervention|Register the ICU admission|Register the Hospital stay|Register the Mortality',\n",
       "  'Sponsor/Collaborators': 'Hospital Universitari de Bellvitge',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 2530.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Crossover|Time Perspective: Retrospective',\n",
       "  'Other IDs': 'COVID19 surgical impact',\n",
       "  'Start Date': 'February 13, 2020',\n",
       "  'Primary Completion Date': 'May 15, 2020',\n",
       "  'Completion Date': 'December 9, 2020',\n",
       "  'First Posted': 'March 3, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 3, 2021',\n",
       "  'Locations': 'Marta Caballero, Hospitalet de Llobregat, Barcelona, Spain',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04780594/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04780594'},\n",
       " {'Rank': 1280,\n",
       "  'NCT Number': 'NCT04630054',\n",
       "  'Title': 'Face Masks to Reduce COVID-19 in Bangladesh',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': 'Device: Face mask|Behavioral: Face mask awareness',\n",
       "  'Outcome Measures': 'Symptomatic SARS-CoV2 infection|SARS-CoV2 infection|Observed prevalence of proper mask wearing|Respiratory infection prevalence',\n",
       "  'Sponsor/Collaborators': 'Yale University|Stanford University|Innovations for Poverty Action|North South University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 450000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '2000028482',\n",
       "  'Start Date': 'November 15, 2020',\n",
       "  'Primary Completion Date': 'February 15, 2021',\n",
       "  'Completion Date': 'February 15, 2021',\n",
       "  'First Posted': 'November 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 22, 2021',\n",
       "  'Locations': 'Innovations for Poverty Action, Dhaka, Bangladesh',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04630054/SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04630054'},\n",
       " {'Rank': 1307,\n",
       "  'NCT Number': 'NCT04384380',\n",
       "  'Title': 'Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus Infection',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]',\n",
       "  'Outcome Measures': 'Time to negatively RT-PCR|Virologic assessment|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0',\n",
       "  'Sponsor/Collaborators': 'Taoyuan General Hospital|Center for Drug Evaluation, Taiwan|Centers for Disease Control, Taiwan|Taiwan Food and Drug Administration|National Health Research Institutes, Taiwan',\n",
       "  'Gender': 'All',\n",
       "  'Age': '20 Years to 79 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 33.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'TYGH109014',\n",
       "  'Start Date': 'April 1, 2020',\n",
       "  'Primary Completion Date': 'May 31, 2020',\n",
       "  'Completion Date': 'May 31, 2020',\n",
       "  'First Posted': 'May 12, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 4, 2020',\n",
       "  'Locations': 'Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04384380/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04384380'},\n",
       " {'Rank': 1352,\n",
       "  'NCT Number': 'NCT04638842',\n",
       "  'Title': 'Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Grief|Anxiety|Depression|Sleep Disturbance|Quality of Life',\n",
       "  'Interventions': 'Behavioral: Online Intervention Grief COVID-19',\n",
       "  'Outcome Measures': 'Decrease in the scores of the Center for Epidemiologic Studies Depression (CES-D) scale|Change in the score of Anxiety Symptoms in the Depression Anxiety Stress Scale (DASS-21)|Decrease in the score of The Pittsburgh Sleep Quality Index.|Decrease in the scores of the Post-Traumatic Stress Disorder Symptom Scale|Increase in Satisfaction with Life Scale|Decrease in the symptoms of General Anxiety Disorder|Decrease in the Plutchik Suicide Risk Scale|Decrease in Grief symptoms',\n",
       "  'Sponsor/Collaborators': 'Universidad Internacional de Valencia|Universidad Nacional Autonoma de Mexico|Universidad Autonoma de Ciudad Juarez|University of Buenos Aires',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 60 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 42.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'VIU-Grief-COVID',\n",
       "  'Start Date': 'December 24, 2020',\n",
       "  'Primary Completion Date': 'June 1, 2021',\n",
       "  'Completion Date': 'June 1, 2021',\n",
       "  'First Posted': 'November 20, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 15, 2021',\n",
       "  'Locations': 'Universidad Autónoma de Ciudad Juárez, Juárez, Chihuahua, Mexico',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04638842/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04638842'},\n",
       " {'Rank': 1423,\n",
       "  'NCT Number': 'NCT04332991',\n",
       "  'Title': 'Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease',\n",
       "  'Acronym': 'ORCHID',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Coronavirus|Acute Respiratory Infection|SARS-CoV Infection',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine|Drug: Placebo',\n",
       "  'Outcome Measures': 'COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization)|COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization)|All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)|All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)|Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28|Oxygen-free Days Through Day 28|Ventilator-free Days Through Day 28|Vasopressor-free Days Through Day 28|ICU-free Days to Day 28|Hospital-free Days to Day 28',\n",
       "  'Sponsor/Collaborators': 'Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 479.0,\n",
       "  'Funded Bys': 'Other|NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'PETAL 05 Orchid',\n",
       "  'Start Date': 'April 2, 2020',\n",
       "  'Primary Completion Date': 'June 19, 2020',\n",
       "  'Completion Date': 'July 23, 2020',\n",
       "  'First Posted': 'April 3, 2020',\n",
       "  'Results First Posted': 'March 17, 2021',\n",
       "  'Last Update Posted': 'March 17, 2021',\n",
       "  'Locations': \"University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States\",\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04332991/Prot_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04332991/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04332991'},\n",
       " {'Rank': 1446,\n",
       "  'NCT Number': 'NCT04689711',\n",
       "  'Title': 'Prognostic Models for COVID-19 Care',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Enrolling by invitation',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Changes in model discrimination (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model discrimination (Model 2: mortality in patients receiving MV)|Changes in model discrimination (Model 3: length of stay in the ICU)|Changes in model calibration (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model calibration (Model 2: mortality in patients receiving MV)|Changes in model calibration (Model 3: length of stay in the ICU)|Changes in net benefit (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in net benefit (Model 2: mortality in patients receiving MV)|Changes in net benefit (Model 3: length of stay in the ICU)|Changes in model discrimination in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model discrimination in external database after updating (Model 2: mortality in patients receiving MV)|Changes in model discrimination in external database after updating (Model 3: length of stay in the ICU)|Changes in model calibration in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in model calibration in external database after updating (Model 2: mortality in patients receiving MV)|Changes in model calibration in external database after updating (Model 3: length of stay in the ICU)|Changes in net benefit in external database after updating (Model 1: need for MV in patients hospitalized with COVID-19)|Changes in net benefit in external database after updating (Model 2: mortality in patients receiving MV)|Changes in net benefit in external database after updating (Model 3: length of stay in the ICU)|Stakeholder perceptions, beliefs and opinions on COVID prediction models',\n",
       "  'Sponsor/Collaborators': 'Tufts Medical Center|Northwell Health|Erasmus Medical Center',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 16.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'PCORI-ME-1606-35555',\n",
       "  'Start Date': 'December 7, 2020',\n",
       "  'Primary Completion Date': 'August 31, 2021',\n",
       "  'Completion Date': 'August 31, 2021',\n",
       "  'First Posted': 'December 30, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 30, 2020',\n",
       "  'Locations': 'Tufts Medical Center, Boston, Massachusetts, United States|Northwell Health (The Feinstein Institutes for Medical Research), Manhasset, New York, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04689711/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04689711'},\n",
       " {'Rank': 1460,\n",
       "  'NCT Number': 'NCT04510441',\n",
       "  'Title': 'Artificial Intelligence-assisted Diagnosis and Prognostication in COVID-19 Using Electrocardiograms',\n",
       "  'Acronym': 'AI-COV-19',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus',\n",
       "  'Interventions': 'Other: Nil intervention',\n",
       "  'Outcome Measures': 'Accuracy of machine learning to be able to predict outcome of coronavirus (COVID-19) infection|Accuracy of machine learning to be able to predict prognosis of coronavirus (COVID-19) infection|Accuracy of machine learning to be able to predict cardiac involvement of coronavirus (COVID-19) infection|Accuracy of machine learning vs human assessment to diagnose coronavirus (COVID-19) infection',\n",
       "  'Sponsor/Collaborators': 'Imperial College London|Imperial College Healthcare NHS Trust|Chelsea and Westminster Hospital NHS Foundation Trust|LONDON NORTH WEST UNIVERSITY HEALTHCARE NHS TRUST',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 2000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Retrospective',\n",
       "  'Other IDs': '20HH5967',\n",
       "  'Start Date': 'May 26, 2020',\n",
       "  'Primary Completion Date': 'May 1, 2022',\n",
       "  'Completion Date': 'May 1, 2022',\n",
       "  'First Posted': 'August 12, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 12, 2020',\n",
       "  'Locations': \"London North West University Healthcare NHS Trust, London, United Kingdom|Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom|Imperial College London (Hammersmith campus), London, United Kingdom|St Mary's Hospital, London, United Kingdom\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04510441/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04510441'},\n",
       " {'Rank': 1461,\n",
       "  'NCT Number': 'NCT04406038',\n",
       "  'Title': 'Study of the Spread of COVID-19 in Saint Petersburg, Russia',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID19',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia|Prevalence odds ratios|Immune response dynamics',\n",
       "  'Sponsor/Collaborators': 'European University at St. Petersburg',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 1038.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'CDRU-001',\n",
       "  'Start Date': 'May 27, 2020',\n",
       "  'Primary Completion Date': 'October 28, 2021',\n",
       "  'Completion Date': 'October 28, 2021',\n",
       "  'First Posted': 'May 28, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 3, 2021',\n",
       "  'Locations': 'Clinic \"Scandinavia\", Saint Petersburg, Russian Federation',\n",
       "  'Study Documents': '\"Study Protocol and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04406038/Prot_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04406038'},\n",
       " {'Rank': 1490,\n",
       "  'NCT Number': 'NCT04401033',\n",
       "  'Title': 'Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study)',\n",
       "  'Acronym': 'DECORE',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'SARS-CoV 2|COVID',\n",
       "  'Interventions': 'Behavioral: Telephonic medical visit|Procedure: Gastrointestinal endoscopy|Procedure: Abdominal ultrasound',\n",
       "  'Outcome Measures': 'SARS-CoV-2 infection in patients|SARS-CoV-2 infection in HCW',\n",
       "  'Sponsor/Collaborators': 'Hospital del Río Hortega',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 450.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '003',\n",
       "  'Start Date': 'May 11, 2020',\n",
       "  'Primary Completion Date': 'June 30, 2020',\n",
       "  'Completion Date': 'June 30, 2020',\n",
       "  'First Posted': 'May 26, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'July 28, 2020',\n",
       "  'Locations': 'Hospital Rio Hortega, Valladolid, Spain',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/33/NCT04401033/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04401033'},\n",
       " {'Rank': 1504,\n",
       "  'NCT Number': 'NCT04434131',\n",
       "  'Title': 'Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Convalescent Plasma',\n",
       "  'Outcome Measures': 'Correlation between the NAb dose titer in the convalescent plasma and change or lack of change when comparing pre-treatment and day one NAb titers to inpatients with documented COIVD-19 infection|Rapid deterioration as evidenced by increase in ordinal or news score within 4 hours of transfusion|Number of participants with clearance of viral shedding of SARSCoV-2 in nasopharyngeal or nasal samples',\n",
       "  'Sponsor/Collaborators': 'University of New Mexico',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '20-227',\n",
       "  'Start Date': 'April 28, 2020',\n",
       "  'Primary Completion Date': 'April 28, 2021',\n",
       "  'Completion Date': 'April 28, 2025',\n",
       "  'First Posted': 'June 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 16, 2020',\n",
       "  'Locations': 'University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04434131/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04434131'},\n",
       " {'Rank': 1543,\n",
       "  'NCT Number': 'NCT04668222',\n",
       "  'Title': 'Changing Susceptible Body Constitution for COVID-19 Prevention by Chinese Medicine in Hong Kong Residents',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID19|Herbal Medicine',\n",
       "  'Interventions': 'Drug: Yu-Ping-Feng formula|Drug: Xiang-Sha-Liu-Jun formula|Drug: Liu-Wei-Di-Huang formula|Drug: Placebo for \"Deficiency of Qi and Yang\"|Drug: Placebo for \"Deficiency of Qi and Yin\"',\n",
       "  'Outcome Measures': 'Potential COVID-19 susceptible body constitutions will be measured by the scale of \"Self-test for classification and judgment of body constitution by traditional Chinese medicine (TCM) theory\"|Changes of TCM-based syndromes will be measured by the \"Questionnaire of TCM symptom\"|Potential changes of fatigue status will be measured by Fatigue Scale|Complete Blood Count will be measured by Automated Cell Counter|Liver function biomarkers in blood will be measured by Automatic Blood Biochemistry Analyzer|Heart function biomarkers in blood will be measured by Automatic Blood Biochemistry|Kidney function biomarkers in blood will be measured by Automatic Blood Biochemistry|Inflammatory biomarker in blood will be measured by Automatic Blood Biochemistry|The changes of quantification of blood CD4 and CD8 populations will be measured by flow cytometric analyzer',\n",
       "  'Sponsor/Collaborators': 'The University of Hong Kong',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 1|Phase 2',\n",
       "  'Enrollment': 480.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'UW20-480',\n",
       "  'Start Date': 'December 15, 2020',\n",
       "  'Primary Completion Date': 'November 30, 2022',\n",
       "  'Completion Date': 'November 30, 2022',\n",
       "  'First Posted': 'December 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 19, 2020',\n",
       "  'Locations': 'The University of Hong Kong, Hong Kong, Hong Kong, China, Hong Kong',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04668222/ICF_000.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04668222/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04668222'},\n",
       " {'Rank': 1559,\n",
       "  'NCT Number': 'NCT04597034',\n",
       "  'Title': 'Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19',\n",
       "  'Acronym': 'oXAKI-COV',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|AKI',\n",
       "  'Interventions': 'Procedure: AN69-Oxiris|Procedure: AN69-Standard',\n",
       "  'Outcome Measures': 'Primary outcome:|Secondary outcomes measures:',\n",
       "  'Sponsor/Collaborators': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 75 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 35.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'NMM-3401-20-20-1',\n",
       "  'Start Date': 'October 2, 2020',\n",
       "  'Primary Completion Date': 'December 30, 2021',\n",
       "  'Completion Date': 'March 30, 2022',\n",
       "  'First Posted': 'October 22, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 22, 2020',\n",
       "  'Locations': 'Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico',\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/34/NCT04597034/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04597034'},\n",
       " {'Rank': 1640,\n",
       "  'NCT Number': 'NCT04542694',\n",
       "  'Title': 'Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Favipiravir|Drug: Standard of care',\n",
       "  'Outcome Measures': 'Rate of Clinical Status Improvement|Time to Clinical Improvement|Rate of Viral Elimination by Day 10|Time Before the End of Fever|Change in the Level of Lung Damage According to CT|Rate of Transfer to the Intensive Care Unit|Rate of the Use of Non-invasive Lung Ventilation|Rate of the Use of Mechanical Ventilation|Mortality',\n",
       "  'Sponsor/Collaborators': 'Promomed, LLC',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 80 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 200.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'FAV052020',\n",
       "  'Start Date': 'May 21, 2020',\n",
       "  'Primary Completion Date': 'August 10, 2020',\n",
       "  'Completion Date': 'August 20, 2020',\n",
       "  'First Posted': 'September 9, 2020',\n",
       "  'Results First Posted': 'November 5, 2020',\n",
       "  'Last Update Posted': 'November 5, 2020',\n",
       "  'Locations': \"State Clinical Hospital №50, Moscow, Russian Federation|Regional Clinic Hospital of Ryazan, Ryazan', Russian Federation|City Hospital N40 of Kurortny District, Saint Petersburg, Russian Federation|Medical institute Ogarev Mordovia State university, Saransk, Russian Federation|Smolensk clinical hospital №1, Smolensk, Russian Federation\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04542694/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04542694'},\n",
       " {'Rank': 1660,\n",
       "  'NCT Number': 'NCT04646109',\n",
       "  'Title': 'Ivermectin for Severe COVID-19 Management',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Ivermectin',\n",
       "  'Outcome Measures': 'Gender Distribution of the Patients|Age Distribution of the Patients|Percentage of Patients With Accompanying Diseases|Percentage of Patients With Baseline Clinical Symptoms|Body Temperature Means of the Patients|Heart Rate Means of the Patients|Respiratory Rate Means of the Patients|Systolic and Diastolic Pressure Means of the Patients|Number of Participants With Clinical Response|Changes in Oxygen Saturation (SpO2) Values|Changes in the Ratio of Partial Pressure of Oxygen (PaO2) to Fraction of Inspired Oxygen (FiO2) (PaO2/FiO2)|Changes in Serum Lymphocyte Counts|Changes in the Ratio of Polymorphonuclear Leukocyte Count to Lymphocyte Count (PNL/L)|Changes in Serum Ferritin Levels|Changes in Serum D-dimer Levels|Genetic Examination of Haplotypes and Mutations That Cause Function Losing for Ivermectin Metabolism|Treatment-Related Adverse Events as Assessed by CTCAE v4.0|Mortality|Rate of COVID-19 Polymerase Chain Reaction (PCR) Test Negativity',\n",
       "  'Sponsor/Collaborators': 'Afyonkarahisar Health Sciences University|NeuTec Pharma',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 66.0,\n",
       "  'Funded Bys': 'Other|Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'IVMC_03',\n",
       "  'Start Date': 'May 11, 2020',\n",
       "  'Primary Completion Date': 'September 2, 2020',\n",
       "  'Completion Date': 'September 2, 2020',\n",
       "  'First Posted': 'November 27, 2020',\n",
       "  'Results First Posted': 'January 27, 2021',\n",
       "  'Last Update Posted': 'January 27, 2021',\n",
       "  'Locations': 'Afyonkarahisar Health Science University, Afyonkarahisar, Turkey|Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey|Yıldırım Beyazıt University, Ankara City Hospital, Ankara, Turkey|Haydarpasa Sultan Abdulhamid Han Training and Research Hospital, İstanbul, Turkey',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/Prot_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/ICF_001.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04646109/SAP_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04646109'},\n",
       " {'Rank': 1708,\n",
       "  'NCT Number': 'NCT04730323',\n",
       "  'Title': 'TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': 'Drug: Tocilizumab',\n",
       "  'Outcome Measures': 'Decreased Mortality in Participants|Hospital & ICU stay in days',\n",
       "  'Sponsor/Collaborators': 'FMH College of Medicine and Dentistry',\n",
       "  'Gender': 'All',\n",
       "  'Age': '16 Years to 85 Years \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': 'Phase 4',\n",
       "  'Enrollment': 93.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'IRB# FMH-05-2020-IRB-75',\n",
       "  'Start Date': 'May 12, 2020',\n",
       "  'Primary Completion Date': 'June 12, 2020',\n",
       "  'Completion Date': 'June 12, 2020',\n",
       "  'First Posted': 'January 29, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 29, 2021',\n",
       "  'Locations': 'Fatima Memorial Hospital College of Medicine & Dentistry, Lahore, Punjab, Pakistan',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04730323/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04730323'},\n",
       " {'Rank': 1742,\n",
       "  'NCT Number': 'NCT04623255',\n",
       "  'Title': 'Randomised Study of Plasma Exchange in Severe COVID-19',\n",
       "  'Acronym': 'COVIPLEX',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID19',\n",
       "  'Interventions': 'Drug: OCTAPLAS',\n",
       "  'Outcome Measures': 'Change in Inflammatory Marker-CRP|Change in Inflammatory Marker-D Dimer|Change in Inflammatory Marker-LDH|Rates of mechanical ventilation|Rates of clinical thrombotic events|Change in inflammatory-thrombotic response|To compare the incidence of acute kidney injury|Mortality at day 28',\n",
       "  'Sponsor/Collaborators': 'University College, London',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 70 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 20.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '132796',\n",
       "  'Start Date': 'October 16, 2020',\n",
       "  'Primary Completion Date': 'October 15, 2021',\n",
       "  'Completion Date': 'November 1, 2021',\n",
       "  'First Posted': 'November 10, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 10, 2020',\n",
       "  'Locations': 'University College London Hospital, London, United Kingdom',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/55/NCT04623255/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04623255'},\n",
       " {'Rank': 1744,\n",
       "  'NCT Number': 'NCT04329923',\n",
       "  'Title': 'The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)',\n",
       "  'Acronym': 'PATCH',\n",
       "  'Status': 'Terminated',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet',\n",
       "  'Outcome Measures': 'Time to Release From Quarantine Time|Time to Hospital Discharge|Number of Health Care Workers Who Developed SARS-COV-2 Infection|Rate of Housemate Infection|Rate of Hospitalization',\n",
       "  'Sponsor/Collaborators': 'Ravi Amaravadi, MD|University of Pennsylvania',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 173.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '842838',\n",
       "  'Start Date': 'April 9, 2020',\n",
       "  'Primary Completion Date': 'November 11, 2020',\n",
       "  'Completion Date': 'November 13, 2020',\n",
       "  'First Posted': 'April 1, 2020',\n",
       "  'Results First Posted': 'December 10, 2020',\n",
       "  'Last Update Posted': 'December 10, 2020',\n",
       "  'Locations': 'University of Pennsylvania, Philadelphia, Pennsylvania, United States',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04329923/Prot_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04329923/SAP_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04329923'},\n",
       " {'Rank': 1760,\n",
       "  'NCT Number': 'NCT04315298',\n",
       "  'Title': 'Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Sarilumab|Drug: Placebo',\n",
       "  'Outcome Measures': 'Percent change in C-reactive protein (CRP) levels in patients with serum IL-6 level greater than the upper limit of normal|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with critical COVID-19 receiving mechanical ventilation at baseline|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale in patients with COVID-19 receiving mechanical ventilation at baseline|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Proportion of patients with at least 1-point improvement in clinical status using the 7-point ordinal scale|Proportion of patients who recover|Proportion of deaths|Proportion of patients alive not receiving mechanical ventilation|Proportion of patients alive not requiring extracorporeal membrane oxygenation (ECMO)|Proportion of patients with a 2-point improvement in clinical status on the 7-point ordinal scale|Time to at least 1-point improvement in clinical status assessment on the 7-point ordinal scale|Time to at least 2-point improvement in clinical status assessment on the 7-point ordinal scale|Proportion of patients receiving mechanical ventilation|Proportion of patients receiving ECMO|Proportion of patients discharged and alive|Time to recovery|Time to death due to any cause|Number of ventilator free days|Proportion of patients with serious adverse events|Proportion of patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Proportion of patients with severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia (ANC <500/mm3)|Proportion of patients with hypersensitivity reactions|Proportion of patients with infusion reactions|Proportion of patients with gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level',\n",
       "  'Sponsor/Collaborators': 'Regeneron Pharmaceuticals|Sanofi',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2|Phase 3',\n",
       "  'Enrollment': 1912.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '6R88-COV-2040',\n",
       "  'Start Date': 'March 18, 2020',\n",
       "  'Primary Completion Date': 'July 24, 2020',\n",
       "  'Completion Date': 'September 2, 2020',\n",
       "  'First Posted': 'March 19, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 1, 2020',\n",
       "  'Locations': 'Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04315298'},\n",
       " {'Rank': 1851,\n",
       "  'NCT Number': 'NCT04327206',\n",
       "  'Title': 'BCG Vaccination to Protect Healthcare Workers Against COVID-19',\n",
       "  'Acronym': 'BRACE',\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus Disease 2019 (COVID-19)|Respiratory Illness|Corona Virus Infection|COVID-19',\n",
       "  'Interventions': 'Drug: BCG Vaccine|Drug: 0.9%NaCl',\n",
       "  'Outcome Measures': 'COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Fever or respiratory illness|Episodes of fever or respiratory illness|Work absenteeism due to fever or respiratory illness|Bed confinement due to fever or respiratory illness|Symptom duration of fever or respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with fever or respiratory illness|Unplanned work absenteeism|Local and systemic adverse events to BCG vaccination in healthcare workers',\n",
       "  'Sponsor/Collaborators': \"Murdoch Childrens Research Institute|Royal Children's Hospital\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 10078.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '62586|U1111-1256-4104',\n",
       "  'Start Date': 'March 30, 2020',\n",
       "  'Primary Completion Date': 'June 30, 2021',\n",
       "  'Completion Date': 'March 30, 2022',\n",
       "  'First Posted': 'March 31, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 12, 2021',\n",
       "  'Locations': \"St Vincent's Hospital, Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|Fundação de Medicina Tropical Dr Heitor Vieira Dourado (FMT-HVD), Manaus, Amazonas, Brazil|Santa Casa Hospital, Campo Grande, Mato Grosso Do Sul, Brazil|CASSEMS Hospital, Campo Grande, Mato Grosso Do Sul, Brazil|Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso Do Sul, Brazil|Hospital Regional de Mato Grosso do Sul, Campo Grande, Mato Grosso Do Sul, Brazil|Centro de Estudos da Saúde do Trabalhador e Ecologia Humana, Rio de Janeiro, RJ, Brazil|Centro de Referência Prof Hélio Fraga, Rio de Janeiro, RJ, Brazil|Noord West Ziekenhuis, Alkmaar, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Hospital, Breda, Netherlands|St Antonius Hospital, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|University hospital in Utrecht (UMCU), Utrecht, Netherlands|University Hospital German Trias I Pujol, Badalona, Barcelona, Spain|Mutua Terrassa Univeristy Hospital, Terrassa, Barcelona, Spain|University Hospital Cruces, Barakaldo, Bizkaia, Spain|Marqués de Valdecilla University Hospital, Santander, Spain|University Hospital Virgen Macarena, Sevilla, Spain|Ide Lane Surgery, Alphington, Exeter, United Kingdom|St Leonard's Practice, St Leonards, Exeter, United Kingdom|Travel Clinic, Exeter, United Kingdom\",\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/06/NCT04327206/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04327206'},\n",
       " {'Rank': 1872,\n",
       "  'NCT Number': 'NCT04468009',\n",
       "  'Title': 'Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'SARS-Associated Coronavirus|Covid19|SARS-CoV Infection',\n",
       "  'Interventions': 'Biological: Convalescent plasma',\n",
       "  'Outcome Measures': 'Mortality at ICU at 30 days|Mortality at ICU at 90 days|SOFA score of study days 1, 3, 5, 7, 14 and 28|Need for supportive therapy after enrollment|Lenght of stay in ICU|Lenght of mechanical ventilation|Lenght of hospitalization',\n",
       "  'Sponsor/Collaborators': 'Hospital de Infecciosas Francisco Javier Muniz',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 100 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 36.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '1725',\n",
       "  'Start Date': 'June 25, 2020',\n",
       "  'Primary Completion Date': 'January 19, 2021',\n",
       "  'Completion Date': 'February 2021',\n",
       "  'First Posted': 'July 13, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 22, 2021',\n",
       "  'Locations': 'Hospital Francisco Javier Muñiz, Ciudad Autonoma de Buenos Aire, Argentina',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04468009/ICF_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04468009/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04468009'},\n",
       " {'Rank': 1899,\n",
       "  'NCT Number': 'NCT04407273',\n",
       "  'Title': 'Statin Therapy and COVID-19 Infection',\n",
       "  'Acronym': 'STACOV',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID|Statin|Cardiovascular Diseases',\n",
       "  'Interventions': 'Drug: observational',\n",
       "  'Outcome Measures': 'SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy',\n",
       "  'Sponsor/Collaborators': 'Institut Investigacio Sanitaria Pere Virgili',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 2159.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Only|Time Perspective: Prospective',\n",
       "  'Other IDs': '106/2020',\n",
       "  'Start Date': 'May 14, 2020',\n",
       "  'Primary Completion Date': 'August 20, 2020',\n",
       "  'Completion Date': 'December 30, 2020',\n",
       "  'First Posted': 'May 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 11, 2021',\n",
       "  'Locations': 'Facultat de Medicina i Ciències de la Salut de Reus, Reus, Tarragona, Spain',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/73/NCT04407273/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04407273'},\n",
       " {'Rank': 1909,\n",
       "  'NCT Number': 'NCT04419571',\n",
       "  'Title': 'Outcomes in Emergency Laparotomies During COVID-19 Pandemic',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19|Emergency General Surgery',\n",
       "  'Interventions': 'Procedure: Emergency Laparotomy',\n",
       "  'Outcome Measures': '30-day mortality|7-day mortality|Number of participants returning to theatre|Length of stay|Post-operative respiratory failure|Post-operative ARDS|Post-operative sepsis|ITU/HDU admission',\n",
       "  'Sponsor/Collaborators': 'Barking, Havering and Redbridge University Hospitals NHS Trust',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 94.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Retrospective',\n",
       "  'Other IDs': '133196',\n",
       "  'Start Date': 'March 23, 2020',\n",
       "  'Primary Completion Date': 'June 16, 2020',\n",
       "  'Completion Date': 'June 16, 2020',\n",
       "  'First Posted': 'June 5, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'July 23, 2020',\n",
       "  'Locations': \"Queen's Hospital, Romford, United Kingdom\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/71/NCT04419571/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04419571'},\n",
       " {'Rank': 1913,\n",
       "  'NCT Number': 'NCT04519125',\n",
       "  'Title': 'Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Severe Acute Respiratory Syndrome Coronavirus 2|COVID-19',\n",
       "  'Interventions': 'Drug: Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)|Other: Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE)',\n",
       "  'Outcome Measures': 'SARS-CoV-2 infection|Serious and non-serious adverse events|Discontinuation of using TDF/FTC for any reason|Adherence to TDF/FTC|Severity of SARS-CoV-2 infection',\n",
       "  'Sponsor/Collaborators': 'Hospital Universitario San Ignacio|Pontificia Universidad Javeriana|Hospital Universitario Nacional de Colombia|Hospital de la Samaritana, Sede Bogotá y Sede Zipaquirá|Hospital Universitario San Jorge, Pereira.|Fundación Universitaria Autónoma de Las Américas|Universidad Tecnológica de Pereira|Colsanitas',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 70 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2|Phase 3',\n",
       "  'Enrollment': 950.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '2020 /143|77389',\n",
       "  'Start Date': 'August 30, 2020',\n",
       "  'Primary Completion Date': 'December 31, 2020',\n",
       "  'Completion Date': 'April 1, 2021',\n",
       "  'First Posted': 'August 19, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 19, 2020',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/25/NCT04519125/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04519125'},\n",
       " {'Rank': 1933,\n",
       "  'NCT Number': 'NCT04340349',\n",
       "  'Title': 'Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals',\n",
       "  'Acronym': 'ELEVATE',\n",
       "  'Status': 'Enrolling by invitation',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Hydroxychloroquine|Antimalarials|Enzyme Inhibitors|Antirheumatic Agents',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG',\n",
       "  'Outcome Measures': 'Quantification of the expression of mRNA SARS-CoV-2 and presence or absence of antibodies anti-SARS-CoV-2',\n",
       "  'Sponsor/Collaborators': 'Instituto Nacional de Rehabilitacion',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 59 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Early Phase 1',\n",
       "  'Enrollment': 214.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '25/20',\n",
       "  'Start Date': 'February 1, 2021',\n",
       "  'Primary Completion Date': 'May 30, 2021',\n",
       "  'Completion Date': 'June 30, 2021',\n",
       "  'First Posted': 'April 9, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 5, 2021',\n",
       "  'Locations': 'National Institute of Rehabilitation, Luis Guillermo Ibarra Ibarra, Mexico City, Cdmx, Mexico',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/49/NCT04340349/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04340349'},\n",
       " {'Rank': 1978,\n",
       "  'NCT Number': 'NCT04444401',\n",
       "  'Title': 'Registry on NEN Patients and COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Neuroendocrine Tumors|COVID-19',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Correlation between clinical parameters and SARS-CoV-2 infection|Clinical outcome of SARS-CoV-2 Infection|major demographic features|type of NEN',\n",
       "  'Sponsor/Collaborators': 'European Institute of Oncology',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 50.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Only|Time Perspective: Other',\n",
       "  'Other IDs': 'IEO-1291',\n",
       "  'Start Date': 'June 15, 2020',\n",
       "  'Primary Completion Date': 'June 15, 2021',\n",
       "  'Completion Date': 'December 15, 2021',\n",
       "  'First Posted': 'June 23, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 22, 2021',\n",
       "  'Locations': 'European Institute of Oncology, IEO, IRCCS, Milan, MI, Italy',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan: version 1.0\", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04444401/Prot_SAP_000.pdf|\"Study Protocol and Statistical Analysis Plan: version 1.1\", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04444401/Prot_SAP_001.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04444401/ICF_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04444401'},\n",
       " {'Rank': 2003,\n",
       "  'NCT Number': 'NCT04757285',\n",
       "  'Title': 'Copeptin and Psychological Stress of Medic During COVID-19 Pandemic',\n",
       "  'Acronym': 'COVID-19',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Psychological Stress|Hemostatic Disorder',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'evaluation of psychological stress|determine stress hormones in serum cortisol and copeptin|correlation of psychological stress with stress hormone copeptin',\n",
       "  'Sponsor/Collaborators': 'Alexandria University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '24 Years to 37 Years \\xa0 (Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 90.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '0304842',\n",
       "  'Start Date': 'May 10, 2020',\n",
       "  'Primary Completion Date': 'October 30, 2020',\n",
       "  'Completion Date': 'October 30, 2020',\n",
       "  'First Posted': 'February 17, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 17, 2021',\n",
       "  'Locations': 'Alexandria University Faculty of Medicine, Alexandria, Egypt',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04757285/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/85/NCT04757285/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04757285'},\n",
       " {'Rank': 2004,\n",
       "  'NCT Number': 'NCT04354428',\n",
       "  'Title': 'Treatment for COVID-19 in High-Risk Adult Outpatients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19|SARS-CoV-2',\n",
       "  'Interventions': 'Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]',\n",
       "  'Outcome Measures': 'Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]',\n",
       "  'Sponsor/Collaborators': 'University of Washington|Bill and Melinda Gates Foundation',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 80 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2|Phase 3',\n",
       "  'Enrollment': 300.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'STUDY00009878|INV-017062',\n",
       "  'Start Date': 'April 16, 2020',\n",
       "  'Primary Completion Date': 'December 2020',\n",
       "  'Completion Date': 'January 2021',\n",
       "  'First Posted': 'April 21, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 12, 2020',\n",
       "  'Locations': 'Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States',\n",
       "  'Study Documents': '\"Study Protocol: Hydroxychloroquine and Azithromycin arms\", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_002.pdf|\"Study Protocol: Lopinavir-Ritonavir arm\", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/Prot_003.pdf|\"Informed Consent Form: Hydroxychloroquine and Azithromycin arms\", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_004.pdf|\"Informed Consent Form: Lopinavir-Ritonavir arm\", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04354428/ICF_005.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04354428'},\n",
       " {'Rank': 2010,\n",
       "  'NCT Number': 'NCT04549337',\n",
       "  'Title': 'Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Behavioral: Exercise training',\n",
       "  'Outcome Measures': '10-point Likert scale|Participant adherence to the training dose|Participant adherence to the training intensity|Adverse effects|Rate of perceived exertion|Post COVID-19 Functional scale',\n",
       "  'Sponsor/Collaborators': 'Rigshospitalet, Denmark',\n",
       "  'Gender': 'All',\n",
       "  'Age': '40 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 10.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'H-20033733|75068',\n",
       "  'Start Date': 'September 25, 2020',\n",
       "  'Primary Completion Date': 'May 1, 2021',\n",
       "  'Completion Date': 'May 1, 2021',\n",
       "  'First Posted': 'September 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 30, 2020',\n",
       "  'Locations': 'Rigshospitalet, Copenhagen, Denmark',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/37/NCT04549337/Prot_SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04549337'},\n",
       " {'Rank': 2126,\n",
       "  'NCT Number': 'NCT04425850',\n",
       "  'Title': 'USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19',\n",
       "  'Acronym': 'IVERCAR',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': 'Combination Product: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)',\n",
       "  'Outcome Measures': 'Number of Infected Subjects|Adverse Events Other Than Those Resulting From Contagion or Disease Progression',\n",
       "  'Sponsor/Collaborators': 'Eurnekian Public Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 229.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'IVERCAR',\n",
       "  'Start Date': 'June 1, 2020',\n",
       "  'Primary Completion Date': 'August 10, 2020',\n",
       "  'Completion Date': 'August 10, 2020',\n",
       "  'First Posted': 'June 11, 2020',\n",
       "  'Results First Posted': 'October 19, 2020',\n",
       "  'Last Update Posted': 'October 19, 2020',\n",
       "  'Locations': 'Hospital Eurnekian, Buenos Aires, Argentina',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04425850/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04425850'},\n",
       " {'Rank': 2127,\n",
       "  'NCT Number': 'NCT04609423',\n",
       "  'Title': 'Cod Liver Oil for Covid-19 Prevention Study',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid-19|Respiratory Tract Infections',\n",
       "  'Interventions': 'Dietary Supplement: Cod liver oil|Dietary Supplement: Corn oil (placebo)',\n",
       "  'Outcome Measures': 'Number of participants diagnosed with serious Covid-19|Number of participants diagnosed with New Covid-19|Number of participants with laboratory confirmed respiratory tract infection|Number of participants with self-reported airway infection|Number of participants hospitalized due to Covid-19|Number of participants in Intensiv Care Unit (ICU) caused by Covid-19|Number of participants with any admissions to hospital|Infection with each of the mentioned pathogens|Number of visits at GP for infections|Number of visits at GP',\n",
       "  'Sponsor/Collaborators': 'Oslo University Hospital|University of Oslo|Norwegian Institute of Public Health',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 75 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 4',\n",
       "  'Enrollment': 80000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'REK-172796',\n",
       "  'Start Date': 'November 10, 2020',\n",
       "  'Primary Completion Date': 'May 2021',\n",
       "  'Completion Date': 'May 2023',\n",
       "  'First Posted': 'October 30, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 12, 2020',\n",
       "  'Locations': 'Oslo University Hospital, Oslo, Norway',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/23/NCT04609423/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04609423'},\n",
       " {'Rank': 2128,\n",
       "  'NCT Number': 'NCT04346342',\n",
       "  'Title': 'PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID|Mechanical Ventilation|Acute Respiratory Failure',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Ventilation Mode|Tidal volume set|Expiratory tidal volume|Positive end-expiratory pressure|Maximum airway pressure or plateau pressure (P plateau) or peak pressure (P peak) (cm H2O);|Level of pressure support above positive end-expiratory pressure (PEEP)|Inspired fraction of oxygen|Set and measured respiratory rate|Inspiration to expiration ratio|Number of ventilation-free days and alive at day 28|Duration of ventilation in survivors;|Use of prone positioning|Use of recruitment maneuvers|Incidence of acute kidney injury|Duration of ICU stay|Duration of hospital stay|ICU mortality|Hospital mortality|28-day mortality|90-day mortality',\n",
       "  'Sponsor/Collaborators': 'Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 1122.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Retrospective',\n",
       "  'Other IDs': 'PRoVENT-COVID',\n",
       "  'Start Date': 'March 6, 2020',\n",
       "  'Primary Completion Date': 'September 1, 2020',\n",
       "  'Completion Date': 'September 1, 2020',\n",
       "  'First Posted': 'April 15, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'September 22, 2020',\n",
       "  'Locations': 'Flevoziekenhuis, Almere, Netherlands|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Gelre ziekenhuizen, Apeldoorn, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Maxima Medical Center, Eindhoven, Netherlands|St Anna Ziekenhuis, Geldrop, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Spaarne Gasthuis, Haarlem, Netherlands|Dijklander Ziekenhuis, Hoorn, Netherlands|Leeuwarden Medisch Centrum, Leeuwarden, Netherlands|Maastricht Universitair Medisch Centrum, Maastricht, Netherlands|St Antonius Ziekenhuis, Nieuwegein, Netherlands|Maasstad Hospital, Rotterdam, Netherlands|Zuyderland Medisch Centrum, Sittard, Netherlands|Isala Ziekenhuis, Zwolle, Netherlands',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04346342/Prot_SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04346342'},\n",
       " {'Rank': 2143,\n",
       "  'NCT Number': 'NCT04446429',\n",
       "  'Title': 'Anti-Androgen Treatment for COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19|SARS-CoV2|Androgenetic Alopecia|Prostate Cancer|Benign Prostatic Hyperplasia|SARS (Severe Acute Respiratory Syndrome)',\n",
       "  'Interventions': 'Drug: Proxalutamide|Other: Standard of Care',\n",
       "  'Outcome Measures': 'COVID-19 Hospitalization',\n",
       "  'Sponsor/Collaborators': 'Applied Biology, Inc.',\n",
       "  'Gender': 'Male',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 262.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'AB-DRUG-SARS-004',\n",
       "  'Start Date': 'September 15, 2020',\n",
       "  'Primary Completion Date': 'December 24, 2020',\n",
       "  'Completion Date': 'January 21, 2021',\n",
       "  'First Posted': 'June 24, 2020',\n",
       "  'Results First Posted': 'February 3, 2021',\n",
       "  'Last Update Posted': 'February 3, 2021',\n",
       "  'Locations': 'Corpometria Institute, Brasilia, Brazil',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/29/NCT04446429/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04446429'},\n",
       " {'Rank': 2207,\n",
       "  'NCT Number': 'NCT04686734',\n",
       "  'Title': 'Long-term Effects of COVID-19 in Adolescents',\n",
       "  'Acronym': 'LoTECA',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': 'Other: No active intervention (observational only)',\n",
       "  'Outcome Measures': 'Fatigue',\n",
       "  'Sponsor/Collaborators': 'University Hospital, Akershus',\n",
       "  'Gender': 'All',\n",
       "  'Age': '12 Years to 25 Years \\xa0 (Child, Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 500.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'LoTECA',\n",
       "  'Start Date': 'January 6, 2021',\n",
       "  'Primary Completion Date': 'May 30, 2021',\n",
       "  'Completion Date': 'December 2021',\n",
       "  'First Posted': 'December 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 8, 2021',\n",
       "  'Locations': 'Vegard Bratholm Wyller, Oslo, Norway',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/34/NCT04686734/Prot_002.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/34/NCT04686734/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04686734'},\n",
       " {'Rank': 2250,\n",
       "  'NCT Number': 'NCT04494893',\n",
       "  'Title': 'ImmuneRACE - Immune Response Action to COVID-19 Events',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': \"Comparison of disease-specific TCR signatures in patients and controls|Identify the immunodominant antigens that elicit a T-cell response to COVID-19|Risk Stratification based on an individual's immune signature|Determine whether an immune signature can be detected in individuals exposed to SARS-CoV-2 earlier than currently available tests|Explore whether additional research assays could potential identify and/or confirm antigenic binding\",\n",
       "  'Sponsor/Collaborators': 'Adaptive Biotechnologies|Covance',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 89 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 808.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'ADAP-006',\n",
       "  'Start Date': 'April 24, 2020',\n",
       "  'Primary Completion Date': 'March 23, 2021',\n",
       "  'Completion Date': 'June 30, 2021',\n",
       "  'First Posted': 'July 31, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 6, 2021',\n",
       "  'Locations': 'Adaptive Biotechnologies, Seattle, Washington, United States',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04494893/Prot_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04494893/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04494893'},\n",
       " {'Rank': 2279,\n",
       "  'NCT Number': 'NCT04569188',\n",
       "  'Title': 'Convalescent Plasma in COVID-19 Elderly Patients',\n",
       "  'Acronym': 'RESCUE',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Biological: Convalescent plasma',\n",
       "  'Outcome Measures': 'Death|Viral load',\n",
       "  'Sponsor/Collaborators': 'Azienda Socio Sanitaria Territoriale di Mantova',\n",
       "  'Gender': 'All',\n",
       "  'Age': '65 Years and older \\xa0 (Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 21.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'Asstmantova',\n",
       "  'Start Date': 'May 15, 2020',\n",
       "  'Primary Completion Date': 'August 15, 2020',\n",
       "  'Completion Date': 'September 3, 2020',\n",
       "  'First Posted': 'September 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 5, 2020',\n",
       "  'Locations': 'Transfusion Service, Mantova, Italy',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04569188/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04569188'},\n",
       " {'Rank': 2355,\n",
       "  'NCT Number': 'NCT04343092',\n",
       "  'Title': 'Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID 19',\n",
       "  'Interventions': 'Drug: Ivermectin (IVM)',\n",
       "  'Outcome Measures': 'Number of Cured Patients|Time to Cure of COVID-19 Patients in the IVM +HCQ+AZT Group',\n",
       "  'Sponsor/Collaborators': 'University of Baghdad',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 1',\n",
       "  'Enrollment': 16.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'PRO20040001',\n",
       "  'Start Date': 'April 18, 2020',\n",
       "  'Primary Completion Date': 'May 31, 2020',\n",
       "  'Completion Date': 'June 1, 2020',\n",
       "  'First Posted': 'April 13, 2020',\n",
       "  'Results First Posted': 'November 4, 2020',\n",
       "  'Last Update Posted': 'November 4, 2020',\n",
       "  'Locations': 'General Directorate of Medical City, Bagdad, Baghdad, Iraq',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04343092/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04343092'},\n",
       " {'Rank': 2364,\n",
       "  'NCT Number': 'NCT04434417',\n",
       "  'Title': 'Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV',\n",
       "  'Acronym': 'I-GLOBAL',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID',\n",
       "  'Interventions': 'Device: 2019-nCoV IgG/IgM Rapid Test Cassette',\n",
       "  'Outcome Measures': 'Evaluation of the rate of SARS-CoV-2 positive cancer patients and health professionals in a comprehensive cancer center or in a cancer setting.|Evaluation of test accuracy|Interleukin-6 quantification|Interleukin-2 quantification|Interleukin-1 quantification|Tumor Necrosis Factor (TNF) quantification|Interferon gamma quantification',\n",
       "  'Sponsor/Collaborators': 'European Institute of Oncology|Azienda Socio-Sanitaria Territoriale di Cremona|Azienda Ospedaliera Niguarda Cà Granda|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Papa Giovanni XXIII Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 1000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'I-GLOBAL',\n",
       "  'Start Date': 'April 15, 2020',\n",
       "  'Primary Completion Date': 'July 31, 2021',\n",
       "  'Completion Date': 'December 31, 2021',\n",
       "  'First Posted': 'June 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 22, 2020',\n",
       "  'Locations': 'Papa Giovanni XXIII Hospital, Bergamo, Italy|Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy|European IO, Division of Early Drug Development for Innovative Therapies, Milan, Italy',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04434417/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04434417'},\n",
       " {'Rank': 2396,\n",
       "  'NCT Number': 'NCT04358068',\n",
       "  'Title': 'Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Terminated',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19|SARS-CoV 2',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin',\n",
       "  'Outcome Measures': 'Number of Participants Who Died From Any Cause or Were Hospitalized|Number of Participants Who Died From Any Cause|Number of Participants Who Died From Any Cause, or Were Hospitalized, or Had an Urgent Visit to Emergency Room or Clinic|Number of Participants Who Died From Any Cause or Were Hospitalized Through the End of Follow-up|Number of Participants Who Prematurely Discontinue Study Treatment Due to an Adverse Event|Number of Participants Who Had Any Cardiac Adverse Events|Duration of Fever|Duration of Symptoms Associated With COVID-19 Disease|Participant-specific Area Under the Curve (AUC) of the Symptom Score Associated With COVID-19 Disease Over Time|Time to Self-reported Return to Usual (Pre-COVID) Health.|SARS-CoV-2 RNA Detection Status From Self-collected Nasal and Site-collected NP Swabs Among Subset|SARS-CoV-2 RNA Level (Continuous) From Self-collected Nasal and Site-collected NP Swabs Among Subset|Number of Participants With an Occurrence of Fainting',\n",
       "  'Sponsor/Collaborators': 'National Institute of Allergy and Infectious Diseases (NIAID)|Teva Pharmaceuticals Industries LTD',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 20.0,\n",
       "  'Funded Bys': 'NIH|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'ACTG A5395|38720',\n",
       "  'Start Date': 'May 13, 2020',\n",
       "  'Primary Completion Date': 'July 7, 2020',\n",
       "  'Completion Date': 'July 7, 2020',\n",
       "  'First Posted': 'April 22, 2020',\n",
       "  'Results First Posted': 'April 1, 2021',\n",
       "  'Last Update Posted': 'April 12, 2021',\n",
       "  'Locations': 'Alabama CRS, Birmingham, Alabama, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Harbor-UCLA CRS, Torrance, California, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04358068/Prot_002.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04358068/SAP_001.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04358068/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04358068'},\n",
       " {'Rank': 2403,\n",
       "  'NCT Number': 'NCT04511429',\n",
       "  'Title': 'COVID-19 in Immunosuppressed Children',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Infections, Coronavirus|Kidney Transplantation|Liver Transplantation|Cancer|Covid19',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Serology (IgM, IgG) for COVID-19.|Hospital admission|Intensive care admission|Death|Positive PCR for COVID-19|Clinical characteristics of patients with COVID-19|Proportion of patients with viral excretion in respiratory secretion and faeces on days 3, 7, 14, 21 and 30 after confirmation of covid 19.',\n",
       "  'Sponsor/Collaborators': \"D'Or Institute for Research and Education|Hospital Estadual da Criança|Hospital Federal de Bonsucesso|Rio de Janeiro State Research Supporting Foundation (FAPERJ)\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '1 Month to 18 Years \\xa0 (Child, Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 200.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '062-2020',\n",
       "  'Start Date': 'June 30, 2020',\n",
       "  'Primary Completion Date': 'October 2020',\n",
       "  'Completion Date': 'April 2021',\n",
       "  'First Posted': 'August 13, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 13, 2020',\n",
       "  'Locations': 'Hospital Federal de Bonsucesso, Rio de Janeiro, RJ, Brazil|Hospital Estadual da Criança, Rio De Janeiro, RJ, Brazil',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/29/NCT04511429/ICF_000.pdf|\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/29/NCT04511429/Prot_SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04511429'},\n",
       " {'Rank': 2407,\n",
       "  'NCT Number': 'NCT04308668',\n",
       "  'Title': 'Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2',\n",
       "  'Acronym': 'COVID-19 PEP',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine|Other: Placebo',\n",
       "  'Outcome Measures': 'Incidence of COVID19 Disease among those who are asymptomatic at baseline|Overall change in disease severity over 14 days among those who are symptomatic at baseline|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 days|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry',\n",
       "  'Sponsor/Collaborators': 'University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 1309.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'MED-2020-28673',\n",
       "  'Start Date': 'March 17, 2020',\n",
       "  'Primary Completion Date': 'May 20, 2020',\n",
       "  'Completion Date': 'May 20, 2020',\n",
       "  'First Posted': 'March 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'July 17, 2020',\n",
       "  'Locations': 'Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04308668/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04308668'},\n",
       " {'Rank': 2486,\n",
       "  'NCT Number': 'NCT04467931',\n",
       "  'Title': 'ACEI or ARB and COVID-19 Severity and Mortality in US Veterans',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Hypertension|COVID',\n",
       "  'Interventions': 'Drug: ACEI/ARB|Drug: Non-ACEI/ARB|Drug: ACEI|Drug: ARB',\n",
       "  'Outcome Measures': 'All-Cause-Hospitalization or All-Cause Mortality|All-Cause Mortality|ICU admission|Duration of hospitalization|Mechanical ventilation|Dialysis',\n",
       "  'Sponsor/Collaborators': 'University of Utah|VA Salt Lake City Health Care System|University of Pennsylvania|Wake Forest University Health Sciences|University of Florida|Johns Hopkins Bloomberg School of Public Health|Boston University|Northwestern University|Edith Nourse Rogers Memorial Veterans Hospital|Columbia University|MedStar Georgetown University Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 10000.0,\n",
       "  'Funded Bys': 'Other|U.S. Fed',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Retrospective',\n",
       "  'Other IDs': '00132408',\n",
       "  'Start Date': 'January 19, 2020',\n",
       "  'Primary Completion Date': 'October 21, 2020',\n",
       "  'Completion Date': 'December 31, 2020',\n",
       "  'First Posted': 'July 13, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 3, 2020',\n",
       "  'Locations': 'University of Utah, Salt Lake City, Utah, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/31/NCT04467931/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04467931'},\n",
       " {'Rank': 2496,\n",
       "  'NCT Number': 'NCT04518410',\n",
       "  'Title': 'ACTIV-2: A Study for Outpatients With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus|Covid19',\n",
       "  'Interventions': 'Biological: bamlanivimab|Drug: Placebo (IV)|Biological: BRII-196/BRII-198|Biological: AZD7442 (IV)|Biological: AZD7442 (IM)|Drug: SNG001|Drug: Camostat|Drug: Placebo (IM)|Drug: Placebo (Inhaled solution)|Drug: Placebo (oral tablet)|Biological: C135-LS + C144-LS|Drug: Placebo (SC injections)',\n",
       "  'Outcome Measures': 'Duration of targeted clinical COVID-19 symptoms (Phase 2)|Quantification of SARS-CoV-2 RNA (Phase 2)|Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2)|Cumulative incidence of death from any cause or hospitalization (Phase 3)|Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3)|Duration of targeted clinical COVID-19 symptoms (Phase 3)|Cumulative incidence of death from any cause or hospitalization (Phase 2)|Level of SARS-CoV-2 RNA from participant-collected nasal swabs (Phases 2 and 3)|COVID-19 symptom severity ranking (Phases 2 and 3)|Proportion of participants with ≥1 worsening symptom of COVID-19 (Phases 2 and 3)|Time to self-reported return to usual (pre-COVID-19) health (Phases 2 and 3)|Cumulative incidence of death from any cause or hospitalization (Phases 2 and 3)|Oxygen saturation level (Phase 2)|AUC of SARS-CoV-2 RNA from site-collected nasal swabs (Phases 2 and 3)|AUC of SARS-CoV-2 RNA from participant-collected nasal swabs (Phases 2 and 3)|Incidence of new adverse event (AE) ≥ Grade 2 (Phase 2)|Incidence of new adverse event (AE) ≥ Grade 3 (Phase 3)|Level (quantitative) of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)',\n",
       "  'Sponsor/Collaborators': 'National Institute of Allergy and Infectious Diseases (NIAID)|Eli Lilly and Company|AIDS Clinical Trials Group|Brii Biosciences Limited|AstraZeneca|Sagent Pharmaceuticals|Synairgen Research Ltd.|Bristol-Myers Squibb',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2|Phase 3',\n",
       "  'Enrollment': 2000.0,\n",
       "  'Funded Bys': 'NIH|Industry|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'A5401/ACTIV-2|38742',\n",
       "  'Start Date': 'August 19, 2020',\n",
       "  'Primary Completion Date': 'May 2023',\n",
       "  'Completion Date': 'May 2023',\n",
       "  'First Posted': 'August 19, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 8, 2021',\n",
       "  'Locations': \"Pinnacle Research Group (Site 1082), 321 E. 10th Street, Anniston, Alabama, United States|North Alabama Research Center LLC (Site 1194), 721 W. Market St., Ste. B, Athens, Alabama, United States|University of Alabama at Birmingham (Site 1005), 908 20th Street South, Birmingham, Alabama, United States|Cullman Clinical Trials (Site 1140), 501 Clark St. NE., Cullman, Alabama, United States|Jasper Summit Research, LLC. (Site 1056), 1280 Summit, Jasper, Alabama, United States|Absolute Clinical Research, LLC. (Site 1186), 7725 North 43rd Avenue, Ste. 211, Phoenix, Arizona, United States|University of Arizona (Site 1043), 1501 N. Campbell Ave., Rm. 6410, Tucson, Arizona, United States|Franco A. Felizarta MD (Site 1174), 3535 San Dimas St., Bakersfield, California, United States|St. Jude Heritage Medical Group (Site 1093), 2151 N. Harbor Blvd., Fullerton, California, United States|University of California San Diego (Site 1160), 9350 Campus Point Drive, Perlman Cancer Cancer, La Jolla, California, United States|Fadi A. Haddad, MD, Inc. (Site 1146), 8860 Center Dr., Ste. 320, La Mesa, California, United States|Atella Clinical Research (Site 1111), 5451 La Palma Avenue, La Palma, California, United States|Loma Linda University Health (Site 1110), 11374 Mountain View, Dover Bldg, Ste. C, Loma Linda, California, United States|University of Southern California (Site 1057), 1300 N. Mission Rd., Rm 349, Los Angeles, California, United States|UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100, Los Angeles, California, United States|Science 37, Inc. (Site 1124), 12121 Bluff Creek Dr., Ste. 100, Los Angeles, California, United States|VA Northern California Health Care System (NAVREF) (Site 1137), 10535 Hospital Way, Mather, California, United States|Central Valley Research, LLC (Site 1085), 400 E. Orangeburg Ave., Ste. 5, Modesto, California, United States|Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210, Northridge, California, United States|University of California Irvine (Site 1083), 843 Health Sciences Road, Orange, California, United States|FOMAT Medical Research (Site 1136), 300 South A Street, Oxnard, California, United States|Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive, Rancho Mirage, California, United States|Paradigm Research (Site 1150), 3652 Eureka Way, Redding, California, United States|University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd., Sacramento, California, United States|Premier Urgent Care Centers of California, Inc. (Site 1176), 284 E. Highland Ave., San Bernardino, California, United States|University of California San Diego (Site 1002), 220 Dickinson Street, San Diego, California, United States|Zion Medical Center (Site 1063), 4647 Zion Avenue, San Diego, California, United States|VA San Diego Health System (Stie 1127), 3350 La Jolla, San Diego, California, United States|University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84, San Francisco, California, United States|San Francisco Research Institute (Site 1210), 2435 Ocean Ave., San Francisco, California, United States|Stanford University (Site 1213), 1201 Welch Road, Stanford, California, United States|Office of Ramesh V. Nathan, MD (Site 1073), 2220 Lynn Rd., Ste. 301, Thousand Oaks, California, United States|Harbor UCLA (Site 1022), 1124 West Carson Street, Torrance, California, United States|Allianz Research Institute Inc. (Site 1159), 14120 Beach Blvd., Ste. 101, Westminster, California, United States|University of Colorado (Site 1007), 12401 East 17th Avenue, Aurora, Colorado, United States|UConn - Institute for Collaboration on Health (Site 1169), 2006 Hillside Rd., Unit 1248, Storrs, Connecticut, United States|Whitman-Walker Health (Site 1027), 1337 R Street NW., Washington, District of Columbia, United States|Bradenton Research Center Inc. (Site 1109), 3924 9th Ave. W, Bradenton, Florida, United States|Synergy Healthcare (Site 1099), 300 Riverside Drive E., Ste. 1350, Bradenton, Florida, United States|Midland Florida Clinical Research Center LLC (Site 1130), 665 Peachwood Drive, DeLand, Florida, United States|Universal Axon Clinical Research (Site 1077), 3650 NW 82nd Ave., Doral, Florida, United States|Holy Cross Health (Site 1072), 4725 North Federal Highway, Fort Lauderdale, Florida, United States|NW FL Clinical Research Group, LLC. (Site 1046), 400 Gulf Breeze Parkway, Gulf Breeze, Florida, United States|Indago Research and Health Center (Site 1050), 3700 W. 12th Ave., Ste. 300, Hialeah, Florida, United States|AGA Clinical Trials (Site 1026), 900 West 49th Street, Hialeah, Florida, United States|Community Research of South Florida (Site 1197), 7100 W. 20th Ave., Ste. 403, Hialeah, Florida, United States|New Generation Medical Research (Site 1204), 7600 W. 20th Ave., Ste. 106, Hialeah, Florida, United States|Innovative Health Medical Center (Site 1222), 6750 Taft Street, Hollywood, Florida, United States|University of Florida Jacksonville (Site 1039), 655 West 8th Street, Jacksonville, Florida, United States|QC Trials (Site 1117), 300 W. 41st Street, Ste. 203, Miami Beach, Florida, United States|Lakes Research (Site 1037), 5801 NW 151 Street, Miami Lakes, Florida, United States|Savin Medical Group, LLC. (Site 1212), 5789B NW. 151st Street, Miami Lakes, Florida, United States|Amber Clinical Research, LLC. (Site 1206), 9000 NE. 2nd Avenue, Miami Shores, Florida, United States|Advance Medical Research Center (Site 1193) 330 SW. 27th Ave., Ste. 701, Miami, Florida, United States|D&H National Research Centers (Site 1205), 8485 Bird Road, Miami, Florida, United States|Allied Biomedical Research Institute (Site 1227), 7100 SW. 47th St., Ste. 220, Miami, Florida, United States|Miami Clinical Research (Site 1089), 2400 SW. 69th Ave., Miami, Florida, United States|RM Medical Research, Inc. (Site 1230), 10346 W. Flagler St., Miami, Florida, United States|Pro Live Medical Research Corp (Site 1219), 12781 SW. 42nd Street, Miami, Florida, United States|Orlando Immunology Center (Site 1045), 1707 North Mills Avenue, Orlando, Florida, United States|Clintheory (Site 1203), 7350 Sandlake Commons Blvd., Orlando, Florida, United States|IMIC, Inc. (Site 1141), 18320 Franjo Rd, Palmetto Bay, Florida, United States|Family Clinical Trials (Site 1236), 1601 N. Palm Ave., Ste. 102, Pembroke Pines, Florida, United States|ETNA Medical Center (Site 1225), 7401 N. University Drive, Tamarac, Florida, United States|Moore Clinical Research, Inc. (Site 1164), 4257 W. Kennedy Blvd., Tampa, Florida, United States|Tampa General Hospital Family Care Center Healthpark (Site 1088), 5802 N. 30th Street, Tampa, Florida, United States|Infectious Disease Consultants of the Treasure Coast (Site 1171), 3735 11th Cir., Ste. 201, Vero Beach, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast (Site 1095), 981 37th Place, Vero Beach, Florida, United States|Triple O Research Institute PA (Site 1121), 2580 Metrocentre Blvd., Ste. 4, West Palm Beach, Florida, United States|The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast, Atlanta, Georgia, United States|Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive, Atlanta, Georgia, United States|IACT Health (Site 1035), 800 Talbotton Road, Columbus, Georgia, United States|Renew Health Clinical Research, LLC. (Site 1161), 1550 Janmar Rd., Snellville, Georgia, United States|Snake River Research, PLLC (Site 1120), 2900 Cortez Ave., Idaho Falls, Idaho, United States|Metro Infectious Disease Consultants (Site 1106), 901 McClintock Dr., Ste. 201, Burr Ridge, Illinois, United States|Chicago Clinical Research Institute (Site 1132), 611 W. Roosevelt Rd., Chicago, Illinois, United States|Northwestern University (Site 1025), 645 North Michigan Ave, Chicago, Illinois, United States|Rush University Medical Center (Site 1017), 600 Paulina St., Chicago, Illinois, United States|University of Chicago (Site 1064), 5841 S. Maryland Ave., Chicago, Illinois, United States|Great Lakes Clinical Trials (Site 1049), 5149 N. Ashland Ave., Chicago, Illinois, United States|Roudebush VA Medical Center (Site 1217), 550 University Blvd, Indianapolis, Indiana, United States|University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard, Kansas City, Kansas, United States|MedPharmics (Site 1065), 3800 Houma Blvd., Metairie, Louisiana, United States|New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center (Site 1153), 2000 Canal Street, New Orleans, Louisiana, United States|Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States|Walter Reed Army Institute of Research (Site 1118), 503 Robert Grant Ave., Silver Spring, Maryland, United States|Massachusetts General Hospital (Site 1016), 55 Fruit Street, Boston, Massachusetts, United States|Brigham and Women's Hospital - Therapeutics Clinical Research Site (Site 1023), 75 Francis Street, Boston, Massachusetts, United States|University of Massachusetts Medical School (Site 1054), 55 Lake Avenue N., Worcester, Massachusetts, United States|Memorial Hospital at Gulfport (Site 1104), 4500 13th Street, Gulfport, Mississippi, United States|MedPharmics, LLC. (Site 1032), 15190 Community Rd., Gulfport, Mississippi, United States|Hannibal Clinic (Site 1129), 100 Medical Drive, Hannibal, Missouri, United States|Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital (Site 1115), 931 Highland Blvd, Ste. 3103, Bozeman, Montana, United States|Mercury Street Medical Group (Site 1074), 300 W. Mercury St., Butte, Montana, United States|Quality Clinical Research (Site 1112), 10040 Regency Circle, Omaha, Nebraska, United States|Las Vegas Medical Research (Site 1048), 8530 W. Sunset Rd., Las Vegas, Nevada, United States|Lincoln Hospital (Site 1092), 249 East 149th Street, Bronx, New York, United States|Jacobi Medical Center (Site 1105), 1400 Pelham Parkway South, Bronx, New York, United States|James J. Peters VA Medical Center (Site 1053), 130 West Kingsbridge Road, Bronx, New York, United States|Maimonides Medical Center (Site 1138), 4802 10th Avenue, Brooklyn, New York, United States|University at Buffalo, Emergency Medicine (Site 1172), 77 Goodell Street, Buffalo, New York, United States|Flushing Hospital Medical Center (Site 1067), 4500 Parsons Blvd, Flushing, New York, United States|Jamaica Hospital Medical Center (Site 1066), 8900 Van Wyck Expressway, Jamaica, New York, United States|Columbia Partnership for Prevention and Control of HIV/AIDS CTU (Site 1019), Columbia University Irving Medical Center, Department of Medicine - Division of Infectious Diseases, 180 Fort Washington Avenue, HP6 - Rm 604, New York, New York, United States|Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street, New York, New York, United States|Canton-Potsdam Hospital (Site 1076), 50 Leroy Street, Potsdam, New York, United States|University of Rochester (Site 1010), 601 Elmwood Ave, Rochester, New York, United States|SUNY Stony Brook NICHD (Site 1094), HSC L-02, Rm. 142 C, Stony Brook, New York, United States|University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor, Chapel Hill, North Carolina, United States|Carolina Clinical Research (Site 1167), 9040 Nations Ford Rd., Charlotte, North Carolina, United States|Duke University Medical Center (Site 1041), 40 Duke Medicine Circle, Durham, North Carolina, United States|Wake Forest University Health Sciences (Site 1038), 1 Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Health (Site 1084), 801 Broadway N., Fargo, North Dakota, United States|The Christ Hospital (Site 1119), 2123 Auburn Avenue, Cincinnati, Ohio, United States|Case Western Reserve University (Site 1033), 2061 Cornell Road, Cleveland, Ohio, United States|MetroHealth Medical Center (Site 1195), 2500 Metrohealth Dr., Cleveland, Ohio, United States|Ohio State University Medical Center (Site 1020), 480 Medical Center Drive, Columbus, Ohio, United States|Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way, Ohio City, Ohio, United States|STAT Research (Site 1107), 66 Remick Blvd., Springboro, Ohio, United States|Ascension St. John Clinical Research Institute (Site 1090), 1725 East 19th Street, Tulsa, Oklahoma, United States|Kaiser Permanente Center for Health Research (Site 1079), 3800 N. Interstate Ave., Portland, Oregon, United States|Doylestown Hospital (Site 1122), 595 W. State Street, Doylestown, Pennsylvania, United States|University of Pennsylvania (Site 1031), 3400 Spruce Street, Philadelphia, Pennsylvania, United States|The University of Pittsburgh (Site 1018), 3471 5th Ave., Pittsburgh, Pennsylvania, United States|Veterans Affairs Pittsburgh Healthcare System (Site 1070), University Drive C., Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (1142), 164 Summit Avenue, Providence, Rhode Island, United States|Medtrial, LLC (Site 1134), 1718 Saint Julian Pl., Ste. 2, Columbia, South Carolina, United States|American Indian Clinical Trials Research Network (Site 1148), 717 Meade Street, Rapid City, South Dakota, United States|Sanford USD Medical Center (Site 1078), 1305 W. 18th St., Sioux Falls, South Dakota, United States|Clinical Trials Center of Middle Tennessee (Site 1183), 100 Covey Drive, Franklin, Tennessee, United States|Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183, Nashville, Tennessee, United States|Saint Hope Foundation Inc. (Site 1100), 6800 West Loop Street, Ste. 560, Bellaire, Texas, United States|PanAmerican Clinical Research, LLC. (Site 1069), 1416 Palm Blvd., Brownsville, Texas, United States|Trinity Health and Wellness Center (Site 1030), 219 Sunset Avenue, Dallas, Texas, United States|Doctors Hospital at Renaissance Health Institute for Research and Development (Site 1145), 5323 S. McColl Rd., Edinburg, Texas, United States|Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive, Galveston, Texas, United States|Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street, Houston, Texas, United States|University of Texas Health Science Center at Houston (Site 1055), 6431 Fannin Street, Ste. 2.112, Houston, Texas, United States|Houston Methodist Hospital (Site 1123), 6565 Fannin Street, Houston, Texas, United States|Dynamic Medical Research Group (Site 1081), 8314 Southwest Fwy, Houston, Texas, United States|Fairway Medical Clinic (Site 1156), 4910 Telephone Road, Houston, Texas, United States|SMS Clincial Research, LLC. (Site 1060), 1210 N. Galloway Ave., Mesquite, Texas, United States|Epic Medical Research, LLC (Site 1233), 106 Plaza Drive, Red Oak, Texas, United States|Inova Fairfax Medical Campus (Site 1029), 3300 Gallows Road, Falls Church, Virginia, United States|Clinical Research Partners LLC (Site 1196), 7110 Forest Ave., Ste. 201, Richmond, Virginia, United States|EvergreenHealth (Site 1080), 12040 NE 128th Street, Ste MS-77, Kirkland, Washington, United States|University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave., Seattle, Washington, United States|Providence Medical Research Center (Site 1075), 105 W. 8th Ave., Ste. 6050W, Spokane, Washington, United States|Hershel Woody Williams VA Medical Center (Site 1128), 1540 Spring Valley Drive, Huntington, West Virginia, United States|West VA University, Mary Babb Randolph Cancer Center (Site 1178), 1 Medical Center Drive, Morgantown, West Virginia, United States|Medical College of Wisconsin, Inc. (Site 1036), 8701 Watertown Plank Road, Milwaukee, Wisconsin, United States|Allegiance Research Specialists (Site 1162), 2645 N. Mayfair Rd., Ste. 200, Wauwatosa, Wisconsin, United States|Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II, San Juan, Puerto Rico\",\n",
       "  'Study Documents': '\"Informed Consent Form: Main ICF\", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04518410/ICF_000.pdf|\"Informed Consent Form: Multiple Study Drugs ICF\", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04518410/ICF_001.pdf|\"Informed Consent Form: Optional Extra Samples ICF\", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04518410/ICF_002.pdf|\"Informed Consent Form: Study Drug LY3819253 (Bamlanivimab) ICF\", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04518410/ICF_003.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04518410'},\n",
       " {'Rank': 2524,\n",
       "  'NCT Number': 'NCT04419610',\n",
       "  'Title': 'RAS and Coagulopathy in COVID19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID',\n",
       "  'Interventions': 'Biological: TRV027|Other: sodium chloride 0.9%',\n",
       "  'Outcome Measures': 'Coagulopathy associated with COVID-19|Markers of dysregulation of coagulation system|Markers of dysregulation of RAS|Markers of Haemolysis/inflammation|Markers of Haemolysis/Inflammation|Markers of Inflammation (bacterial sepsis)|Markers of organ dysregulation - kidney|Markers of dysregulation of cardiovascular system|marker of dysregulation of endocrine system',\n",
       "  'Sponsor/Collaborators': 'Imperial College London',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Early Phase 1',\n",
       "  'Enrollment': 60.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Health Services Research',\n",
       "  'Other IDs': '283093',\n",
       "  'Start Date': 'October 9, 2020',\n",
       "  'Primary Completion Date': 'April 1, 2021',\n",
       "  'Completion Date': 'June 2021',\n",
       "  'First Posted': 'June 5, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 19, 2021',\n",
       "  'Locations': 'Imperial College NHS Trust, London, United Kingdom',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04419610/Prot_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04419610'},\n",
       " {'Rank': 2633,\n",
       "  'NCT Number': 'NCT04390022',\n",
       "  'Title': 'Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial',\n",
       "  'Acronym': 'SAINT',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Covid-19|Coronavirus Infection|SARS-CoV-2 Infection',\n",
       "  'Interventions': 'Drug: Ivermectin|Drug: Placebo',\n",
       "  'Outcome Measures': 'Proportion of Patients With a Positive SARS-CoV-2 PCR|Median Viral Load|Fever and Cough Progression|Seroconversion at Day 21|Proportion of Drug-related Adverse Events|Levels of IgG, IgM and IgA|Frequency of Innate Immune Cells|Frequency SARS-CoV-2-specific CD4+ T and and CD8+ T Cells|Results From Cytokine Human Magnetic 30-Plex Panel',\n",
       "  'Sponsor/Collaborators': 'Clinica Universidad de Navarra, Universidad de Navarra|Barcelona Institute for Global Health',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 59 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 24.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'SAINT',\n",
       "  'Start Date': 'July 31, 2020',\n",
       "  'Primary Completion Date': 'September 17, 2020',\n",
       "  'Completion Date': 'October 9, 2020',\n",
       "  'First Posted': 'May 15, 2020',\n",
       "  'Results First Posted': 'December 17, 2020',\n",
       "  'Last Update Posted': 'December 17, 2020',\n",
       "  'Locations': 'Clinica Universidad de Navarra, Pamplona, Navarra, Spain',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04390022/SAP_000.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/22/NCT04390022/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04390022'},\n",
       " {'Rank': 2656,\n",
       "  'NCT Number': 'NCT04465474',\n",
       "  'Title': 'Coronavirus Disease 2019 (COVID-19) During Pregnancy: Prevalence of Seroconversion, Effect on Maternal and Perinatal Outcomes and Risk of Vertical Transmission (COVID-MAP)',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Other: Non Intervention',\n",
       "  'Outcome Measures': 'Seroconversion during pregnancy - DSS1|Seroconversion during pregnancy - At delivery|Pregnancy loss|Pregnancy course and perinatal outcome|Vertical transmission|Potential mechanisms for vertical transmission 1) placental barrier, 2) immune response and 3) fetal damage of vertical transmission and mechanism in SARS-CoV-2 infection.',\n",
       "  'Sponsor/Collaborators': 'Chinese University of Hong Kong|Peking University First Hospital|Hospital Universitario de Torrejón|Queen Mary Hospital, Hong Kong|Pamela Youde Nethersole Eastern Hospital|Queen Elizabeth Hospital, Hong Kong|United Christian Hospital|Kwong Wah Hospital|Princess Margaret Hospital, Hong Kong|Tuen Mun Hospital',\n",
       "  'Gender': 'Female',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 3000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Other|Time Perspective: Other',\n",
       "  'Other IDs': 'COVID-MAP',\n",
       "  'Start Date': 'May 1, 2020',\n",
       "  'Primary Completion Date': 'April 30, 2022',\n",
       "  'Completion Date': 'December 31, 2022',\n",
       "  'First Posted': 'July 10, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 27, 2021',\n",
       "  'Locations': 'Peking University First Hospital, Beijing, Beijing, China|Kwong Wah Hospital, Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|United Christian Hospital, Hong Kong, Hong Kong|Hospital Universitario de Torrejón, Torrejón De Ardoz, Madrid, Spain',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/74/NCT04465474/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04465474'},\n",
       " {'Rank': 2685,\n",
       "  'NCT Number': 'NCT04358081',\n",
       "  'Title': 'Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Covid-19',\n",
       "  'Interventions': 'Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo',\n",
       "  'Outcome Measures': 'Number of Participants Who Achieved Clinical Response by Day 15|Number of Participants Who Achieved Viral Clearance|Number of Participants Discharged or Ready for Discharge|Time to Return to Pre-morbid Supplemental Oxygen Requirement in Participants Receiving Hydrochloroquine or Hydrochloroquine Plus Azithromycin Relative to Placebo',\n",
       "  'Sponsor/Collaborators': 'Novartis Pharmaceuticals|Novartis',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 20.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'CJWT629A12301',\n",
       "  'Start Date': 'May 1, 2020',\n",
       "  'Primary Completion Date': 'July 27, 2020',\n",
       "  'Completion Date': 'July 27, 2020',\n",
       "  'First Posted': 'April 22, 2020',\n",
       "  'Results First Posted': 'March 17, 2021',\n",
       "  'Last Update Posted': 'April 2, 2021',\n",
       "  'Locations': 'Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04358081/Prot_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04358081/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04358081'},\n",
       " {'Rank': 2723,\n",
       "  'NCT Number': 'NCT04441424',\n",
       "  'Title': 'Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'IMMUNOTHERAPY',\n",
       "  'Interventions': 'Biological: Convalescent plasma|Drug: Hydroxychloroquin with Azithromycin',\n",
       "  'Outcome Measures': 'Death versus survival of treated patients|The length of stay in hospitals',\n",
       "  'Sponsor/Collaborators': 'Alkarkh Health Directorate-Baghdad',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 49.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'CPT-COVID-19',\n",
       "  'Start Date': 'April 3, 2020',\n",
       "  'Primary Completion Date': 'June 1, 2020',\n",
       "  'Completion Date': 'June 1, 2020',\n",
       "  'First Posted': 'June 22, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 23, 2020',\n",
       "  'Locations': 'Akarkh Healt hdirectorate, Baghdad, Iraq',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04441424/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04441424'},\n",
       " {'Rank': 2777,\n",
       "  'NCT Number': 'NCT04280705',\n",
       "  'Title': 'Adaptive COVID-19 Treatment Trial (ACTT)',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Other: Placebo|Drug: Remdesivir',\n",
       "  'Outcome Measures': 'Time to Recovery|Change From Baseline in Alanine Transaminase (ALT)|Change From Baseline in Aspartate Transaminase (AST)|Change From Baseline in Creatinine|Change From Baseline in Glucose|Change From Baseline in Hemoglobin|Change From Baseline in Platelets|Change From Baseline in Prothrombin Time (PT)|Change From Baseline in Total Bilirubin|Change From Baseline in White Blood Cell Count (WBC)|Change From Baseline in Neutrophils|Change From Baseline in Lymphocytes|Change From Baseline in Monocytes|Change From Baseline in Basophils|Change From Baseline in Eosinophils|Change in National Early Warning Score (NEWS) From Baseline|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22|Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29|Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)|Percentage of Participants Reporting Serious Adverse Events (SAEs)|Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics|Duration of Hospitalization|Duration of New Non-invasive Ventilation or High Flow Oxygen Use|Duration of New Oxygen Use|Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use|Percentage of Participants Requiring New Oxygen Use|Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use|Mean Change in the Ordinal Scale|14-day Participant Mortality|29-day Participant Mortality|Time to an Improvement by at Least One Category Using an Ordinal Scale|Time to an Improvement of at Least Two Categories Using an Ordinal Scale|Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First',\n",
       "  'Sponsor/Collaborators': 'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 99 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 1062.0,\n",
       "  'Funded Bys': 'NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '20-0006',\n",
       "  'Start Date': 'February 21, 2020',\n",
       "  'Primary Completion Date': 'May 21, 2020',\n",
       "  'Completion Date': 'May 21, 2020',\n",
       "  'First Posted': 'February 21, 2020',\n",
       "  'Results First Posted': 'September 25, 2020',\n",
       "  'Last Update Posted': 'December 9, 2020',\n",
       "  'Locations': \"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece|Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom|John Radcliffe Hospital, Headington, Oxford, United Kingdom\",\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/ICF_000.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/Prot_001.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04280705/SAP_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04280705'},\n",
       " {'Rank': 2837,\n",
       "  'NCT Number': 'NCT04435808',\n",
       "  'Title': 'Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Terminated',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine',\n",
       "  'Outcome Measures': 'SARS-CoV-2 Infection|Symptomatic vs. Asymptomatic Infection With SARS-CoV-2|Occupational Health Exposure|Impact of Hydroxychloroquine Use on Need for Hospitalization With SARS-CoV-2 Infection|Impact of Hydroxychloroquine Use on Need for ICU Care With SARS-CoV-2 Infection|Adverse Effect Profile of Hydroxychloroquine|Seroconversion Following SARS-CoV-2 Infection|Metagenomic Next Generation Sequencing of SARS-CoV-2 Isolates',\n",
       "  'Sponsor/Collaborators': 'University of New Mexico',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 1|Phase 2',\n",
       "  'Enrollment': 1.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '20-206',\n",
       "  'Start Date': 'April 14, 2020',\n",
       "  'Primary Completion Date': 'July 15, 2020',\n",
       "  'Completion Date': 'July 15, 2020',\n",
       "  'First Posted': 'June 17, 2020',\n",
       "  'Results First Posted': 'November 16, 2020',\n",
       "  'Last Update Posted': 'November 16, 2020',\n",
       "  'Locations': 'University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04435808/ICF_000.pdf|\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04435808/Prot_SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04435808'},\n",
       " {'Rank': 2858,\n",
       "  'NCT Number': 'NCT04713878',\n",
       "  'Title': 'Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus Disease 2019 (COVID-19) Pneumonia',\n",
       "  'Interventions': 'Other: Mesenchymal stem cells',\n",
       "  'Outcome Measures': 'Change of clinical symptoms as respiratory distress or need for oxygen support|Change of cytokine storm parameters|Change of pulmonary functions|Change of clinical symptoms',\n",
       "  'Sponsor/Collaborators': 'Kanuni Sultan Suleyman Training and Research Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 90 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 21.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '2020.05.20',\n",
       "  'Start Date': 'May 8, 2020',\n",
       "  'Primary Completion Date': 'June 30, 2020',\n",
       "  'Completion Date': 'July 15, 2020',\n",
       "  'First Posted': 'January 19, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 20, 2021',\n",
       "  'Locations': 'University of Health Sciences, Istanbul, Turkey',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04713878/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04713878'},\n",
       " {'Rank': 2885,\n",
       "  'NCT Number': 'NCT04437121',\n",
       "  'Title': 'Dietary and Lifestyle Habits During the Pandemic of COVID-19 in Greece',\n",
       "  'Acronym': 'COV-EAT',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Eating Behavior|COVID-19',\n",
       "  'Interventions': 'Other: Online Survey about Dietary and Lifestyle Habits',\n",
       "  'Outcome Measures': 'Change in weight (child)|Behaviour (child)|Behaviour (parents)|Physical Activity Levels (child)|Screen Time (child)|Sleep Duration (child)',\n",
       "  'Sponsor/Collaborators': 'University of Thessaly',\n",
       "  'Gender': 'All',\n",
       "  'Age': '24 Months to 18 Years \\xa0 (Child, Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 397.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Crossover|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': 'COV-EAT',\n",
       "  'Start Date': 'April 30, 2020',\n",
       "  'Primary Completion Date': 'May 24, 2020',\n",
       "  'Completion Date': 'May 24, 2020',\n",
       "  'First Posted': 'June 18, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 18, 2020',\n",
       "  'Locations': 'Department of Nutrition-Dietetics, Tríkala, Thessaly, Greece',\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/21/NCT04437121/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04437121'},\n",
       " {'Rank': 2955,\n",
       "  'NCT Number': 'NCT04410159',\n",
       "  'Title': 'Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients',\n",
       "  'Acronym': 'GARGLES',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Povidone-Iodine|Drug: Essential oils|Other: Tap water',\n",
       "  'Outcome Measures': 'Number of Participants With Early Viral Clearance|Number of Participants With Negative RT-PCR Results|Number of Patients That Progress to More Severe Disease|Number of Patients With Abnormal Radiological Findings|Number of Patients With Abnormal Laboratory Findings',\n",
       "  'Sponsor/Collaborators': 'Universiti Sains Islam Malaysia|Universiti Kebangsaan Malaysia Medical Centre',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 20.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'USIMalaysia',\n",
       "  'Start Date': 'June 22, 2020',\n",
       "  'Primary Completion Date': 'June 29, 2020',\n",
       "  'Completion Date': 'July 6, 2020',\n",
       "  'First Posted': 'June 1, 2020',\n",
       "  'Results First Posted': 'July 21, 2020',\n",
       "  'Last Update Posted': 'July 21, 2020',\n",
       "  'Locations': 'Universiti Kebangsaan Malaysia Medical Centre, Bandar Tun Razak, Wilayah Persekutuan Kuala Lumpur, Malaysia',\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/59/NCT04410159/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04410159'},\n",
       " {'Rank': 2991,\n",
       "  'NCT Number': 'NCT04403035',\n",
       "  'Title': 'Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid-19',\n",
       "  'Interventions': 'Diagnostic Test: ID NOW vs. Accula',\n",
       "  'Outcome Measures': 'Test characteristics',\n",
       "  'Sponsor/Collaborators': 'Ascension South East Michigan',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 95 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 100.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '1599159',\n",
       "  'Start Date': 'May 10, 2020',\n",
       "  'Primary Completion Date': 'July 1, 2020',\n",
       "  'Completion Date': 'May 9, 2021',\n",
       "  'First Posted': 'May 27, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'July 9, 2020',\n",
       "  'Locations': 'Ascension St. John Hospital, Detroit, Michigan, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04403035/Prot_SAP_002.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04403035/ICF_003.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04403035'},\n",
       " {'Rank': 2999,\n",
       "  'NCT Number': 'NCT04292899',\n",
       "  'Title': 'Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Remdesivir|Drug: Standard of Care',\n",
       "  'Outcome Measures': 'Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 14|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)',\n",
       "  'Sponsor/Collaborators': 'Gilead Sciences',\n",
       "  'Gender': 'All',\n",
       "  'Age': '12 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 4891.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'GS-US-540-5773|2020-000841-15|ISRCTN15874265',\n",
       "  'Start Date': 'March 6, 2020',\n",
       "  'Primary Completion Date': 'April 9, 2020',\n",
       "  'Completion Date': 'June 30, 2020',\n",
       "  'First Posted': 'March 3, 2020',\n",
       "  'Results First Posted': 'December 31, 2020',\n",
       "  'Last Update Posted': 'December 31, 2020',\n",
       "  'Locations': \"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom|Royal Infirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom\",\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/Prot_000.pdf|\"Statistical Analysis Plan: Part A\", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/SAP_001.pdf|\"Statistical Analysis Plan: Part B\", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04292899/SAP_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04292899'},\n",
       " {'Rank': 3027,\n",
       "  'NCT Number': 'NCT04372199',\n",
       "  'Title': 'SEVERITY SCORE FOR COVID-19 PNEUMONIA',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID|Pneumonia',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'To identify the best predictors of critical coronavirus pneumonia and to realize a simple severity score able to early classify high-risk individuals admitted to Internal Medicine Department for COVID-19 disease, needing an intensive approach',\n",
       "  'Sponsor/Collaborators': 'Fondazione Policlinico Universitario Agostino Gemelli IRCCS',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 248.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '3112',\n",
       "  'Start Date': 'April 29, 2020',\n",
       "  'Primary Completion Date': 'May 27, 2020',\n",
       "  'Completion Date': 'May 27, 2020',\n",
       "  'First Posted': 'May 1, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'May 1, 2020',\n",
       "  'Locations': 'Massimo Montalto, Roma, Italy',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/99/NCT04372199/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04372199'},\n",
       " {'Rank': 3041,\n",
       "  'NCT Number': 'NCT04794062',\n",
       "  'Title': 'Myocardial Injury and Quality of Life After COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19|Myocardial Injury|Myocarditis Post Infection',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Proportion of patients (%) recovered from COVID-19 with signs of myocardial injury on cardiac magnetic resonance imaging.|Proportion of patients (%) recovered from COVID-19 with signs of myocardial injury on echocardiography.|Evaluation of quality of life of the patients recovered from the COVID-19 by the means of EQ-5D questionnaire.|Evaluation of quality of life of the patients recovered from the COVID-19 by the means of EQ-5D visual analogue scale.|Evaluation of quality of life of the patients recovered from the COVID-19 by the Duke Activity Status Index.',\n",
       "  'Sponsor/Collaborators': 'Voronezh Regional Clinical Consultative and Diagnostic Center|Voronezh State Medical University named after N.N. Burdenko|Charles University, Czech Republic',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 100.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '08092020',\n",
       "  'Start Date': 'September 16, 2020',\n",
       "  'Primary Completion Date': 'March 31, 2021',\n",
       "  'Completion Date': 'December 31, 2021',\n",
       "  'First Posted': 'March 11, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 11, 2021',\n",
       "  'Locations': 'Voronezh Region Clinical, Consultative and Diagnostic Center, Voronezh, Voronezh Region, Russian Federation',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04794062/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04794062/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04794062'},\n",
       " {'Rank': 3046,\n",
       "  'NCT Number': 'NCT04292730',\n",
       "  'Title': 'Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Remdesivir|Drug: Standard of Care',\n",
       "  'Outcome Measures': 'Part A: Percentage of Participants in Each Clinical Status Category as Assessed by a 7-Point Ordinal Scale on Day 11|Part A: Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)',\n",
       "  'Sponsor/Collaborators': 'Gilead Sciences',\n",
       "  'Gender': 'All',\n",
       "  'Age': '12 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 1113.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'GS-US-540-5774|2020-000842-32|ISRCTN85762140',\n",
       "  'Start Date': 'March 15, 2020',\n",
       "  'Primary Completion Date': 'April 29, 2020',\n",
       "  'Completion Date': 'June 26, 2020',\n",
       "  'First Posted': 'March 3, 2020',\n",
       "  'Results First Posted': 'January 26, 2021',\n",
       "  'Last Update Posted': 'January 26, 2021',\n",
       "  'Locations': \"Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Alta Bates Summit Medical Center, Berkeley, California, United States|Mills-Peninsula Medical Center, Burlingame, California, United States|Eden Medical Center, Castro Valley, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Mission Hospital Regional Medical Center, Mission Viejo, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|El Camino Hospital, Mountain View, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Riverside, California, United States|Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 2425 Geary Blvd, San Francisco, California, United States|Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States|Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States|SCL Health St. Joseph Hospital, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States|Yale University, New Haven, Connecticut, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States|St. Joseph's University Medical Center, Paterson, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States|The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|University of Utah Health, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|CHU Pellegrin, Bordeaux, France|CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France|CHU de Nantes-Hotel Dieu, Nantes, France|Hopital Saint-Louis, Paris, France|Hopital Saint Antoine, Paris, France|Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Klinik für Hämatologie, Onkologie, Immunologie, München, Germany|Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy|Yokohama Municipal Citizen's Hospital, Kanagawa, Japan|Nagoya City East Medical Center, Nagoya, Japan|Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden|SUS (Skanes University Hospital), Malmo, Sweden|Karolinska University Hospital, Stockholm, Sweden|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Imperial College NHS Trust, London, Greater London, United Kingdom|NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom|Royal Lancaster Hospital, Lancaster, United Kingdom|Liverpool University Hospital, Liverpool, United Kingdom|Northwick Park Hospital, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|King's College Hospital NHS Trust, London, United Kingdom|University College London, London, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom\",\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/Prot_000.pdf|\"Statistical Analysis Plan: GS-US-540-5774-appendix-16.1.9-SAP part A_f-redact\", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/SAP_001.pdf|\"Statistical Analysis Plan: GS-US-540-5774-appendix-16.1.9-SAP part B_f-redact\", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04292730/SAP_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04292730'},\n",
       " {'Rank': 3069,\n",
       "  'NCT Number': 'NCT04328441',\n",
       "  'Title': 'Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine',\n",
       "  'Acronym': 'BCG-CORONA',\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: BCG Vaccine|Drug: Placebo',\n",
       "  'Outcome Measures': 'Health Care Workers absenteeism|the cumulative incidence of documented COVID-19|the cumulative incidence of Hospital Admission due to documented COVID-19|the number of days of unplanned absenteeism, because of documented COVID-19|the cumulative incidence of self-reported acute respiratory symptoms or fever|the cumulative incidence of death due to documented COVID-19|the cumulative incidence of Intensive Care Admission due to documented COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of exposure to COVID-19|the number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented COVID-19|the number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|the number of days of self-reported fever (≥38 gr C)|the cumulative incidence of self-reported fever (≥38 gr C)|the number of days of self-reported acute respiratory symptoms|the cumulative incidence of self-reported acute respiratory symptoms|the cumulative incidence of death for any reason|the cumulative incidence of Intensive Care Admission for any reason|the cumulative incidence of Hospital Admission for any reason|the cumulative incidence and magnitude of plasma/serum antibodies (IgA,M,G) and SARS-CoV-2-specific antibodies at 12 weeks after vaccination and at the end of the study period',\n",
       "  'Sponsor/Collaborators': 'UMC Utrecht|Radboud University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 1500.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'NL73249.041.20',\n",
       "  'Start Date': 'March 25, 2020',\n",
       "  'Primary Completion Date': 'March 31, 2021',\n",
       "  'Completion Date': 'April 30, 2021',\n",
       "  'First Posted': 'March 31, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 19, 2020',\n",
       "  'Locations': 'Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/41/NCT04328441/SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04328441'},\n",
       " {'Rank': 3124,\n",
       "  'NCT Number': 'NCT04841681',\n",
       "  'Title': 'Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Distress, Emotional',\n",
       "  'Interventions': 'Behavioral: Video-based Psychotherapy',\n",
       "  'Outcome Measures': 'Change from Baseline Subjective Units of Distress (SUDS) at Right After Receiving Video-based Psychotherapy',\n",
       "  'Sponsor/Collaborators': 'Indonesia University|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 42.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care',\n",
       "  'Other IDs': '20-05-0546',\n",
       "  'Start Date': 'June 7, 2020',\n",
       "  'Primary Completion Date': 'August 25, 2020',\n",
       "  'Completion Date': 'August 26, 2020',\n",
       "  'First Posted': 'April 12, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 12, 2021',\n",
       "  'Locations': 'dr. Cipto Mangunkusumo National General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/81/NCT04841681/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04841681'},\n",
       " {'Rank': 3159,\n",
       "  'NCT Number': 'NCT04422561',\n",
       "  'Title': 'Prophylactic Ivermectin in COVID-19 Contacts',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID',\n",
       "  'Interventions': 'Drug: Ivermectin Tablets',\n",
       "  'Outcome Measures': 'Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)|Development of COVID',\n",
       "  'Sponsor/Collaborators': 'Zagazig University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '16 Years to 70 Years \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2|Phase 3',\n",
       "  'Enrollment': 340.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'ZU-IRB#6150/31-5-2020',\n",
       "  'Start Date': 'May 31, 2020',\n",
       "  'Primary Completion Date': 'July 14, 2020',\n",
       "  'Completion Date': 'July 27, 2020',\n",
       "  'First Posted': 'June 9, 2020',\n",
       "  'Results First Posted': 'August 27, 2020',\n",
       "  'Last Update Posted': 'August 27, 2020',\n",
       "  'Locations': 'Zagazig University, Zagazig, Sharkia, Egypt',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04422561'},\n",
       " {'Rank': 3174,\n",
       "  'NCT Number': 'NCT04407468',\n",
       "  'Title': 'Awake Prone Positioning and Oxygen Therapy in Patients With COVID-19',\n",
       "  'Acronym': 'APRONOX',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID|ARDS|Pneumonia',\n",
       "  'Interventions': 'Procedure: Prone position',\n",
       "  'Outcome Measures': 'To analyze the relationship between the prone position and the need for orotracheal intubation.|The impact of the prone position on the partial oxygen saturation / inspired oxygen fraction index (SaO2 / FiO2).',\n",
       "  'Sponsor/Collaborators': 'Hospital General San Juan del Rio|Instituto Nacional de Cancerologia de Mexico',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 827.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Retrospective',\n",
       "  'Other IDs': '1178/SESEQ-HSGJR/08-05-20/UTI',\n",
       "  'Start Date': 'May 1, 2020',\n",
       "  'Primary Completion Date': 'July 13, 2020',\n",
       "  'Completion Date': 'July 13, 2020',\n",
       "  'First Posted': 'May 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'July 15, 2020',\n",
       "  'Locations': 'Hospital Materno Celaya, Celaya, Guanajuato, Mexico|Hospital Santo Tomas, Querétaro City, Queretaro, Mexico|Hospital General San Juan del Rio, Querétaro City, Queretaro, Mexico|ISSSTE Hospital Regional Merida, Mérida, Yucatan, Mexico|Hospital General de Zona 48 San PEDRO Xalpa IMSS, Estado De México, Mexico|Hospital Fernando Quiroz Gutierrez, Mexico City, Mexico',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04407468/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04407468'},\n",
       " {'Rank': 3277,\n",
       "  'NCT Number': 'NCT04425863',\n",
       "  'Title': 'Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19',\n",
       "  'Acronym': 'IDEA',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Severe Acute Respiratory Syndrome|Ventilation Pneumonitis',\n",
       "  'Interventions': 'Drug: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets|Other: Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets|Other: Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.',\n",
       "  'Outcome Measures': 'Patients Who Improved Their Condition or Did Not Worsen it|ICU-treated Patients After 2-week Treatment|Mortality|Patients Needing Drug Dose Adjustment|Adverse Events',\n",
       "  'Sponsor/Collaborators': 'Eurnekian Public Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '5 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 167.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'IDEA',\n",
       "  'Start Date': 'May 1, 2020',\n",
       "  'Primary Completion Date': 'August 30, 2020',\n",
       "  'Completion Date': 'August 30, 2020',\n",
       "  'First Posted': 'June 11, 2020',\n",
       "  'Results First Posted': 'October 19, 2020',\n",
       "  'Last Update Posted': 'October 19, 2020',\n",
       "  'Locations': 'Hospital Eurnekian, Buenos Aires, Argentina',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/63/NCT04425863/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04425863'},\n",
       " {'Rank': 3303,\n",
       "  'NCT Number': 'NCT03376854',\n",
       "  'Title': 'Pilot RCT of Therapeutic Hypothermia Plus Neuromuscular Blockade in COVID-19 Patients With ARDS',\n",
       "  'Acronym': 'CHILL-pilot',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Respiratory Distress Syndrome, Adult|Sars-CoV2',\n",
       "  'Interventions': 'Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of Care',\n",
       "  'Outcome Measures': 'Targeted temperature compliance|Adverse event|28-day ICU-free days|Survival|non neurologic Sequential Organ Failure (SOFA) scores|Oxygen saturation (SpO2)|Plateau airway pressure|Mean airway pressure|Airway driving pressure|Oxygen saturation index|Core temperature|Urine output|comprehensive metabolic panel|Complete blood count with differential count and platelet count|Biomarkers|Serum electrolytes|Blood glucose|28-day ventilator-free days',\n",
       "  'Sponsor/Collaborators': 'University of Maryland, Baltimore',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 65 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 20.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'HP-00078506',\n",
       "  'Start Date': 'May 1, 2018',\n",
       "  'Primary Completion Date': 'November 30, 2020',\n",
       "  'Completion Date': 'December 31, 2020',\n",
       "  'First Posted': 'December 19, 2017',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 16, 2020',\n",
       "  'Locations': 'University of Maryland Medical Center, Baltimore, Maryland, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/ICF_011.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/SAP_012.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03376854/Prot_013.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03376854'},\n",
       " {'Rank': 3327,\n",
       "  'NCT Number': 'NCT04352517',\n",
       "  'Title': 'Influence Physical Activity Psychological Responses COVID-19 Pandemic',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Sedentary Behavior|Mental Health Wellness 1',\n",
       "  'Interventions': 'Other: Online Survey',\n",
       "  'Outcome Measures': 'Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of COVID-19 through IES-R|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through DASS-21|IImpact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through DASS-21|Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through DASS-21',\n",
       "  'Sponsor/Collaborators': 'University of Extremadura',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 3500.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': '3.954.038',\n",
       "  'Start Date': 'March 16, 2020',\n",
       "  'Primary Completion Date': 'August 31, 2020',\n",
       "  'Completion Date': 'September 30, 2020',\n",
       "  'First Posted': 'April 20, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 21, 2021',\n",
       "  'Locations': 'Universidade da Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil|Universidad Autonoma de Chile, Santiago, Región Metropolitana, Chile|Universidad de la República, Rivera, Uruguay',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/17/NCT04352517/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04352517'},\n",
       " {'Rank': 3395,\n",
       "  'NCT Number': 'NCT04468893',\n",
       "  'Title': 'Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Anxiety|Depression|Sleep Disturbance',\n",
       "  'Interventions': 'Behavioral: Online Intervention Mental Health COVID-19',\n",
       "  'Outcome Measures': 'Decrease in the score of Anxiety symptoms|Change in the symptoms of depression|Change in the symptoms of General Anxiety Disorder|Change in the score of Posttraumatic stress symptoms|Changes in the Widespread fear Scale|Change in the score of The Pittsburgh Sleep Quality Index.|Change on the Suicidal Thoughts Scale',\n",
       "  'Sponsor/Collaborators': 'Universidad Internacional de Valencia|Universidad Nacional Autonoma de Mexico|Universidad Autonoma de Ciudad Juarez',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 70 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 128.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'VIU-PP',\n",
       "  'Start Date': 'May 20, 2020',\n",
       "  'Primary Completion Date': 'December 31, 2020',\n",
       "  'Completion Date': 'January 15, 2021',\n",
       "  'First Posted': 'July 13, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 4, 2020',\n",
       "  'Locations': 'Universidad Autónoma de Ciudad Juárez, Juarez, Chihuahua, Mexico',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04468893/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04468893'},\n",
       " {'Rank': 3398,\n",
       "  'NCT Number': 'NCT04568889',\n",
       "  'Title': 'Minnesota COVID-19 Testing Project',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Infectious Disease',\n",
       "  'Interventions': 'Behavioral: A $10 Survey Incentive|Behavioral: A $20 Survey Incentive|Behavioral: Emphasis of Government Involvement|Behavioral: Emphasis of Academic Researchers Involvement|Behavioral: Cost-Benefit Frame|Behavioral: Duty Frame|Behavioral: Racial/Ethnic Frame|Behavioral: No Messaging',\n",
       "  'Outcome Measures': 'Effect of monetary incentives in increasing unit response 1|Effect of monetary incentives in increasing unit response 2|Effect of a government frame in reducing unit response 1|Effect of a government frame in reducing unit response 2|Interactions between monetary incentives and a government frame 1|Interactions between monetary incentives and a government frame 2|Interactions between monetary incentives and a government frame 3|Interactions between monetary incentives and a government frame 4|Demographic characteristics of participants assigned into each treatment arm|Effect of various messaging frames in increasing item non-response',\n",
       "  'Sponsor/Collaborators': 'Harvard University|Abdul Latif Jameel Poverty Action Lab|Government of Minnesota',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 1000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research',\n",
       "  'Other IDs': 'IRB20-1444',\n",
       "  'Start Date': 'September 28, 2020',\n",
       "  'Primary Completion Date': 'October 26, 2020',\n",
       "  'Completion Date': 'June 30, 2021',\n",
       "  'First Posted': 'September 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 10, 2021',\n",
       "  'Locations': 'Volunteers Enlisted to Assist People, Bloomington, Minnesota, United States|Southern Anoka Community Assistance, Columbia Heights, Minnesota, United States|People Reaching Out to People Food Shelf, Eden Prairie, Minnesota, United States|Fridley Covenant Church, Fridley, Minnesota, United States|Calvary Lutheran Church Food Shelf, Minneapolis, Minnesota, United States|NorthPoint Health and Wellness, Minneapolis, Minnesota, United States|Community Emergency Assistance Programs, Minneapolis, Minnesota, United States|Intercongregation Communities Association, Minnetonka, Minnesota, United States|Valley Outreach, Stillwater, Minnesota, United States|White Bear Area Foodshelf, White Bear Lake, Minnesota, United States',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/89/NCT04568889/SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04568889'},\n",
       " {'Rank': 3477,\n",
       "  'NCT Number': 'NCT04331366',\n",
       "  'Title': 'Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19',\n",
       "  'Acronym': 'GO2 PEEP',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Device: GO2 PEEP MOUTHPIECE',\n",
       "  'Outcome Measures': 'Oxygen Saturation by Pulse Oximetry|Respiratory Rate|Heart Rate|Blood Pressure|Count of Participants With Subjective Work of Breathing',\n",
       "  'Sponsor/Collaborators': 'Emory University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 2.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care',\n",
       "  'Other IDs': 'STUDY00000381',\n",
       "  'Start Date': 'April 8, 2020',\n",
       "  'Primary Completion Date': 'August 31, 2020',\n",
       "  'Completion Date': 'August 31, 2020',\n",
       "  'First Posted': 'April 2, 2020',\n",
       "  'Results First Posted': 'February 10, 2021',\n",
       "  'Last Update Posted': 'February 18, 2021',\n",
       "  'Locations': \"Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/66/NCT04331366/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04331366'},\n",
       " {'Rank': 3481,\n",
       "  'NCT Number': 'NCT04629157',\n",
       "  'Title': 'The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19',\n",
       "  'Acronym': 'LAVA',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'This is a Pilot Study Which Aims to Assess the Validity and Applicability of Lateral Flow Assays (LFAs) Which Can be Used as a Point of Care Test for COVID-19|Covid19',\n",
       "  'Interventions': 'Device: Innova Lateral Flow Device',\n",
       "  'Outcome Measures': 'Acceptability of test|Test failure rate',\n",
       "  'Sponsor/Collaborators': \"Alder Hey Children's NHS Foundation Trust\",\n",
       "  'Gender': 'All',\n",
       "  'Age': 'up to 17 Years \\xa0 (Child)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 400.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic',\n",
       "  'Other IDs': '290989',\n",
       "  'Start Date': 'November 5, 2020',\n",
       "  'Primary Completion Date': 'November 19, 2020',\n",
       "  'Completion Date': 'November 19, 2020',\n",
       "  'First Posted': 'November 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 16, 2020',\n",
       "  'Locations': \"Alder Hey in the Park, Liverpool, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/57/NCT04629157/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/57/NCT04629157/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04629157'},\n",
       " {'Rank': 3486,\n",
       "  'NCT Number': 'NCT04570462',\n",
       "  'Title': 'Mild Hypothermia for COVID-19 ARDS',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID19 ARDS',\n",
       "  'Interventions': 'Other: Hypothermia Via Cooling Machine- Arctic Sun 5000',\n",
       "  'Outcome Measures': 'Changes in metabolic requirement during and after hypothermia|Changes in oxygen requirements and levels during and after hypothermia|length of intubation|Changes in carbon dioxide levels during and after hypothermia|does application of hypothermia reduce pro inflammatory response',\n",
       "  'Sponsor/Collaborators': 'Northwell Health',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 100 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 20.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'Protocol 5.18.2020 Approved',\n",
       "  'Start Date': 'May 18, 2020',\n",
       "  'Primary Completion Date': 'December 31, 2020',\n",
       "  'Completion Date': 'December 31, 2020',\n",
       "  'First Posted': 'September 30, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'September 30, 2020',\n",
       "  'Locations': 'North Shore University Hospital, Manhasset, New York, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/62/NCT04570462/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04570462'},\n",
       " {'Rank': 3538,\n",
       "  'NCT Number': 'NCT04579627',\n",
       "  'Title': 'Facial Hair, PPE and COVID-19',\n",
       "  'Acronym': 'FACIAL HAIR',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID|Safety Issues',\n",
       "  'Interventions': 'Behavioral: Questionnaire',\n",
       "  'Outcome Measures': 'Change in facial hair between January 2020 and during April 2020.|Does facial hair change adhere to the PPE guidance from PHE',\n",
       "  'Sponsor/Collaborators': 'Royal Cornwall Hospitals Trust',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 358.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': '283609',\n",
       "  'Start Date': 'May 14, 2020',\n",
       "  'Primary Completion Date': 'June 8, 2020',\n",
       "  'Completion Date': 'June 8, 2020',\n",
       "  'First Posted': 'October 8, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 8, 2020',\n",
       "  'Locations': 'Royal Cornwall Hospital, Truro, Cornwall, United Kingdom',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/27/NCT04579627/ICF_000.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/27/NCT04579627/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04579627'},\n",
       " {'Rank': 3666,\n",
       "  'NCT Number': 'NCT04700137',\n",
       "  'Title': 'Mental Health Among Patients, Providers, and Staff During the COVID-19 Era',\n",
       "  'Acronym': 'MHAPPS',\n",
       "  'Status': 'Enrolling by invitation',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Mental Health',\n",
       "  'Interventions': 'Other: Caring Contacts Plus Introductory Phone Call (CC+)|Other: Caring Contacts without an introductory phone call (CC)',\n",
       "  'Outcome Measures': 'Loneliness as measured by the National Institutes of Health (NIH) Toolbox Social Relationship Scale for Loneliness|Suicidal Ideation & Behavior as measured by the Columbia Suicide Severity Rating Scale|Suicide Attempts & Self-Harm as measured by the Columbia Suicide Severity Rating Scale|Perceived Burdensomeness & Thwarted Belongingness as measured by the Interpersonal Needs Questionnaire (INQ15)|Psychological Stress as measured by the National Institutes of Health (NIH) Toolbox Stress and Self-Efficacy Scales Perceived Stress measure|Alcohol and Illicit Drug Use as measured by questions adapted from Youth Risk Behavior Survey and related to COVID-19|Depression as measured by the Patient Health Questionnaire (PHQ-9)|Anxiety as measured by the Generalized Anxiety Disorder 7 Item Scale (GAD-7)|Attendance at Mental Healthcare Appointments: Self-Report',\n",
       "  'Sponsor/Collaborators': \"St. Luke's Health System, Boise, Idaho|Patient-Centered Outcomes Research Institute|Idaho Suicide Prevention Hotline (Jannus, Inc.)|University of Washington\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '12 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 660.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '20-0052|PCORI HIS-2018C3-14695',\n",
       "  'Start Date': 'January 18, 2021',\n",
       "  'Primary Completion Date': 'January 17, 2022',\n",
       "  'Completion Date': 'January 17, 2022',\n",
       "  'First Posted': 'January 7, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 22, 2021',\n",
       "  'Locations': \"St. Luke's Health System, Boise, Idaho, United States\",\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/37/NCT04700137/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04700137'},\n",
       " {'Rank': 3690,\n",
       "  'NCT Number': 'NCT04349410',\n",
       "  'Title': 'The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol',\n",
       "  'Acronym': 'FMTVDM',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'CoVid 19 Positive',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum',\n",
       "  'Outcome Measures': 'Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status',\n",
       "  'Sponsor/Collaborators': 'The Camelot Foundation',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': 'Phase 2|Phase 3',\n",
       "  'Enrollment': 1800.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'FMTVDM2020',\n",
       "  'Start Date': 'April 11, 2020',\n",
       "  'Primary Completion Date': 'September 14, 2020',\n",
       "  'Completion Date': 'September 14, 2020',\n",
       "  'First Posted': 'April 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 12, 2020',\n",
       "  'Locations': 'FHHI-OI-Camelot; QME, Los Angeles, California, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan: Study Protocol with Statistical Analysis\", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04349410/Prot_SAP_001.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/10/NCT04349410/ICF_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04349410'},\n",
       " {'Rank': 3701,\n",
       "  'NCT Number': 'NCT04542226',\n",
       "  'Title': 'Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Infections, Coronavirus',\n",
       "  'Interventions': 'Drug: Polyoxidonium',\n",
       "  'Outcome Measures': 'Clinical Status of the Patient (According to 7-point Ordinal Scale)|Time to Improvement in Clinical Status of the Patient (According to Ordinal Scale) by 1 Point for Each OS Score|Clinical Status of the Patient (According to National Early Warning Score (NEWS Scale))|Number of Patients Requiring Supplementary Oxygen|Hospitalisation Duration|Mortality|The Number of Participants With Serious Adverse Events|The Number of Participants With Adverse Events|Number of Participants With Discontinuation of Drug Administration',\n",
       "  'Sponsor/Collaborators': 'NPO Petrovax',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 81.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'Covid_v_1.0',\n",
       "  'Start Date': 'March 31, 2020',\n",
       "  'Primary Completion Date': 'July 15, 2020',\n",
       "  'Completion Date': 'October 30, 2020',\n",
       "  'First Posted': 'September 9, 2020',\n",
       "  'Results First Posted': 'December 3, 2020',\n",
       "  'Last Update Posted': 'December 9, 2020',\n",
       "  'Locations': 'Healthcare Institution \"Grodno Regional Infectious Clinical Hospital\", Grodno, Belarus|State-Funded Healthcare Institution \"Emergency Hospital\" of Ministry of Health of Chuvash Republic, Cheboksary, Chuvashia, Russian Federation|State-Funded Healthcare Institution \"Infectious Disease Hospital No.3\" of Ministry of Health of Krasnodar Krai, Novorossiysk, Krasnodar Krai, Russian Federation|State-Funded Institution of Mari El Republic \"Yoshkar-Ola City Hospital\", Yoshkar-Ola, Mari El Republic, Russian Federation|State-Funded Healthcare Institution of Voronezh Region \"Novaya Usman District Hospital\", Novaya Usman, Voronezh Region, Russian Federation',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04542226/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04542226'},\n",
       " {'Rank': 3727,\n",
       "  'NCT Number': 'NCT04429854',\n",
       "  'Title': 'Donated Antibodies Working Against nCoV',\n",
       "  'Acronym': 'DAWN-Plasma',\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Biological: Convalescent Plasma|Drug: Standard of care',\n",
       "  'Outcome Measures': 'Patients requiring mechanical ventilation or death|Clinical status of subject at day 15 and day 30 (on a 10-point \"WHO progression\" ordinal scale)',\n",
       "  'Sponsor/Collaborators': 'Universitaire Ziekenhuizen Leuven|Federal Knowledge Centre (KCE)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 483.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'S63992',\n",
       "  'Start Date': 'May 2, 2020',\n",
       "  'Primary Completion Date': 'April 30, 2021',\n",
       "  'Completion Date': 'November 2, 2021',\n",
       "  'First Posted': 'June 12, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 18, 2021',\n",
       "  'Locations': 'ZNA, Antwerpen, Belgium|Imelda Ziekenhuis Bonheiden, Bonheiden, Belgium|Institut Bordet, Brussel, Belgium|UMC Sint-Pieter, Brussel, Belgium|CHU Brugmann, Brussel, Belgium|Erasmus Ziekenhuis, Brussel, Belgium|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St Luc, Brussel, Belgium|AZ Sint-Vincentius, Deinze, Belgium|AZ Maria Middelares, Gent, Belgium|AZ Sint-Lucas, Gent, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHC Liège Mont Légia, Liège, Belgium|CHR Citadelle Liège, Liège, Belgium|CHU Liège Sart-Tilman, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|CHR Jolimont Mons-Hainaut, Mons, Belgium|AZ Delta, Roeselare, Belgium|Sint-Trudo Ziekenhuis, Sint-Truiden, Belgium|Centre Hospitalier de Wallonie Picarde (CHwapi), Tournai, Belgium',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04429854/Prot_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04429854/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04429854'},\n",
       " {'Rank': 3729,\n",
       "  'NCT Number': 'NCT04413058',\n",
       "  'Title': 'Menstrual Cycle Characteristics of Healthcare Professionals',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Menstrual Irregularity|Covid 19',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Rate of irregular menstrual cycle|Length of cycle|Rate of prolonged bleeding|Amount of flow|Rate of dysmenorrhea|The number of difference in menstrual cycle length|The number of difference in bleeding days|The number of difference in amount of flow',\n",
       "  'Sponsor/Collaborators': 'Haydarpasa Numune Training and Research Hospital',\n",
       "  'Gender': 'Female',\n",
       "  'Age': '18 Years to 47 Years \\xa0 (Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 260.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Crossover|Time Perspective: Prospective',\n",
       "  'Other IDs': 'HNEAH KAEK 2020/KK/|Ministry of Health',\n",
       "  'Start Date': 'April 10, 2020',\n",
       "  'Primary Completion Date': 'September 10, 2020',\n",
       "  'Completion Date': 'September 10, 2020',\n",
       "  'First Posted': 'June 2, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 19, 2020',\n",
       "  'Locations': 'University of Health Sciences Turkey, Istanbul, Turkey',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04413058/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04413058'},\n",
       " {'Rank': 3793,\n",
       "  'NCT Number': 'NCT04286503',\n",
       "  'Title': 'The Clinical Study of Carrimycin on Treatment Patients With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Novel Coronavirus Infectious Disease (COVID-19)',\n",
       "  'Interventions': 'Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment',\n",
       "  'Outcome Measures': 'Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment',\n",
       "  'Sponsor/Collaborators': \"Beijing YouAn Hospital|Shenyang Tonglian Group CO., Ltd|Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences|Huangshi Central Hospital|Shenyang Pharmaceutical University|First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Harbin Medical University|No.2 People's Hospital of Fuyang City|First Affiliated Hospital Bengbu Medical College|Renmin Hospital of Wuhan University|The sixth people's hospital of Shenyang|Nanyang Central Hospital\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 75 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 4',\n",
       "  'Enrollment': 520.0,\n",
       "  'Funded Bys': 'Other|Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'BeijingYouan Hospital',\n",
       "  'Start Date': 'February 23, 2020',\n",
       "  'Primary Completion Date': 'February 28, 2021',\n",
       "  'Completion Date': 'February 28, 2021',\n",
       "  'First Posted': 'February 27, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 27, 2020',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04286503'},\n",
       " {'Rank': 3833,\n",
       "  'NCT Number': 'NCT04663555',\n",
       "  'Title': 'Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19',\n",
       "  'Acronym': 'REMED',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|ARDS',\n",
       "  'Interventions': 'Drug: Dexamethasone',\n",
       "  'Outcome Measures': 'Number of ventilator-free days (VFDs) at 28 days after randomization|Mortality from any cause at 60 days after randomization|WHO clinical progression scale at day 14|Dynamics of inflammatory marker|Adverse events related to corticosteroids|Functional independence',\n",
       "  'Sponsor/Collaborators': \"Brno University Hospital|Masaryk University|Vascular surgery, University hospital Královské Vinohrady, Prague|General University Hospital in Prague|University Hospital Ostrava|St. Anne's University Hospital Brno|University Hospital Motol Prague|University Hospital Olomouc|University Hospital Plzeň|Tomáš Baťa Regional Hospital|Military University Hospital Praha\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 4',\n",
       "  'Enrollment': 300.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'CZECRIN No. 2020/47|2020-005887-70',\n",
       "  'Start Date': 'February 2, 2021',\n",
       "  'Primary Completion Date': 'March 31, 2022',\n",
       "  'Completion Date': 'March 31, 2023',\n",
       "  'First Posted': 'December 11, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 4, 2021',\n",
       "  'Locations': 'University Hospital Brno, Brno, Czechia',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/55/NCT04663555/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04663555'},\n",
       " {'Rank': 3850,\n",
       "  'NCT Number': 'NCT04323592',\n",
       "  'Title': 'Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome',\n",
       "  'Acronym': 'MP-C19',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human',\n",
       "  'Interventions': 'Drug: Methylprednisolone|Other: standard care',\n",
       "  'Outcome Measures': 'Composite Primary End-point: Admission to ICU, Need for Invasive Mechanical Ventilation (MV), or All-cause Death by Day 28|In-hospital Death Within 28 Days|Admission to Intensive Care Unit (ICU)|Endotracheal Intubation (Invasive Mechanical Ventilation)|Change in C-reactive Protein (CRP)|Number of Days Free From Mechanical Ventilation',\n",
       "  'Sponsor/Collaborators': 'University of Trieste',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 80 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 173.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'MP-19 023_2020',\n",
       "  'Start Date': 'March 23, 2020',\n",
       "  'Primary Completion Date': 'May 10, 2020',\n",
       "  'Completion Date': 'May 10, 2020',\n",
       "  'First Posted': 'March 26, 2020',\n",
       "  'Results First Posted': 'June 4, 2020',\n",
       "  'Last Update Posted': 'June 24, 2020',\n",
       "  'Locations': 'Marco Confalonieri, Trieste, TS, Italy',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_003.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/SAP_004.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_006.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04323592'},\n",
       " {'Rank': 3858,\n",
       "  'NCT Number': 'NCT04409886',\n",
       "  'Title': 'Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients',\n",
       "  'Acronym': 'HBOT',\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID, Coronavirus',\n",
       "  'Interventions': 'Device: Hyperbaric Chamber',\n",
       "  'Outcome Measures': 'Oxygenation index|SpO2|Symptoms level|Chest Xray',\n",
       "  'Sponsor/Collaborators': 'Maimonides Medical Center',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '120-20-ASF',\n",
       "  'Start Date': 'June 1, 2020',\n",
       "  'Primary Completion Date': 'December 31, 2020',\n",
       "  'Completion Date': 'March 30, 2021',\n",
       "  'First Posted': 'June 1, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 11, 2020',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/86/NCT04409886/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04409886'},\n",
       " {'Rank': 3878,\n",
       "  'NCT Number': 'NCT04492475',\n",
       "  'Title': 'Adaptive COVID-19 Treatment Trial 3 (ACTT-3)',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Interferon beta-1a|Other: Placebo|Drug: Remdesivir',\n",
       "  'Outcome Measures': \"Time to recovery for patients with baseline ordinal score 4, 5, and 6|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in C-reactive protein (CRP)|Change from baseline in creatinine|Change from baseline in d-dimer concentration|Change from baseline in hemoglobin|Change from baseline in international normalized ratio (INR)|Change from baseline in platelets|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of invasive mechanical ventilation|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of non invasive ventilation or high flow oxygen use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of study product administration|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change from baseline in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale for patients with baseline ordinal score 4 and 5|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Time to recovery for patients with a baseline ordinal score of 4 and 5\",\n",
       "  'Sponsor/Collaborators': 'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 99 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 969.0,\n",
       "  'Funded Bys': 'NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '20-0006 ACTT-3',\n",
       "  'Start Date': 'August 5, 2020',\n",
       "  'Primary Completion Date': 'December 21, 2020',\n",
       "  'Completion Date': 'December 21, 2020',\n",
       "  'First Posted': 'July 30, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 9, 2021',\n",
       "  'Locations': 'University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|UCSF Fresno Center for Medical Education and Research - Clinical Research Center, Fresno, California, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of HIV, ID, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Florida Health - Jacksonville - Department of Emergency Medicine, Jacksonville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago Division of Infectious Diseases, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics - Department of Internal Medicine, Iowa City, Iowa, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|Methodist Hospital - Houston, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Seongnam, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04492475/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04492475'},\n",
       " {'Rank': 3885,\n",
       "  'NCT Number': 'NCT04401579',\n",
       "  'Title': 'Adaptive COVID-19 Treatment Trial 2 (ACTT-2)',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Other: Placebo|Drug: Remdesivir|Drug: Baricitinib',\n",
       "  'Outcome Measures': \"Time to recovery|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count (WBC) with differential|Change in National Early Warning Score (NEWS) from baseline|Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Duration of oxygen use|Incidence of discontinuation or temporary suspension of investigational therapeutics|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Participant's clinical status at Day 15 by ordinal scale|Percentage of subjects reporting each severity rating on an 8 point ordinal scale|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Change from baseline in C-reactive protein (CRP)|Change from baseline in d-dimer concentration\",\n",
       "  'Sponsor/Collaborators': 'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 99 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 1034.0,\n",
       "  'Funded Bys': 'NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '20-0006 ACTT-2',\n",
       "  'Start Date': 'May 8, 2020',\n",
       "  'Primary Completion Date': 'July 31, 2020',\n",
       "  'Completion Date': 'July 31, 2020',\n",
       "  'First Posted': 'May 26, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 2, 2020',\n",
       "  'Locations': \"University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Eastern Colorado Health Care System, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|Georgetown University Medical Center - Division of Infectious Diseases, Washington, District of Columbia, United States|University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States|University of Miami Miller School of Medicine - Infectious Diseases, Miami, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Indiana University School of Medicine - Infectious Diseases, Indianapolis, Indiana, United States|Ochsner Medical Center - Kenner - Department of Infectious Diseases, Kenner, Louisiana, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Baltimore, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|University of New Mexico Clinical and Translational Science Center, Albuquerque, New Mexico, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Womack Army Medical Center - Pulmonary and Respiratory Services, Fort Bragg, North Carolina, United States|Kaiser Permanente Northwest - Center for Health Research, Portland, Oregon, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Baylor Scott & White Health - Baylor University Medical Center - North Texas Infectious Disease Consultants, Dallas, Texas, United States|University of Texas Southwestern Medical Center - Internal Medicine - Infectious Diseases, Dallas, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Utah - Infectious Diseases, Salt Lake City, Utah, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National University Health System - Division of Infectious Diseases, Singapore, Singapore|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore|Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore|Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain|Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain|Hospital Clinico San Carlos - Enfermedades Infecciosas, Madrid, Spain|Royal Sussex County Hospital - Department of Intensive Care Medicine, Brighton, United Kingdom|Saint Thomas' Hospital - Directorate of Infection, City Of London, United Kingdom|St. James's University Hospital - Infectious Diseases, Leeds, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom\",\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/79/NCT04401579/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04401579'},\n",
       " {'Rank': 3909,\n",
       "  'NCT Number': 'NCT04535154',\n",
       "  'Title': 'Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19',\n",
       "  'Acronym': 'PROLUN',\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19|Lung Function Decreased',\n",
       "  'Interventions': 'Other: No interventions',\n",
       "  'Outcome Measures': 'Forced vital capacity|Gas diffusion capacity of carbon monoxide|modified Medical Respiratory Council Dyspnea Scale|Parenchymal opacities of the lungs|Forced expiratory capacity during 1st second of expiration|FEV1/FVC|Gas diffusion capacity adjusted for alveolar ventilation (KCO)',\n",
       "  'Sponsor/Collaborators': 'University Hospital, Akershus|Oslo University Hospital|Ostfold Hospital Trust|Haukeland University Hospital|St. Olavs Hospital|The National Association for Heart and Lung Disease, Jessheim, Norway',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 264.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'PROLUN',\n",
       "  'Start Date': 'March 31, 2020',\n",
       "  'Primary Completion Date': 'June 1, 2021',\n",
       "  'Completion Date': 'June 1, 2022',\n",
       "  'First Posted': 'September 1, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'September 1, 2020',\n",
       "  'Locations': 'Dept Pulmonary Medicine, Lørenskog, Viken, Norway',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04535154/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04535154'},\n",
       " {'Rank': 3990,\n",
       "  'NCT Number': 'NCT04370678',\n",
       "  'Title': 'Changes in Preference for Surgery of Patients Signed up for Arthroscopic Procedures',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Arthroscopy',\n",
       "  'Interventions': 'Behavioral: Change in preference to surgery under COVID-19 pandemic.',\n",
       "  'Outcome Measures': 'Change in preference|Change in preference between groups',\n",
       "  'Sponsor/Collaborators': 'Region Zealand',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 79.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Other|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': 'ArthrocancellationSUH2020',\n",
       "  'Start Date': 'April 17, 2020',\n",
       "  'Primary Completion Date': 'April 24, 2020',\n",
       "  'Completion Date': 'April 24, 2020',\n",
       "  'First Posted': 'May 1, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'May 7, 2020',\n",
       "  'Locations': 'Zealand University Hospital, Køge, Zealand Region, Denmark',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/78/NCT04370678/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04370678'},\n",
       " {'Rank': 4036,\n",
       "  'NCT Number': 'NCT04371419',\n",
       "  'Title': 'COVID-19 Health Messaging to Underserved Communities',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus',\n",
       "  'Interventions': 'Behavioral: Messaging',\n",
       "  'Outcome Measures': 'Knowledge Beliefs and Practices related to COVID-19|Video Ratings',\n",
       "  'Sponsor/Collaborators': 'National Bureau of Economic Research, Inc.|Massachusetts General Hospital|Stanford University|Yale University|Massachusetts Institute of Technology|Harvard University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 15475.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention',\n",
       "  'Other IDs': '2003000118',\n",
       "  'Start Date': 'May 13, 2020',\n",
       "  'Primary Completion Date': 'May 24, 2020',\n",
       "  'Completion Date': 'May 24, 2020',\n",
       "  'First Posted': 'May 1, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 19, 2020',\n",
       "  'Locations': 'JPAL North America, Cambridge, Massachusetts, United States',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/19/NCT04371419/SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04371419'},\n",
       " {'Rank': 4199,\n",
       "  'NCT Number': 'NCT04642326',\n",
       "  'Title': 'Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Covid19',\n",
       "  'Interventions': 'Device: Test Group: experimental - UVC Therapy applied',\n",
       "  'Outcome Measures': 'PCR Sampling|Blood Tests|Radiological Imaging',\n",
       "  'Sponsor/Collaborators': 'RD Global Araştirma Geliştirme Sağlik Ilaç Inşaat Yatirimlari A.Ş.',\n",
       "  'Gender': 'All',\n",
       "  'Age': '40 Years to 75 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 50.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'MD2020/001',\n",
       "  'Start Date': 'June 26, 2020',\n",
       "  'Primary Completion Date': 'July 1, 2020',\n",
       "  'Completion Date': 'May 4, 2021',\n",
       "  'First Posted': 'November 24, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 24, 2020',\n",
       "  'Locations': 'Diyarbakır SBÜ Gazi Yaşargil Eğitim Ve Araştırma Hastanesi, Diyarbakır, Kayapınar, Turkey',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04642326/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04642326'},\n",
       " {'Rank': 4322,\n",
       "  'NCT Number': 'NCT04366791',\n",
       "  'Title': 'Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19',\n",
       "  'Acronym': 'RESCUE 1-19',\n",
       "  'Status': 'Suspended',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Pneumonia|Coronavirus Infection in 2019 (COVID-19)|Severe Acute Respiratory Syndrome (SARS) Pneumonia',\n",
       "  'Interventions': 'Radiation: Low Dose Radiation Therapy',\n",
       "  'Outcome Measures': 'Rate of extubation (for intubated patients)|Clinical outcome - Temperature|Clinical outcome - Heart Rate|Clinical outcome - Systolic blood pressure|Clinical outcome - Oxygenation|Clinical outcome - Respirations|Clinical outcome - FiO2|Clinical outcome - PEEP|Clinical outcome - Tidal volume|Clinical outcome - Intubation/Extubation events|Clinical outcome - Overall survival|Radiographic outcome - Chest xray|Radiographic outcome - CT can|Serologic outcome - WBC|Serologic outcome - Hgb|Serologic outcome - Procalcitonin|Serologic outcome - ANC|Serologic outcome - Creatine kinase|Serologic outcome - Myoglobin|Serologic outcome - Albumin|Serologic outcome - PT/PTT|Serologic outcome - D-Dimer|Serologic outcome - GGT|Serologic outcome -Triglycerides|Serologic outcome -Ferritin|Serologic outcome -Fibrinogen|Serologic Immune markers flow cytometry|Serologic outcome -Bilirubin|Serologic outcome - LDH|Serologic outcome - Creatinine|Serologic outcome - EGFR|Serologic outcome - CRP|Serologic outcome - ALT|Serologic outcome - AST|Serologic outcome - Troponin-I|Serologic outcome - BNP|Serologic outcome - Blood Gases pH|Serologic outcome - Blood Gases pO2|Serologic outcome - Blood Gases pCO2|Serologic outcome - Lactic Acid|Serologic outcome - IL-6|Serologic outcome - Potassium',\n",
       "  'Sponsor/Collaborators': 'Emory University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 1|Phase 2',\n",
       "  'Enrollment': 10.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'STUDY00000476|NCI-2020-02676|RAD5002-20|P30CA138292',\n",
       "  'Start Date': 'April 23, 2020',\n",
       "  'Primary Completion Date': 'April 15, 2021',\n",
       "  'Completion Date': 'April 15, 2021',\n",
       "  'First Posted': 'April 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 19, 2020',\n",
       "  'Locations': \"Emory University Hospital Midtown/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hosptial, Atlanta, Georgia, United States\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/91/NCT04366791/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04366791'},\n",
       " {'Rank': 4345,\n",
       "  'NCT Number': 'NCT04327401',\n",
       "  'Title': 'COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III',\n",
       "  'Acronym': 'CoDEX',\n",
       "  'Status': 'Terminated',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome',\n",
       "  'Interventions': 'Drug: Dexamethasone',\n",
       "  'Outcome Measures': 'Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score',\n",
       "  'Sponsor/Collaborators': 'Hospital Sirio-Libanes|Hospital Israelita Albert Einstein|Hospital do Coracao|Brazilian Research In Intensive Care Network|Ache Laboratorios Farmaceuticos S.A.',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 299.0,\n",
       "  'Funded Bys': 'Other|Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'CAAE: 30227020.5.1001.0008',\n",
       "  'Start Date': 'April 13, 2020',\n",
       "  'Primary Completion Date': 'July 22, 2020',\n",
       "  'Completion Date': 'July 22, 2020',\n",
       "  'First Posted': 'March 31, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 7, 2020',\n",
       "  'Locations': 'Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/01/NCT04327401/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04327401'},\n",
       " {'Rank': 4377,\n",
       "  'NCT Number': 'NCT04407208',\n",
       "  'Title': 'Convalescent Plasma Therapy in Patients With COVID-19',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Convalescence|Corona Virus Infection|Plaque',\n",
       "  'Interventions': 'Biological: Convalescent plasma',\n",
       "  'Outcome Measures': 'Plaque reduction neutralization test (PNRT)|D-dimer|C-Reactive Protein (CRP)|International Normalized Ratio (INR)|Oxygenation Index|Chest X-ray|severe adverse event',\n",
       "  'Sponsor/Collaborators': 'Biofarma|Rumah Sakit Pusat Angkatan Darat Gatot Soebroto|Eijkman Institute for Molecular Biology',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 1',\n",
       "  'Enrollment': 10.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research',\n",
       "  'Other IDs': '3471041S322342020040800002',\n",
       "  'Start Date': 'May 1, 2020',\n",
       "  'Primary Completion Date': 'June 22, 2020',\n",
       "  'Completion Date': 'June 22, 2020',\n",
       "  'First Posted': 'May 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 30, 2020',\n",
       "  'Locations': 'Gatot Soebroto central army presidential hospital, Jakarta Pusat, Indonesia',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04407208/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04407208'},\n",
       " {'Rank': 4450,\n",
       "  'NCT Number': 'NCT04659135',\n",
       "  'Title': 'ASCO Survey on COVID-19 in Oncology (ASCO) Registry',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Neoplasms|Coronavirus',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Changes to Cancer Treatments|All-cause mortality at 30 days|COVID-19 Symptoms|COVID-19 Treatments|Patient vital status|Overall survival|Patient cancer status (for patients who had active cancer at covid-19 dx)|Patient cancer status (for patients who are disease-free at COVID-19 diagnosis)',\n",
       "  'Sponsor/Collaborators': 'American Society of Clinical Oncology',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 2000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Only|Time Perspective: Prospective',\n",
       "  'Other IDs': 'Pro00014181',\n",
       "  'Start Date': 'April 19, 2020',\n",
       "  'Primary Completion Date': 'December 2022',\n",
       "  'Completion Date': 'December 2022',\n",
       "  'First Posted': 'December 9, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 9, 2020',\n",
       "  'Locations': \"Anchorage Oncology Center, Anchorage, Alaska, United States|AIS Cancer Center, Bakersfield, California, United States|Long Beach Memorial Medical Center, Fountain Valley, California, United States|Orange Coast Medical Center, Fountain Valley, California, United States|Saddleback Memorial Medical Center, Fountain Valley, California, United States|Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|PIH Health, Whittier, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Hartford HealthCare Cancer Institute, Hartford, Connecticut, United States|Bayhealth Medical Center, Dover, Delaware, United States|Florida Precision Oncology, A Division of 21st Centry Oncology, Fort Myers, Florida, United States|Florida Cancer Specialists & Research Institute, LLC, Sarasota, Florida, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Hawaii Cancer Care, Honolulu, Hawaii, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Joliet Oncology-Hematology Associates, Joliet, Illinois, United States|Edward-Elmhurst Healthcare, Naperville, Illinois, United States|Illinois Cancer Care, Peoria, Illinois, United States|Goshen Center for Cancer Care, Goshen, Indiana, United States|Michiana Hematology Oncology, Mishawaka, Indiana, United States|MidAmerica Oncology Associates, Overland Park, Kansas, United States|University of Kansas Medical Center, Westwood, Kansas, United States|Baptist Health Madisonville, Madisonville, Kentucky, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|LifeBridge Health, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Great Lakes Cancer Management Specialists, Grosse Pointe Woods, Michigan, United States|Lakeland Hospitals, Saint Joseph, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Mosaic Cancer Care, Saint Joseph, Missouri, United States|Nebraska Hematology Oncology, Lincoln, Nebraska, United States|Callahan Cancer Center, North Platte, Nebraska, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Bayonne Medical Center, Bayonne, New Jersey, United States|CarePoint Health - Christ Hospital, Jersey City, New Jersey, United States|Penn Medicine, Princeton Health, Plainsboro, New Jersey, United States|Hematology Oncology Associates of Central New York, East Syracuse, New York, United States|Northwell Health Cancer Institute, Lake Success, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Levine Cancer Institute Atrium Health, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Carteret Health Care, Morehead City, North Carolina, United States|CarolinaEast Medical Center, New Bern, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Florida Cancer Specialists, Massillon, Ohio, United States|Columbia Memorial Hospital, Astoria, Oregon, United States|Samaritan Health Services Corvallis, Corvallis, Oregon, United States|Penn Medicine, Lancaster General Health, Lancaster, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Monument Health, Rapid City, South Dakota, United States|Baptist Clinical Research Institute, Memphis, Tennessee, United States|Tennessee Oncology, Nashville, Tennessee, United States|BSA Harrington Cancer Center, Amarillo, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States\",\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/35/NCT04659135/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04659135'},\n",
       " {'Rank': 4486,\n",
       "  'NCT Number': 'NCT04388514',\n",
       "  'Title': 'Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure',\n",
       "  'Acronym': 'CORMOR',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'SARS-CoV-2 Respiratory Failure',\n",
       "  'Interventions': 'Procedure: Medical Ozone procedure',\n",
       "  'Outcome Measures': 'Time of respiratory improvement and earlier weaning from oxygen support|The time of respiratory improvement and earlier weaning from oxygen support|Assessment of the length of hospitalization|Assessment of the length of Intensive Care Unit (ICU) stay|Improvment in chest imaging finding|Improvment in cytokine release syndrome',\n",
       "  'Sponsor/Collaborators': 'Azienda Sanitaria-Universitaria Integrata di Udine|Fondazione Toscana Gabriele Monasterio|Policlinico Militare, Roma - Italy|Ospedale San Liberatore di Atri|Ospedale Umberto I di Torino|Università di Siena|Ospedale Civile di Lucca|Ospedale di Siracusa|Azienda Sanitaria Locale di Vercelli',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 99 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 90.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'CIG: Z7C2CA5837',\n",
       "  'Start Date': 'April 8, 2020',\n",
       "  'Primary Completion Date': 'October 8, 2020',\n",
       "  'Completion Date': 'October 8, 2020',\n",
       "  'First Posted': 'May 14, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'May 14, 2020',\n",
       "  'Locations': 'Dott. Amato De Monte, Udine, Italy',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04388514/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04388514'},\n",
       " {'Rank': 4513,\n",
       "  'NCT Number': 'NCT04452318',\n",
       "  'Title': 'COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Healthy Participants',\n",
       "  'Interventions': 'Drug: REGN10933 + REGN10987|Drug: Placebo',\n",
       "  'Outcome Measures': 'Proportion of participants who have a RT-qPCR confirmed SARS-CoV-2 infection (either symptomatic or asymptomatic) during the EAP|Proportion of participants with treatment-emergent adverse events (TEAEs) and severity of TEAEs|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and absence of signs and symptoms (broad term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR and absence of signs and symptoms (strict term) during the EAP|Proportion of participants who have a positive SARS-CoV-2 RT-qPCR (based on central lab test) and signs and symptoms (strict term) of SARS-CoV-2 infection during the EAP|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (CDC definition) during the EAP|Number of days of symptomatic SARS-CoV-2 infection (strict-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive SARS-CoV-2 RT-PCR that occurs during the EAP|Number of days of symptomatic SARS-CoV-2 infection (broad-term) from the first day of the first sign or symptom until the last day of the last sign or symptom associated with the first positive SARS-CoV-2 RT-PCR that occurs during the EAP|Time-weighted average of viral load (log10 copies/mL) from the first positive SARS CoV-2 RT-qPCR Nasopharyngeal (NP) swab sample (that has an onset during the EAP) until the visit within the window including 22 days after the positive test during the EAP|Maximum SARS-CoV-2 RT-qPCR log10 viral copies/mL in NP swab samples among individuals with ≥1 RT-qPCR positive that has an onset during the EAP|Area under the curve (AUC) in viral load (log10 copies/mL) from the first positive SARS-CoV-2 RT-qPCR NP swab sample until the first confirmed negative test, that has an onset during the EAP|Number of medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection that has an onset during the EAP|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days missed for daily responsibilities (where applicable) due to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Proportion of subjects who have a positive SARS-CoV-2 RT-qPCR confirmed infection (based on central lab test) during the EAP.|Proportion of baseline seropositive subjects (based on central lab test) with TEAEs and severity of TEAEs|Incidence of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods|Severity of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods|Concentrations of REGN10933 in serum over time and selected PK parameters in seronegative and seropositive participants (based on central lab test)|Concentrations of REGN10987 in serum over time and selected PK parameters in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to REGN10933 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to REGN10987 over time in seronegative and seropositive participants (based on central lab test)|Proportion of participants who subsequently develop signs and symptoms (strict-term) of symptomatic SARS-CoV-2 infection during EAP|Proportion of participants who subsequently develop signs and symptoms (broad-term) of symptomatic SARS-CoV-2 infection during EAP|Proportion of participants who subsequently develop signs and symptoms (CDC definition) of symptomatic SARS-CoV-2 infection during the EAP|Number of days of symptomatic SARS CoV-2 infection (strict-term)|Number of days of symptomatic SARS CoV-2 infection (broad-term)|Time-weighted average change from baseline in viral load (log10 copies/mL) in NP swab samples until the visit within the window including day 23|Area under the curve (AUC) in viral load (log10 copies/mL) in NP swab samples until the first confirmed negative test|Maximum SARS-CoV-2 RT-qPCR log10 viral copies/mL in NP swab samples|Number of medically attended visits in emergency rooms or urgent care centers related to RT-qPCR confirmed SARS-CoV-2 infection|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection|Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection|Number of days missed for daily responsibilities (where applicable) due to a RT-qPCR confirmed SARS-CoV-2 infection|Proportion of participants with TEAEs and severity of TEAEs|Incidence of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods|Severity of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods',\n",
       "  'Sponsor/Collaborators': 'Regeneron Pharmaceuticals',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 3750.0,\n",
       "  'Funded Bys': 'Industry',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'R10933-10987-COV-2069|2020-003654-71',\n",
       "  'Start Date': 'July 13, 2020',\n",
       "  'Primary Completion Date': 'June 15, 2021',\n",
       "  'Completion Date': 'August 15, 2021',\n",
       "  'First Posted': 'June 30, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 8, 2021',\n",
       "  'Locations': 'Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Northridge, California, United States|Regeneron Study Site, Oxnard, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Eatonton, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Sandy Springs, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 2, Chicago, Illinois, United States|Regeneron Study Site 3, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 1, Downers Grove, Illinois, United States|Regeneron Study Site 2, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Metairie, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Gulfport, Mississippi, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Hazelwood, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Fayetteville, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Gaffney, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Charlottesville, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Yakima, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucharest, Romania',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/18/NCT04452318/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04452318'},\n",
       " {'Rank': 4536,\n",
       "  'NCT Number': 'NCT04496245',\n",
       "  'Title': 'Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85',\n",
       "  'Acronym': 'COVIDRASP',\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Respiratory Viral Infection|Covid19',\n",
       "  'Interventions': 'Drug: Broncho-Vaxom®',\n",
       "  'Outcome Measures': 'Acute Respiratory Infection necessitating workforce removal|Time to ARI necessitating workforce removal.|The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal|The proportion of HCW with documented Cov infection.|Time to Lower respiratory infection (LRI) necessitating workforce removal.|The proportion of Health Care Workers contracting a LRI necessitating workforce removal|The proportion of HCW with documented Cov LRI.',\n",
       "  'Sponsor/Collaborators': \"The University of Queensland|Griffith University|The Prince Charles Hospital|Princess Alexandra Hospital, Brisbane, Australia|Telethon Kids Institute|Queensland Children's Hospital, Brisbane, Australia\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 100 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 59.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'BV-2020/19',\n",
       "  'Start Date': 'August 24, 2020',\n",
       "  'Primary Completion Date': 'June 30, 2021',\n",
       "  'Completion Date': 'June 30, 2021',\n",
       "  'First Posted': 'August 3, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 1, 2021',\n",
       "  'Locations': \"The Prince Charles Hospital, Brisbane, Queensland, Australia|The Princess Alexandra Hospital, Brisbane, Queensland, Australia|Queensland Children's Hospital, South Brisbane, Queensland, Australia\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04496245/Prot_SAP_001.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04496245/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04496245'},\n",
       " {'Rank': 4549,\n",
       "  'NCT Number': 'NCT04508920',\n",
       "  'Title': 'A Survey to Assess Effects of Covid-19 on Cardiovascular Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Cardiovascular Diseases|Heart Failure',\n",
       "  'Interventions': 'Other: Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA)',\n",
       "  'Outcome Measures': 'NYHA class deterioration|Dyspnea deterioration|Paroxysmal nocturnal dyspnea deterioration|Edema|Daily activities In the last four weeks? Please, mention if you a perceived limitation on : Walking deterioration',\n",
       "  'Sponsor/Collaborators': 'Centro en Insuficiencia Cardiaca, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez|Medica Sur Clinic & Foundation',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 80 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 76.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '20-1156',\n",
       "  'Start Date': 'May 15, 2019',\n",
       "  'Primary Completion Date': 'June 15, 2021',\n",
       "  'Completion Date': 'July 15, 2021',\n",
       "  'First Posted': 'August 11, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 11, 2020',\n",
       "  'Locations': 'Centro de Insuficiencia Cardiaca Instituto Nacional de Cardiologia, Mexico City, Mexico',\n",
       "  'Study Documents': '\"Study Protocol and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/20/NCT04508920/Prot_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04508920'},\n",
       " {'Rank': 4623,\n",
       "  'NCT Number': 'NCT04385238',\n",
       "  'Title': 'Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19|Pregnancy Complications|Mental Health Wellness 1|Anxiety|Depression|Ptsd|Coronavirus',\n",
       "  'Interventions': 'Other: This is an online survey with no intervention.',\n",
       "  'Outcome Measures': 'Number of Participants With Symptoms of Post-traumatic Stress Disorder|Number of Participants With Symptoms of Anxiety and Depression',\n",
       "  'Sponsor/Collaborators': 'Pregistry|Harvard School of Public Health',\n",
       "  'Gender': 'Female',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 6894.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Only|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': '0002',\n",
       "  'Start Date': 'May 15, 2020',\n",
       "  'Primary Completion Date': 'June 20, 2020',\n",
       "  'Completion Date': 'June 20, 2020',\n",
       "  'First Posted': 'May 12, 2020',\n",
       "  'Results First Posted': 'January 7, 2021',\n",
       "  'Last Update Posted': 'January 7, 2021',\n",
       "  'Locations': 'Pregistry, Los Angeles, California, United States',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04385238/Prot_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04385238/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04385238'},\n",
       " {'Rank': 4880,\n",
       "  'NCT Number': 'NCT04402970',\n",
       "  'Title': 'Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)',\n",
       "  'Acronym': 'DORNASESARS2',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'SARS-CoV 2|ARDS',\n",
       "  'Interventions': 'Drug: Dornase Alfa Inhalation Solution',\n",
       "  'Outcome Measures': 'Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2)|Change in Static Lung Compliance|Duration of Mechanical Ventilation|Length of ICU Stay|Length of Hospitalization|Secondary Bacterial Infections|Mortality',\n",
       "  'Sponsor/Collaborators': 'University of Missouri-Columbia',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '2022206',\n",
       "  'Start Date': 'June 19, 2020',\n",
       "  'Primary Completion Date': 'December 31, 2020',\n",
       "  'Completion Date': 'December 31, 2020',\n",
       "  'First Posted': 'May 27, 2020',\n",
       "  'Results First Posted': 'April 14, 2021',\n",
       "  'Last Update Posted': 'April 14, 2021',\n",
       "  'Locations': 'University of Missouri Hospital and Clinics, Columbia, Missouri, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04402970/Prot_SAP_002.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/70/NCT04402970/ICF_004.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04402970'},\n",
       " {'Rank': 4903,\n",
       "  'NCT Number': 'NCT04458948',\n",
       "  'Title': 'Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Drug: Hydroxychloroquine|Drug: Azithromycin',\n",
       "  'Outcome Measures': 'Duration of viral shedding|Evaluation of Fatality Rate|Evaluation of Clinical Response|Evaluation of Length of Hospital Stay',\n",
       "  'Sponsor/Collaborators': 'University of New Mexico',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 10000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '20-156',\n",
       "  'Start Date': 'March 24, 2020',\n",
       "  'Primary Completion Date': 'March 24, 2021',\n",
       "  'Completion Date': 'March 24, 2025',\n",
       "  'First Posted': 'July 7, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'July 7, 2020',\n",
       "  'Locations': 'University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/48/NCT04458948/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04458948'},\n",
       " {'Rank': 4914,\n",
       "  'NCT Number': 'NCT04592705',\n",
       "  'Title': 'Measurement of IL-6 and Secondary Inflammatory Markers Before and After Therapeutic Plasma Exchange (TPE) in Hospitalized Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Device: Therapeutic plasma exchange',\n",
       "  'Outcome Measures': 'Time to clinical status downgrade or discharge.',\n",
       "  'Sponsor/Collaborators': 'Larkin Community Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 69 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 1',\n",
       "  'Enrollment': 10.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility',\n",
       "  'Other IDs': 'LCH-1-092020',\n",
       "  'Start Date': 'September 11, 2020',\n",
       "  'Primary Completion Date': 'August 30, 2021',\n",
       "  'Completion Date': 'August 30, 2021',\n",
       "  'First Posted': 'October 19, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 19, 2020',\n",
       "  'Locations': 'Larkin Community Hospital, South Miami, Florida, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04592705/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04592705'},\n",
       " {'Rank': 4947,\n",
       "  'NCT Number': 'NCT04315480',\n",
       "  'Title': 'Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'SARS Pneumonia',\n",
       "  'Interventions': 'Drug: Tocilizumab',\n",
       "  'Outcome Measures': 'arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death',\n",
       "  'Sponsor/Collaborators': 'Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 90 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 38.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'TOCICOV-1',\n",
       "  'Start Date': 'March 12, 2020',\n",
       "  'Primary Completion Date': 'April 9, 2020',\n",
       "  'Completion Date': 'May 2020',\n",
       "  'First Posted': 'March 19, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 13, 2020',\n",
       "  'Locations': 'Università Politecnica delle Marche, Ancona, AN, Italy',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04315480'},\n",
       " {'Rank': 4955,\n",
       "  'NCT Number': 'NCT04341584',\n",
       "  'Title': 'CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection',\n",
       "  'Acronym': 'CORIMUNO-ANA',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Corona Virus Infection',\n",
       "  'Interventions': 'Drug: Anakinra',\n",
       "  'Outcome Measures': 'Survival without needs of ventilator utilization at day 14|WHO progression scale ≤ 5|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) or withdrawal of NIV or high flow (for > 48h), at day 14|Decrease of at least one point in WHO progression scale score|WHO progression scale|Survival|28-day ventilator free-days|Respiratory acidosis|PaO2/FiO2 ratio|Time to oxygen supply independency|Duration of hospitalization|Time to negative viral excretion|Time to ICU discharge|Time to hospital discharge',\n",
       "  'Sponsor/Collaborators': 'Assistance Publique - Hôpitaux de Paris',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 161.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'APHP200375-5',\n",
       "  'Start Date': 'April 8, 2020',\n",
       "  'Primary Completion Date': 'May 10, 2020',\n",
       "  'Completion Date': 'July 25, 2020',\n",
       "  'First Posted': 'April 10, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 1, 2021',\n",
       "  'Locations': 'Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/84/NCT04341584/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04341584'},\n",
       " {'Rank': 4967,\n",
       "  'NCT Number': 'NCT04693689',\n",
       "  'Title': 'Novelty, Conformity and Trust in Vaccines',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Trust',\n",
       "  'Interventions': 'Other: RNA vaccine|Other: 20% adoption rate|Other: 40% adoption rate|Other: 60% adoption rate|Other: 80% adoption rate|Other: Conventional vaccine|Other: 0% adoption rate',\n",
       "  'Outcome Measures': 'Willingness to receive COVID-19 vaccine|Belief in how much COVID-19 vaccine should be subsidized by the government|Belief in importance of vaccinating children|Belief in safety of vaccines|Belief in effectiveness of vaccines|Dishonesty index',\n",
       "  'Sponsor/Collaborators': 'National University, Singapore',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 32400.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research',\n",
       "  'Other IDs': 'SG-Trust in Vaccines',\n",
       "  'Start Date': 'February 1, 2021',\n",
       "  'Primary Completion Date': 'March 30, 2021',\n",
       "  'Completion Date': 'March 30, 2021',\n",
       "  'First Posted': 'January 5, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 3, 2021',\n",
       "  'Locations': 'SurveyMonkey, San Mateo, California, United States',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/89/NCT04693689/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04693689'},\n",
       " {'Rank': 4986,\n",
       "  'NCT Number': 'NCT04656626',\n",
       "  'Title': 'Brief Mindfulness Based Intervention to Improve Psychological Wellbeing',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Stress, Psychological',\n",
       "  'Interventions': 'Behavioral: brief mindfulness based intervention|Behavioral: Progressive muscle relaxation',\n",
       "  'Outcome Measures': 'reduction of anxiety symptom severity|change in the level of psychological resilience|mental wellbeing|and functional status',\n",
       "  'Sponsor/Collaborators': 'Imam Abdulrahman Bin Faisal University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '22 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 146.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other',\n",
       "  'Other IDs': 'Mindfullness during a pandemic',\n",
       "  'Start Date': 'July 7, 2020',\n",
       "  'Primary Completion Date': 'July 21, 2020',\n",
       "  'Completion Date': 'September 5, 2020',\n",
       "  'First Posted': 'December 7, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 10, 2020',\n",
       "  'Locations': 'Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04656626/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/26/NCT04656626/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04656626'},\n",
       " {'Rank': 4990,\n",
       "  'NCT Number': 'NCT04747990',\n",
       "  'Title': 'coMpliAnce With evideNce-based cliniCal Guidelines in the managemenT of Acute biliaRy pancreAtitis',\n",
       "  'Acronym': 'MANCTRA-1',\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Acute Pancreatitis|Acute Pancreatic Necrosis|Acute Pancreatitis Due to Gallstones|Acute Pancreatic Fluid Collection|Acute Pancreatitis With Infected Necrosis|Acute Pancreatitis Without Necrosis or Infection|Acute Pancreatitis Due to Common Bile Duct Calculus|Acute Pancreatitis Recurrent|Acute Pancreatitis Without Necrosis or Infection (Diagnosis)|Covid19',\n",
       "  'Interventions': 'Procedure: Early Definitive Treatment',\n",
       "  'Outcome Measures': 'Mortality|Early Cholecystectomy or ERCP and Sphincterotomy|Hospital re-admission|Morbidity|Hospital readmission',\n",
       "  'Sponsor/Collaborators': 'University of Cagliari|Chiara Gerardi - Istituto Di Ricerche Farmacologiche Mario Negri|Federico Coccolini - General, Emergency and Trauma Surgery, Pisa|Salomone di Saverio -Department of Surgery, Varese|Gianluca Pellino - Universitá degli Studi della Campania \\'Luigi Vanvitelli\\', Naples|Francesco Pata - General Surgery Unit, Nicola Giannettasio Hospital, Corigliano-Rossano|Benedetto Ielpo - HPB Surgery Unit, Hospital del Mar, Barcelona|Francesco Virdis - Trauma and Acute Care Surgery Unit, Milan|Dimitrios Damaskos - Royal Infirmary of Edinburgh, Edinburgh|Stavros Gourgiotis - Addenbrooke\\'s Hospital, Cambridge|Gaetano Poillucci - Department of Surgery \"Paride Stefanini\", Rome|Daniela Pacella - University of Naples Federico II, Naples|Kumar Jayant- University of Chicago, USA|Ferdinando Agresta- Vittorio Veneto Civil Hospital, Italy|Ari Leppaniemi - University of Helsinki, Finland|Fausto Catena - Maggiore Hospital, Parma|Yoram Kluger - Rambam Health care campus, Haifa|Adolfo Pisanu - University of Cagliari, Cagliari',\n",
       "  'Gender': 'All',\n",
       "  'Age': '16 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 600.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Retrospective',\n",
       "  'Other IDs': 'Biliary Pancreatitis',\n",
       "  'Start Date': 'March 1, 2021',\n",
       "  'Primary Completion Date': 'July 1, 2021',\n",
       "  'Completion Date': 'September 1, 2021',\n",
       "  'First Posted': 'February 10, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 23, 2021',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/90/NCT04747990/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04747990'},\n",
       " {'Rank': 5026,\n",
       "  'NCT Number': 'NCT04385576',\n",
       "  'Title': 'Taiwan \"Aerosol Box\" Versus UMMC \"Intubation Box\"',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'COVID-19|Airway',\n",
       "  'Interventions': 'Device: Aerosol Box|Device: Intubation Box',\n",
       "  'Outcome Measures': \"Time to successful intubation|Number of intubation attempts|Evaluation of the intubator's experience using both boxes\",\n",
       "  'Sponsor/Collaborators': 'University of Malaya',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science',\n",
       "  'Other IDs': '2020410-8498',\n",
       "  'Start Date': 'May 15, 2020',\n",
       "  'Primary Completion Date': 'September 15, 2020',\n",
       "  'Completion Date': 'December 30, 2020',\n",
       "  'First Posted': 'May 13, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'May 13, 2020',\n",
       "  'Locations': 'University Malaya Medical Centre, Kuala Lumpur, Selangor, Malaysia',\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04385576/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04385576'},\n",
       " {'Rank': 5029,\n",
       "  'NCT Number': 'NCT04424836',\n",
       "  'Title': 'HFNC Treatment in COVID-19 Pneumonia',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Failure',\n",
       "  'Interventions': 'Device: high flow nasal cannula device',\n",
       "  'Outcome Measures': 'short term mortality|icu stay|blood gases',\n",
       "  'Sponsor/Collaborators': 'Sisli Hamidiye Etfal Training and Research Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 43.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Control|Time Perspective: Retrospective',\n",
       "  'Other IDs': '5569',\n",
       "  'Start Date': 'May 15, 2020',\n",
       "  'Primary Completion Date': 'June 4, 2020',\n",
       "  'Completion Date': 'June 5, 2020',\n",
       "  'First Posted': 'June 11, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'July 16, 2020',\n",
       "  'Locations': 'Sisli Etfal Research and Training Hospital, Istanbul, Turkey',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/36/NCT04424836/Prot_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/36/NCT04424836/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04424836'},\n",
       " {'Rank': 5082,\n",
       "  'NCT Number': 'NCT04338009',\n",
       "  'Title': 'Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019',\n",
       "  'Acronym': 'REPLACECOVID',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'COVID-19',\n",
       "  'Interventions': 'Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI',\n",
       "  'Outcome Measures': 'Hierarchical Composite Endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, Invasive Mechanical Ventilation or Extracorporeal Membrane Oxygenation|AUC SOFA',\n",
       "  'Sponsor/Collaborators': 'University of Pennsylvania|Jordana B. Cohen, MD, MSCE|Thomas C. Hanff, MD, MPH|Division of Cardiology, University of Arizona, Tucson, AZ, USA|Department of Medicine, Hospital Nacional Carlos Alberto Seguín Escobedo, Arequipa, Peru|Department of Nephrology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hypertension Unit, Department of Pathology, Hospital Español de Mendoza, National University of Cuyo, IMBECU-CONICET, Mendoza, Argentina|Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA|Division of Infectious Diseases, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada|Unidad de VIH, Hospital Civil de Guadalajara and Universidad de Guadalajara, Guadalajara, Mexico|Universidad Católica de Buenos Aires, Buenos Aires, Argentina|Departamento de Medicina Interna, Hospital Obrero number 3 Caja Nacional de Salud, Santa Cruz de la Sierra, Bolivia|Departamento de Medicina, Hospital Alberto Barton Thompson, Callao, Peru|Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden|Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL, USA|Departamento de Emergencia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Division of Cardiology, Department of Medicine, Hospital Español, Buenos Aires, Argentina|Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA|Jesse Chittams, MS|Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA|Charles R Vasquez, MD',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 152.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '842810',\n",
       "  'Start Date': 'March 31, 2020',\n",
       "  'Primary Completion Date': 'August 20, 2020',\n",
       "  'Completion Date': 'August 20, 2020',\n",
       "  'First Posted': 'April 8, 2020',\n",
       "  'Results First Posted': 'April 9, 2021',\n",
       "  'Last Update Posted': 'April 9, 2021',\n",
       "  'Locations': 'University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT04338009/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04338009'},\n",
       " {'Rank': 5091,\n",
       "  'NCT Number': 'NCT04302766',\n",
       "  'Title': 'Expanded Access Remdesivir (RDV; GS-5734™)',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'No longer available',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Coronavirus Disease 2019',\n",
       "  'Interventions': 'Drug: Remdesivir',\n",
       "  'Outcome Measures': nan,\n",
       "  'Sponsor/Collaborators': 'U.S. Army Medical Research and Development Command',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': nan,\n",
       "  'Funded Bys': 'U.S. Fed',\n",
       "  'Study Type': 'Expanded Access:Intermediate-size Population|Treatment IND/Protocol',\n",
       "  'Study Designs': nan,\n",
       "  'Other IDs': 'S-20-01',\n",
       "  'Start Date': nan,\n",
       "  'Primary Completion Date': nan,\n",
       "  'Completion Date': nan,\n",
       "  'First Posted': 'March 10, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 1, 2021',\n",
       "  'Locations': 'Naval Medical Center San Diego, San Diego, California, United States|Naval Hospital Jacksonville, Jacksonville, Florida, United States|Benning Martin Army Community Hospital, Fort Benning, Georgia, United States|Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Tripler Army Medical Center, Tripler AMC, Hawaii, United States|Blanchfield Army Community Hospital, Fort Campbell North, Kentucky, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Naval Medical Center Camp Lejeune, Camp Lejeune, North Carolina, United States|Womack Army Medical Center, Fort Bragg, North Carolina, United States|William Beaumont Army Medical Center, El Paso, Texas, United States|Carl R. Darnall Army Medical Center, Fort Hood, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Naval Medical Center Portsmouth, Portsmouth, Virginia, United States|Madigan Army Medical Center, Tacoma, Washington, United States|Craig Joint Theater Hospital, Bagrām, Afghanistan|NATO Role 3 Multinational Medical Unit Kandahar Air Field, Kandahar, Afghanistan|EMF Camp Lemonnier, Djibouti, Djibouti|Landstuhl Regional Medical Center, Landstuhl, APO Ae, Germany|US Naval Hospital Guam, Agaña, Guam|Baghdad Diplomatic Support Center, Baghdad, Iraq|US Naval Hospital Okinawa, Okinawa, Japan|US Military Hospital Kuwait 411th Hospital Center, Kuwait, Kuwait',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/66/NCT04302766/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04302766'},\n",
       " {'Rank': 5146,\n",
       "  'NCT Number': 'NCT04453839',\n",
       "  'Title': 'ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)',\n",
       "  'Acronym': 'SAMICARE',\n",
       "  'Status': 'Available',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Critical COVID-19 With Respiratory Failure',\n",
       "  'Interventions': 'Drug: ZYESAMI (aviptadil acetate)',\n",
       "  'Outcome Measures': nan,\n",
       "  'Sponsor/Collaborators': 'NeuroRx, Inc.|Cavendish Impact Foundation',\n",
       "  'Gender': 'All',\n",
       "  'Age': '12 Years to 100 Years \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': nan,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Expanded Access:Intermediate-size Population',\n",
       "  'Study Designs': nan,\n",
       "  'Other IDs': 'RLF-100_EA-1',\n",
       "  'Start Date': nan,\n",
       "  'Primary Completion Date': nan,\n",
       "  'Completion Date': nan,\n",
       "  'First Posted': 'July 1, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 19, 2021',\n",
       "  'Locations': 'Dignity Health-Mercy Gilbert Medical Center, Gilbert, Arizona, United States|Honor Health Shea Medical Center, Scottsdale, Arizona, United States|Kaiser Permanente, Baldwin Park, California, United States|University of California - Irvine, Irvine, California, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Lakeland Regional Health, Lakeland, Florida, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Baycare St. Joseph Hospital, Tampa, Florida, United States|Southeast Georgia Health system, Brunswick, Georgia, United States|Maui Health Systems, Wailuku, Hawaii, United States|St. Anthony Regional Hospital, Carroll, Iowa, United States|University of Louisville, Louisville, Kentucky, United States|St. Tammany Parish Hospital, Covington, Louisiana, United States|Our Ladies of Lourdes Regional Hospital, Lafayette, Louisiana, United States|St. Joseph Heritage Healthcare, Saint Joseph, Missouri, United States|Great Plains Health, North Platte, Nebraska, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Hendrick Medical Center, Abilene, Texas, United States|Baptist Hospitals of Southeast Texas, Beaumont, Texas, United States|Medical City Denton, Denton, Texas, United States|HR Health Institute for Research & Development, Edinburg, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Memorial Hermann Hospital Houston, Houston, Texas, United States|Medical City McKinney, McKinney, Texas, United States',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04453839/Prot_001.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/39/NCT04453839/ICF_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04453839'},\n",
       " {'Rank': 5160,\n",
       "  'NCT Number': 'NCT04399005',\n",
       "  'Title': 'The Efficacy Comparing Daily and After-each-case Room Disinfection.',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Daily Room Disinfection|After-each-case Room Disinfection',\n",
       "  'Interventions': 'Other: after-each-case room disinfection|Other: daily room disinfection',\n",
       "  'Outcome Measures': 'Qualified rate of room disinfection|The number of colony-forming units (CFU)',\n",
       "  'Sponsor/Collaborators': 'The First Affiliated Hospital of Zhejiang Chinese Medical University',\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 240.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other',\n",
       "  'Other IDs': 'DACD-HuY-2005',\n",
       "  'Start Date': 'May 25, 2020',\n",
       "  'Primary Completion Date': 'June 5, 2020',\n",
       "  'Completion Date': 'June 10, 2020',\n",
       "  'First Posted': 'May 22, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 25, 2020',\n",
       "  'Locations': 'First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/05/NCT04399005/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04399005'},\n",
       " {'Rank': 5169,\n",
       "  'NCT Number': 'NCT04787536',\n",
       "  'Title': 'Perioperative Cognitive Trajectories in Deferred Surgery (CoTELE-SURGE)',\n",
       "  'Acronym': 'CoTELE-SURGE',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Postoperative Cognitive Dysfunction|Depressive Symptoms|Postoperative Pain',\n",
       "  'Interventions': 'Procedure: Non-cardiac surgery',\n",
       "  'Outcome Measures': 'Change in perioperative cognitive trajectories assessed using the Cogstate Brief Battery (CBB)|Pain trajectories using the Numeric Pain Rating Scale|Depressive symptoms trajectories using the Geriatric Depression Scale (short form) (GDS)',\n",
       "  'Sponsor/Collaborators': 'McMaster University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '65 Years and older \\xa0 (Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 300.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '10829',\n",
       "  'Start Date': 'June 10, 2020',\n",
       "  'Primary Completion Date': 'December 31, 2022',\n",
       "  'Completion Date': 'December 31, 2022',\n",
       "  'First Posted': 'March 8, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 8, 2021',\n",
       "  'Locations': 'McMaster University, Hamilton, Ontario, Canada',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/36/NCT04787536/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04787536'},\n",
       " {'Rank': 5205,\n",
       "  'NCT Number': 'NCT04636944',\n",
       "  'Title': 'Management of Depression and Anxiety in HF',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Heart Failure|Depression|Anxiety',\n",
       "  'Interventions': 'Other: web-based COMPASS intervention',\n",
       "  'Outcome Measures': \"Explore community heart failure nurses' perception of assessing, managing and treating depression and anxiety in HF and the use of web-based interventions.|Explore community heart failure patients' perception of assessing, managing and treating depression and anxiety in HF and the use of web-based interventions.|Explore nurses' perception of using web-based COMPASS intervention for depression and anxiety management in HF|Explore patients' perception of using web-based COMPASS intervention for depression and anxiety management in HF|Explore with community HF nurses the impact of COVID-19 pandemic on HF patients' depression and anxiety level and changes to management processes.|Explore with community HF patients the impact of COVID-19 pandemic on HF patients' depression and anxiety level and changes to management processes.\",\n",
       "  'Sponsor/Collaborators': \"King's College London\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '19 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 13.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Other|Time Perspective: Other',\n",
       "  'Other IDs': 'IRAS ID: 268951',\n",
       "  'Start Date': 'October 2, 2020',\n",
       "  'Primary Completion Date': 'August 16, 2021',\n",
       "  'Completion Date': 'August 16, 2021',\n",
       "  'First Posted': 'November 19, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 19, 2020',\n",
       "  'Locations': 'Community Heart Failure Team: Elmcourt Health Centre, London, United Kingdom',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04636944/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04636944'},\n",
       " {'Rank': 5217,\n",
       "  'NCT Number': 'NCT03738774',\n",
       "  'Title': 'Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)',\n",
       "  'Acronym': 'APICS',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Post Intensive Care Syndrome',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': 'Number of deaths or hospital readmissions within three months of discharge|Number of ER visits|Healthcare utilization|Cognitive Functional outcome as assessed by Montreal Cognitive Assessment (MoCA) - Blind Instrument|Physical function outcome as assessed by Activity of Daily Living (ADL-Katz Index)|Physical function outcome as assessed by Instrumental Activity of Daily Living (IADL-Lawton)|Mental health Functional outcome as assessed by Hospital Anxiety and Depression Scale (HADS)|Functional outcomes-Post Traumatic Stress Disorder (PTSD)|Coping or social support|Health related quality of life|Number of deaths within 6 Months after discharge|Return to work',\n",
       "  'Sponsor/Collaborators': 'Vanderbilt University Medical Center|United States Department of Defense',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 200.0,\n",
       "  'Funded Bys': 'Other|U.S. Fed',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': 'IRB181120',\n",
       "  'Start Date': 'January 2, 2019',\n",
       "  'Primary Completion Date': 'December 2021',\n",
       "  'Completion Date': 'July 2022',\n",
       "  'First Posted': 'November 13, 2018',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 22, 2020',\n",
       "  'Locations': 'Johns Hopkins Hospital, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Vanderbilt University, Nashville, Tennessee, United States|Intermountain Medical Center, Murray, Utah, United States|George Wahlen Salt Lake City Veterans Administration Hospital, Salt Lake City, Utah, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/74/NCT03738774/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03738774'},\n",
       " {'Rank': 5310,\n",
       "  'NCT Number': 'NCT04799561',\n",
       "  'Title': 'Teleprehabilitation for Surgical Cancer Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Abdominal Cancer|Thoracic Cancer',\n",
       "  'Interventions': 'Behavioral: Multimodal Teleprehabilitation',\n",
       "  'Outcome Measures': 'Recruitment Rate|Adherence|Program Completion Rate|frequency of Technological Failures|Intervention-Related Adverse Events|Rational for Refusal to Participate|Rational for Low Compliance|Rational for Drop-Outs|30 Second Sit-to-Stand|Time-Up and Go (TUG)|2- or 6-Minute Walk Test|Abridged-Scored Patient-Generated Subjective Global Assessment (PG-SGA)|Body Mass Index (BMI)|CRP|Serum Albumin|Duke Activity Status Index (DASI)|Quality of Life (EQ5D)|The Hospital Anxiety and Depression Scale (HADS)|Distress Thermometer|The WHO Disability Assessment Schedule v2.0 (WHODAS)|The Energy Expenditure (CHAMPS)|The Clavien-Dindo Classifications(CDC)|The Comprehensive Complication Index (CCI)|The 30-day Mortality|Length of Intensive Care Stay|Days with a chest tube|Length of Hospital Stay',\n",
       "  'Sponsor/Collaborators': 'McGill University Health Centre/Research Institute of the McGill University Health Centre|Montreal General Hospital Foundation|Peri-Operative Program (POP) Foundation',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 100.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care',\n",
       "  'Other IDs': 'MUHC-2021-6730',\n",
       "  'Start Date': 'March 15, 2021',\n",
       "  'Primary Completion Date': 'September 15, 2022',\n",
       "  'Completion Date': 'December 15, 2022',\n",
       "  'First Posted': 'March 16, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 16, 2021',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04799561/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04799561'},\n",
       " {'Rank': 5349,\n",
       "  'NCT Number': 'NCT04625465',\n",
       "  'Title': 'Proximal Effects of Alcohol on Same-Sex Intimate Partner Violence',\n",
       "  'Acronym': 'PASSION',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Alcohol Consumption|Violence, Domestic|Stress, Psychological|Aggression',\n",
       "  'Interventions': 'Behavioral: CBT Text Messaging|Behavioral: Attention Control Text Messaging',\n",
       "  'Outcome Measures': 'Intimate Partner Violence Events (Burst 1)|Intimate Partner Violence Events (Burst 2)|Intimate Partner Violence Events (Burst 3)|Intimate Partner Violence Events (Burst 4)|Drinking Episodes (Burst 1)|Drinking Episodes (Burst 2)|Drinking Episodes (Burst 3)|Drinking Episodes (Burst 4)|Sexual or Gender Minority Stress (Burst 1)|Sexual or Gender Minority Stress (Burst 2)|Sexual or Gender Minority Stress (Burst 3)|Sexual or Gender Minority Stress (Burst 4)|COVID-19 Stress (Burst 1)|COVID-19 Stress (Burst 2)|COVID-19 Stress (Burst 3)|COVID-19 Stress (Burst 4)',\n",
       "  'Sponsor/Collaborators': 'Georgia State University|University at Buffalo',\n",
       "  'Gender': 'All',\n",
       "  'Age': '21 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 480.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'R01AA025995',\n",
       "  'Start Date': 'November 12, 2020',\n",
       "  'Primary Completion Date': 'September 30, 2022',\n",
       "  'Completion Date': 'September 30, 2022',\n",
       "  'First Posted': 'November 12, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 7, 2021',\n",
       "  'Locations': 'Georgia State University, Atlanta, Georgia, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/65/NCT04625465/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04625465'},\n",
       " {'Rank': 5359,\n",
       "  'NCT Number': 'NCT04487483',\n",
       "  'Title': 'Exploring the Impact of a Sleep App on Sleep Quality',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Sleep',\n",
       "  'Interventions': 'Behavioral: Sleep App',\n",
       "  'Outcome Measures': 'Change in self-reported sleep quality|Change in self-reported sleep|Engagement with the sleep app|Telephone interview qualitative user data',\n",
       "  'Sponsor/Collaborators': 'University College, London|University of California, Los Angeles',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 101.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other',\n",
       "  'Other IDs': 'SleepAppEvaluation',\n",
       "  'Start Date': 'February 13, 2020',\n",
       "  'Primary Completion Date': 'June 17, 2020',\n",
       "  'Completion Date': 'August 15, 2020',\n",
       "  'First Posted': 'July 27, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'August 11, 2020',\n",
       "  'Locations': 'University College London, London, United Kingdom',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/83/NCT04487483/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04487483'},\n",
       " {'Rank': 5368,\n",
       "  'NCT Number': 'NCT04339842',\n",
       "  'Title': 'Eating Habits of Adults During the Quarantine',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Health Behavior|Eating Behavior',\n",
       "  'Interventions': 'Other: Assessment of Dietary Changes in Adults in the Quarantine',\n",
       "  'Outcome Measures': 'Changes in the Eating Habits of Adults during the Quarantine',\n",
       "  'Sponsor/Collaborators': 'Eliz Arter|Cyprus Science University|Eastern Mediterranean University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 80 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 673.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Case-Only|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': 'Nutr2020',\n",
       "  'Start Date': 'April 10, 2020',\n",
       "  'Primary Completion Date': 'May 31, 2020',\n",
       "  'Completion Date': 'May 31, 2020',\n",
       "  'First Posted': 'April 9, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'July 22, 2020',\n",
       "  'Locations': 'Online, Nicosia, Cyprus',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/42/NCT04339842/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04339842'},\n",
       " {'Rank': 5385,\n",
       "  'NCT Number': 'NCT03827109',\n",
       "  'Title': 'Peer Mentoring to Improve Self-management in Youth With IBD',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Pediatric Crohns Disease|Pediatric Ulcerative Colitis|Inflammatory Bowel Diseases',\n",
       "  'Interventions': 'Behavioral: Group educational activities|Behavioral: IBD educational website|Behavioral: Monthly check-in calls from program coordinator|Behavioral: Mentor|Behavioral: Fun group activities|Behavioral: Parent support group',\n",
       "  'Outcome Measures': \"12 month youth quality of life: PedsQL|18 month youth quality of life: PedsQL|12 month change from baseline Youth quality of life: PedsQL|18 month change from baseline Youth quality of life: PedsQL|12 month youth functional disability|18 month youth functional disability|12 month change from baseline youth functional disability|18 month change from baseline youth functional disability|12 month Youth disease outcomes - Crohn's Disease severity|12 month Youth disease outcomes - Ulcerative Colitis severity|18 month Youth disease outcomes - Crohn's Disease severity|18 month Youth disease outcomes - Ulcerative Colitis severity|12 month number of hospital admissions in previous 6 months|18 month number of hospital admissions in previous 6 months|12 month number of clinic appointments in previous 6 months|18 month number of clinic appointments in previous 6 months|12 month number of missed appointments in previous 6 months|18 month number of missed appointments in previous 6 months|12 month number of procedures in previous 6 months|18 month number of procedures in previous 6 months|12 months Mentor QOL|18 months Mentor QOL|12 month change from baseline Mentor QOL|12 month Parent QOL|12 month change from baseline Parent QOL\",\n",
       "  'Sponsor/Collaborators': \"Laura Mackner|Children's Hospital Medical Center, Cincinnati|Rosalind Franklin University of Medicine and Science|Nationwide Children's Hospital\",\n",
       "  'Gender': 'All',\n",
       "  'Age': '10 Years to 17 Years \\xa0 (Child)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 300.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'R01NR017533',\n",
       "  'Start Date': 'June 12, 2019',\n",
       "  'Primary Completion Date': 'February 23, 2023',\n",
       "  'Completion Date': 'February 23, 2023',\n",
       "  'First Posted': 'February 1, 2019',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 20, 2021',\n",
       "  'Locations': \"Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03827109/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/09/NCT03827109/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03827109'},\n",
       " {'Rank': 5390,\n",
       "  'NCT Number': 'NCT04675658',\n",
       "  'Title': 'Stay Active Physical Activity Program',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Healthy Lifestyle|Sedentary Behavior',\n",
       "  'Interventions': 'Behavioral: CBPA + family support|Behavioral: CBPA',\n",
       "  'Outcome Measures': 'Daily minutes of PA (physical activity)|Daily step count|Parent perceptions of interventions|Teacher perceptions of interventions',\n",
       "  'Sponsor/Collaborators': \"Children's Mercy Hospital Kansas City\",\n",
       "  'Gender': 'All',\n",
       "  'Age': 'Child, Adult, Older Adult',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 515.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'STUDY00001495',\n",
       "  'Start Date': 'October 5, 2020',\n",
       "  'Primary Completion Date': 'December 20, 2020',\n",
       "  'Completion Date': 'March 30, 2021',\n",
       "  'First Posted': 'December 19, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 27, 2021',\n",
       "  'Locations': \"Children's Mercy, Kansas City, Missouri, United States\",\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/58/NCT04675658/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04675658'},\n",
       " {'Rank': 5418,\n",
       "  'NCT Number': 'NCT04546854',\n",
       "  'Title': 'Influenza 2020/2021',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Influenza Vaccine',\n",
       "  'Interventions': 'Behavioral: Appeals',\n",
       "  'Outcome Measures': 'Intentions to take up the seasonal influenza vaccination',\n",
       "  'Sponsor/Collaborators': 'University of Warwick',\n",
       "  'Gender': 'All',\n",
       "  'Age': '50 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 200.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other',\n",
       "  'Other IDs': 'BSREC 167/19-20',\n",
       "  'Start Date': 'September 21, 2020',\n",
       "  'Primary Completion Date': 'September 21, 2020',\n",
       "  'Completion Date': 'September 21, 2020',\n",
       "  'First Posted': 'September 14, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'September 25, 2020',\n",
       "  'Locations': 'University of Warwick, Coventry, United Kingdom',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/54/NCT04546854/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04546854'},\n",
       " {'Rank': 5435,\n",
       "  'NCT Number': 'NCT04673513',\n",
       "  'Title': 'Cognitive Behavioral Therapy for Depression: Helping Clients Learn New Skills',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Depression',\n",
       "  'Interventions': 'Other: Psychotherapy',\n",
       "  'Outcome Measures': 'Change in Quick Inventory of Depressive Symptoms-Self-Report at week 12.|Change in Cognitive Change Sustained at week 12.|Change in Ways of Responding Scale at week 12.|Change in CBT Skills - Interview at week 12.|Change in Quick Inventory of Depressive Symptoms-Clinician version at week 12.|Change in Cognitive Change Immediate at week 12.|Change in Competencies of Cognitive Therapy Scale - client version at week 12.|Change in Competencies of Cognitive Therapy Scale - therapist version at week 12.|Change in Work Social Adjustment Scale at week 12.',\n",
       "  'Sponsor/Collaborators': 'Ohio State University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 150.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '2020B0354',\n",
       "  'Start Date': 'December 11, 2020',\n",
       "  'Primary Completion Date': 'July 30, 2023',\n",
       "  'Completion Date': 'December 30, 2023',\n",
       "  'First Posted': 'December 17, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 17, 2020',\n",
       "  'Locations': 'Department of Psychology, The Ohio State University, Columbus, Ohio, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/13/NCT04673513/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04673513'},\n",
       " {'Rank': 5451,\n",
       "  'NCT Number': 'NCT02517489',\n",
       "  'Title': 'Community-Acquired Pneumonia : Evaluation of Corticosteroids',\n",
       "  'Acronym': 'CAPE_COD',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Community Acquired Pneumonia',\n",
       "  'Interventions': 'Drug: Hydrocortisone|Drug: Placebo',\n",
       "  'Outcome Measures': 'Day 28 all causes mortality|Day 21 failure|In patients non-invasively ventilated at inclusion, proportion of patients needing endotracheal intubation|In patients non-ventilated at inclusion, proportion of patients requiring non-invasive ventilation|In patients non-ventilated at inclusion, proportion of patients needing endotracheal intubation|Day 28 ventilator-free-days|Number of patients with vasopressor therapy initiation from inclusion to day 28|Day 28 vasopressor-free-days|ICU and/or intermediate care unit LOS|All-causes mortality at day 90|SF-36 Health Survey at day 90|Biomarkers: procalcitonin at baseline, day 3 and day 7|Biomarkers: C-reactive protein at baseline, day 3 and day 7|Biomarkers: plasmatic concentration of pro-inflammatory cytokines (IL-6, IL-20, IL-22, IL-22BP, HBD2, TNF) at baseline, day 3 and day 7|P/F ratio measured daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28|SOFA calculated daily from baseline to day 7, at the end of treatment, at the end of ICU-stay and/or day 28|Proportion of patients experiencing secondary infection during their ICU-stay|Proportion of patients experiencing gastrointestinal bleeding during their ICU-stay|Daily amount of insulin administered to the patient from day 1 to day 7|Weight-gain at baseline and day 7',\n",
       "  'Sponsor/Collaborators': 'University Hospital, Tours',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 1200.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'PHRN14-PFD/CAPE COD',\n",
       "  'Start Date': 'October 28, 2015',\n",
       "  'Primary Completion Date': 'January 2021',\n",
       "  'Completion Date': 'March 2021',\n",
       "  'First Posted': 'August 7, 2015',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 15, 2020',\n",
       "  'Locations': \"Service de Réanimation - Unité de Soins Continus, CH d'Angoulême, 'Angoulême, France|Service de Réanimation Polyvalente, CH d'Argenteuil, Argenteuil, France|Service de Réanimation, CHR Metz-Thionville, Ars-Laquenexy, France|Service de Réanimation, Aulnay-sous-Bois, France|Service de Réanimation, Belfort, France|Service de Réanimation, Bourg-en-Bresse, France|Service de Réanimation HIA Clermont-Tonnerre, Brest, France|Service de Réanimation Médicale, CHU de Brest, Brest, France|Service de Réanimation, CHU Côte de Nacre, Caen, France|Service de Réanimation Médicale, Hôpital Louis Pasteur, Chartres, Chartres, France|Service de Réanimation Médicale Polyvalente, Hôpital G Montpied, Clermont Ferrand, France|Service de Réanimation, Hôpital Louis Mourier, Colombes, France|Service de Réanimation Médicale, CHU de Dijon, Dijon, France|Service de Réanimation Médico-Chirurgicale, Hôpital Raymond Poincarré, APHP, Garches, France|Service de Réanimation Médicale, CHU de Grenoble, Grenoble, France|Service de Réanimation Polyvalente, CHD La Roche sur Yon, La Roche sur Yon, France|Service de Réanimation, CH Le Mans, Le Mans, France|Service de Réanimation Polyvalente, Hôpital Salengro, CHU de Lille, Lille, France|Service de Réanimation Polyvalente, CHU de Limoges, Limoges, France|Service de Réanimation Médicale, Hôpital Nord, Marseille, France|Service de Réanimation Polyvalente - Surveillance Continue, CH de Montauban, Montauban, France|Service de Réanimation Médicale, CHU de Nancy, Nancy, France|Service de Réanimation Polyvalente, Hôpital Hôtel Dieu, CHU de Nantes, Nantes, France|Service de Réanimation Médicale, CHR d'Orléans, Orléans, France|Service de Réanimation Médicale, Hôpital Cochin, APHP, Paris, France|Service de Réanimation et USC médico-chirurgicale, Hôpital Tenon, APHP, Paris, France|Service de Réanimation Médicale et Médecine Interne, CHU de Poitiers, Poitiers, France|Service des Maladies Infectieuses et Réanimation Médicale, CHU de Rennes, Rennes, France|Service de Réanimation Polyvalente, CH de Saint Malo, Saint Malo, France|Service de Réanimation, Saint-Brieuc, France|Service de Réanimation Médicale, Nouvel Hôpital Civil, CHU de Strasbourg, Strasbourg, France|Service de Réanimation Médicale, Hôpital de Hautepierre, CHU de Strasbourg, Strasbourg, France\",\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02517489/SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT02517489'},\n",
       " {'Rank': 5466,\n",
       "  'NCT Number': 'NCT04497753',\n",
       "  'Title': 'An Epidemiological Investigation on Correct Wearing of Mask by Hood Test',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Respiratory Infectious Diseases',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': \"can or can't fell bitterness\",\n",
       "  'Sponsor/Collaborators': 'Fuwai Yunnan Cardiovascular Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '7 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 6000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': '2020-KZLXB-02-02',\n",
       "  'Start Date': 'June 19, 2020',\n",
       "  'Primary Completion Date': 'August 31, 2020',\n",
       "  'Completion Date': 'August 31, 2020',\n",
       "  'First Posted': 'August 4, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 19, 2020',\n",
       "  'Locations': 'Fuwai hospital, Beijing, Beijing, Beijing, China|Taizhou Health Bureau, Taizhou, Jiangsu, China|Bin Health Wen, Jinzhong, Shanxi, China|Yuanqu Health Bureau, Yuncheng, Shanxi, China|Fuwai Yunnan Cardiovascular Hospital, Kunming, Yunnan, China|Luliang Health Bureau, Qujing, Yunnan, China|Shizong Health Bureau, Qujing, Yunnan, China|Luoping Health Bureau, Qujing, Yunnan, China',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/53/NCT04497753/ICF_001.pdf|\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/53/NCT04497753/Prot_SAP_003.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04497753'},\n",
       " {'Rank': 5467,\n",
       "  'NCT Number': 'NCT04497675',\n",
       "  'Title': 'An Epidemiological Investigation on Correct Wearing of Mask by Direct Spray Test',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Respiratory Infectious Diseases',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': \"can or can't fell bitterness\",\n",
       "  'Sponsor/Collaborators': 'Fuwai Yunnan Cardiovascular Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '7 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 6000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': '2020-KZLXB-02-01',\n",
       "  'Start Date': 'June 19, 2020',\n",
       "  'Primary Completion Date': 'August 31, 2020',\n",
       "  'Completion Date': 'August 31, 2020',\n",
       "  'First Posted': 'August 4, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 19, 2020',\n",
       "  'Locations': 'Fuwai hospital, Beijing, Beijing, Beijing, China|Taizhou Health Bureau, Taizhou, Jiangsu, China|Jiexiu Health Bureau, Jinzhong, Shanxi, China|Yuanqu Health Bureau, Yuncheng, Shanxi, China|Shizong Health Bureau, Qujing, Yunnan, China|Lin Health Duo, Qujing, Yunnan, China|Luliang Health Bureau, Qujing, Yunnan, China|Luoping Health Bureau, Qujing, Yunnan, China',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04497675/ICF_001.pdf|\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/75/NCT04497675/Prot_SAP_003.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04497675'},\n",
       " {'Rank': 5469,\n",
       "  'NCT Number': 'NCT04474028',\n",
       "  'Title': 'An Epidemiological Investigation on the Correct Wearing of Face Mask',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Respiratory Infectious Diseases',\n",
       "  'Interventions': nan,\n",
       "  'Outcome Measures': \"can or can't fell bitterness\",\n",
       "  'Sponsor/Collaborators': 'Fuwai Yunnan Cardiovascular Hospital',\n",
       "  'Gender': 'All',\n",
       "  'Age': '7 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 6000.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional',\n",
       "  'Other IDs': '2020-KZLXB-01',\n",
       "  'Start Date': 'June 19, 2020',\n",
       "  'Primary Completion Date': 'August 31, 2020',\n",
       "  'Completion Date': 'August 31, 2020',\n",
       "  'First Posted': 'July 16, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 6, 2020',\n",
       "  'Locations': 'Fuwai hospital, Beijing, Beijing, Beijing, China|Taizhou Health Bureau, Taizhou, Jiangsu, China|Jiexiu Health Bureau, Jinzhong, Shanxi, China|Yuanqu Health Bureau, Yuncheng, Shanxi, China|Fuwai Yunnan Cardiovascular Hospital, Kunming, Yunnan, China|Luliang Health Bureau, Qujing, Yunnan, China|Shizong Health Bureau, Qujing, Yunnan, China|Luoping Health Bureau, Qujing, Yunnan, China',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04474028/Prot_SAP_003.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/28/NCT04474028/ICF_004.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04474028'},\n",
       " {'Rank': 5470,\n",
       "  'NCT Number': 'NCT04804072',\n",
       "  'Title': 'INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit',\n",
       "  'Acronym': 'INTEGRA',\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'HIV Infections|Drug Use|Opioid Use|Opioid-use Disorder',\n",
       "  'Interventions': 'Drug: Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)|Diagnostic Test: HIV testing|Drug: HIV treatment for HIV-positive participants not already in care|Drug: PrEP for HIV-negative participants|Diagnostic Test: Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)|Diagnostic Test: Testing and referral for treatment for hepatitis C virus (HCV)|Diagnostic Test: Sexually transmitted infection (STI) testing and treatment|Other: Primary care|Behavioral: Harm reduction services|Behavioral: Peer navigation|Diagnostic Test: COVID-19 testing and referral for further evaluation, care and/or treatment',\n",
       "  'Outcome Measures': 'Evaluate whether the intervention improves use of MOUD|Evaluate whether the intervention increases rates of viral suppression among HIV-positive individuals|Evaluate whether the intervention increases use of PrEP among HIV-negative individuals|Evaluate whether the intervention reduces opioid and polysubstance use at 26 and 52 weeks|Evaluate whether the intervention reduces prevalence of bacterial STIs|Evaluate whether the intervention reduces the rate of fatal overdose events by 26 and 52 weeks|Evaluate whether the intervention reduces the rate of non-fatal overdose events by 26 and 52 weeks|Assess whether the intervention increases the proportion of participants with undetectable HCV RNA among those with chronic HCV infection at enrollment|Evaluate whether the intervention reduces HCV incidence|Evaluate whether 26 weeks of \"one stop\" integrated health services delivered in a mobile health delivery unit, supported by peer navigation, increases MOUD use|Evaluate whether 26 weeks of \"one stop\" integrated health services delivered in a mobile health delivery unit, supported by peer navigation, increases viral suppression at 26 and 52 weeks|Evaluate whether 26 weeks of \"one stop\" integrated health services delivered in a mobile health delivery unit, supported by peer navigation, increases PrEP use at 26 and 52 weeks|Evaluate whether 26 weeks of peer navigation to similar health services available at community-based agencies increases MOUD use at 26 and 52 weeks|Evaluate whether 26 weeks of peer navigation to similar health services available at community-based agencies increases viral suppression at 26 and 52 weeks|Evaluate whether 26 weeks of peer navigation to similar health services available at community-based agencies increases PrEP use at 26 and 52 weeks|Assess the prevalence of SARS-CoV-2 seropositivity at baseline, 26 and 52 weeks|Document the impact of the COVID-19 epidemic on participants\\' experiences of seeking, obtaining and/or maintaining health services, housing, food security and drugs',\n",
       "  'Sponsor/Collaborators': 'HIV Prevention Trials Network|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute on Drug Abuse (NIDA)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 60 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 860.0,\n",
       "  'Funded Bys': 'Other|NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'HPTN 094',\n",
       "  'Start Date': 'April 1, 2021',\n",
       "  'Primary Completion Date': 'October 1, 2024',\n",
       "  'Completion Date': 'October 1, 2024',\n",
       "  'First Posted': 'March 18, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 18, 2021',\n",
       "  'Locations': 'UCLA Vine Street Clinic, Los Angeles, California, United States|George Washington University CRS, Washington, District of Columbia, United States|Bronx Prevention Center CRS, Bronx, New York, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|Houston AIDS Research Team CRS, Houston, Texas, United States',\n",
       "  'Study Documents': '\"Study Protocol and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/72/NCT04804072/Prot_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04804072'},\n",
       " {'Rank': 5486,\n",
       "  'NCT Number': 'NCT04844294',\n",
       "  'Title': 'A Randomized Clinical Trial Testing the Effectiveness of Telemental Health for Suicidal Patients',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Suicide|Suicidal Ideation|Suicide Attempt',\n",
       "  'Interventions': 'Behavioral: Brief Cognitive Behavioral Therapy (BCBT)|Behavioral: Present-Centered Therapy (PCT)',\n",
       "  'Outcome Measures': 'Change in number of suicide attempts from baseline.|Change in severity of suicide ideation from baseline.|Change in psychiatric symptom severity will be measured across multiple time points post-treatment.',\n",
       "  'Sponsor/Collaborators': 'Ohio State University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 80.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '2020B0396',\n",
       "  'Start Date': 'April 2021',\n",
       "  'Primary Completion Date': 'April 2022',\n",
       "  'Completion Date': 'April 2023',\n",
       "  'First Posted': 'April 14, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 14, 2021',\n",
       "  'Locations': 'The Ohio State University, Columbus, Ohio, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04844294/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04844294'},\n",
       " {'Rank': 5490,\n",
       "  'NCT Number': 'NCT04571593',\n",
       "  'Title': 'Remote Yoga Nidra for Anxiety and Sleep',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Insomnia Due to Anxiety and Fear',\n",
       "  'Interventions': 'Behavioral: Yoga Nidra',\n",
       "  'Outcome Measures': 'Change in Momentary Anxiety|Change in Sleep Quality|Incidence of Intervention-Emergent Challenges as assessed by a Feedback Survey|Satisfaction as assessed by a Feedback Survey',\n",
       "  'Sponsor/Collaborators': 'National University of Natural Medicine',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 74.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science',\n",
       "  'Other IDs': 'NUNM',\n",
       "  'Start Date': 'April 15, 2020',\n",
       "  'Primary Completion Date': 'August 5, 2020',\n",
       "  'Completion Date': 'September 14, 2020',\n",
       "  'First Posted': 'October 1, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'October 5, 2020',\n",
       "  'Locations': 'National University of Natural Medicine, Helfgott Research Institute, Portland, Oregon, United States',\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/93/NCT04571593/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04571593'},\n",
       " {'Rank': 5501,\n",
       "  'NCT Number': 'NCT04818008',\n",
       "  'Title': 'The Effect of the Arabic Otago Exercise Program on Falls in People With Multiple Sclerosis',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Multiple Sclerosis',\n",
       "  'Interventions': 'Other: Otago Exercise Program',\n",
       "  'Outcome Measures': 'Incidence of falls|Fear of Falling (using the Falls Efficacy Scale-International )|Balance (using Chair balance test and Four test balance scale)|Mobility (using Timed-Up and go)|Quadriceps strength (using a dynamometer)|The severity of fatigue (using Modified Fatigue Impact Scale)|the Quality of sleep (Using Pittsburgh Sleep Quality Index)|the severity of Anxiety and Depression (using Hospital Anxiety and Depression Scale)|The Quality of Life (using Medical Outcomes Study Short Form 12)|Cognitive ability (using Montreal Cognitive Assessment)',\n",
       "  'Sponsor/Collaborators': 'University of Jordan',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 50.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '\"11-2021\"',\n",
       "  'Start Date': 'June 2021',\n",
       "  'Primary Completion Date': 'December 2023',\n",
       "  'Completion Date': 'December 2023',\n",
       "  'First Posted': 'March 26, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'April 6, 2021',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/08/NCT04818008/SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04818008'},\n",
       " {'Rank': 5522,\n",
       "  'NCT Number': 'NCT04291638',\n",
       "  'Title': 'Evaluating an Online Adjunctive Support Following Intensive Services (OASIS) Strategy for Youth With Selective Mutism',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Selective Mutism',\n",
       "  'Interventions': 'Behavioral: Remote Caregiver Training|Behavioral: Remote Intensive Group Behavioral Treatment (IGBT)',\n",
       "  'Outcome Measures': \"Clinical Global Impressions - Improvement (CGI-I) Scale rating at Post-IGBT|Clinical Global Impressions - Improvement (CGI-I) Scale rating at School Year Follow Up|Change from Baseline in Anxiety Disorders Interview Schedule for Children (ADIS) Clinical Severity Ratings (CSRs) at Post-IGBT|Change from Baseline in Anxiety Disorders Interview Schedule for Children (ADIS) Clinical Severity Ratings (CSRs) at School Year Follow Up|Change from Post-IGBT in Anxiety Disorders Interview Schedule for Children (ADIS) Clinical Severity Ratings (CSRs) at School Year Follow Up|Change from Baseline in Children's Global Assessment Scale (CGAS) rating at Post-IGBT|Change from Baseline in Children's Global Assessment Scale (CGAS) rating at School Year Follow Up|Change from Post-IGBT in Children's Global Assessment Scale (CGAS) rating at School Year Follow Up|Change from Baseline in Selective Mutism Questionnaire (SMQ) scores at Post-IGBT|Change from Baseline in Selective Mutism Questionnaire (SMQ) scores at School Year Follow Up|Change from Post-IGBT in Selective Mutism Questionnaire (SMQ) scores at School Year Follow Up|Change from Baseline in School Speech Questionnaire (SSQ) scores at School Year Follow Up|Change from Baseline in Impairment Rating Scale - Parent Version (IRS-P) at School Year Follow Up|Change from Baseline in Impairment Rating Scale - Teacher Version (IRS-T) at School Year Follow Up\",\n",
       "  'Sponsor/Collaborators': 'Florida International University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '4 Years to 10 Years \\xa0 (Child)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 11.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '20-0010',\n",
       "  'Start Date': 'March 6, 2020',\n",
       "  'Primary Completion Date': 'December 7, 2020',\n",
       "  'Completion Date': 'December 7, 2020',\n",
       "  'First Posted': 'March 2, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 16, 2020',\n",
       "  'Locations': 'Florida International University, Miami, Florida, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/38/NCT04291638/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04291638'},\n",
       " {'Rank': 5549,\n",
       "  'NCT Number': 'NCT04545424',\n",
       "  'Title': 'Trial of Therapeutic Hypothermia in Patients With ARDS',\n",
       "  'Acronym': 'CHILL',\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Respiratory Distress Syndrome, Adult',\n",
       "  'Interventions': 'Device: Hypothermia|Drug: Neuromuscular Blocking Agents|Device: Standard of care',\n",
       "  'Outcome Measures': '28-day ventilator-free days (VFDs)|28-day ICU-free days|Survival|non neurologic Sequential Organ Failure (SOFA) scores|Oxygen saturation (SpO2)|Plateau airway pressure|Mean airway pressure|Airway driving pressure|Oxygen saturation index|Core temperature|Urine output|comprehensive metabolic panel blood test (includes sodium, potassium, chloride, bicarb, BUN, creatinine, glucose, albumin, total protein, AST, SLT, alkaline phosphatase, and bilirubin)|Complete blood count with differential count and platelet count|Plasma biomarkers measured by immunoassay and including IL-1ß, IL-6, IL-8, IL-18, surfactant protein D, soluble ICAM-1, MMP8, and soluble TNF receptor-I)|Serum electrolytes|Fingerstick blood glucose level',\n",
       "  'Sponsor/Collaborators': 'University of Maryland, Baltimore|US Department of Veterans Affairs Cooperative Studies Program|KAI Research|United States Department of Defense',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 65 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 340.0,\n",
       "  'Funded Bys': 'Other|U.S. Fed',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'W81XWH2010432',\n",
       "  'Start Date': 'January 31, 2021',\n",
       "  'Primary Completion Date': 'December 1, 2023',\n",
       "  'Completion Date': 'May 31, 2024',\n",
       "  'First Posted': 'September 11, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 5, 2021',\n",
       "  'Locations': 'Christiana Medical Center, Newark, Delaware, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Chicago, Chicago, Illinois, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Mayo Clinic Rochester Minnesota, Rochester, Minnesota, United States|Cleveland Clinc, Cleveland, Ohio, United States|University of Pennsylavia, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States',\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04545424/SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04545424/ICF_001.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/24/NCT04545424/Prot_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04545424'},\n",
       " {'Rank': 5567,\n",
       "  'NCT Number': 'NCT03827057',\n",
       "  'Title': 'RECONsolidation of Traumatic Memories to ResOLve Post Traumatic Stress Disorder (RECONTROLPTSD)',\n",
       "  'Acronym': 'RECONTROLPTSD',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Posttraumatic Stress Disorder|Traumatic Brain Injury',\n",
       "  'Interventions': 'Behavioral: Reconsolidation of Traumatic Memories (RTM)|Behavioral: Prolonged Exposure (PE)',\n",
       "  'Outcome Measures': 'Clinician Administered PTSD Symptom Scale for DSM5 (CAPS-5)|Change in Patient Health Questionnaire (PHQ-9) Score|Change in PTSD Checklist for DSM5 (PCL5) Score|Change in Pittsburgh Sleep Quality Index (PSQI) Score|Change in Neurobehavioral Symptom Inventory (NSI) Score|Change in World Health Organization Quality of Life Inventory (WHOQOL-100) Score',\n",
       "  'Sponsor/Collaborators': 'Uniformed Services University of the Health Sciences|Research and Recognition Project',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 2|Phase 3',\n",
       "  'Enrollment': 108.0,\n",
       "  'Funded Bys': 'U.S. Fed|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'CNRM-83-9763',\n",
       "  'Start Date': 'June 12, 2019',\n",
       "  'Primary Completion Date': 'September 30, 2021',\n",
       "  'Completion Date': 'March 31, 2022',\n",
       "  'First Posted': 'February 1, 2019',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'May 5, 2020',\n",
       "  'Locations': 'Uniformed Services University of Health Sciences (USUHS), Bethesda, Maryland, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/57/NCT03827057/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03827057'},\n",
       " {'Rank': 5598,\n",
       "  'NCT Number': 'NCT03584386',\n",
       "  'Title': 'CAMS Relational Agent System (CAMS-RAS) for Suicide Prevention',\n",
       "  'Acronym': 'V-CAMS',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Suicide',\n",
       "  'Interventions': 'Device: V-CAMS (aka Jaspr)',\n",
       "  'Outcome Measures': 'Change in Suicide Cognitions Scale (SCS)|Change in Patient Health Questionnaire-9 (PHQ-9)|Change in Coping Skills Use|Change in Client Satisfaction Questionnaire (CSQ)|Change in Safety & Imminent Distress Scale (SIDQ)|Change in the Depression Anxiety and Stress Scale (DASS-21)|Change in Suicide-Related Coping Scale (SRCS)|Change in Suicide Attempt and Self-Injury Questions|Change in the Suicide Behaviors Questionnaire - Revised (SBQ-R)|Change in Outpatient Satisfaction Questionnaire|Change in Jaspr-At-Home Patient Satisfaction Survey|Usability Satisfaction and Acceptability Questionnaire (USAQ)|Change in Provider Ratings Questionnaire|Change in Optimism & Hope Scale',\n",
       "  'Sponsor/Collaborators': 'Evidence-Based Practice Institute, Seattle, WA|Mayo Clinic|Allina Health|Aurora Health Care|Harborview Injury Prevention and Research Center|The Catholic University of America',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 303.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'R44MH108222',\n",
       "  'Start Date': 'October 1, 2018',\n",
       "  'Primary Completion Date': 'March 31, 2021',\n",
       "  'Completion Date': 'March 31, 2021',\n",
       "  'First Posted': 'July 12, 2018',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'February 26, 2021',\n",
       "  'Locations': 'Evidence-Based Practice Institute, Seattle, Washington, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03584386/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03584386/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03584386'},\n",
       " {'Rank': 5610,\n",
       "  'NCT Number': 'NCT04792450',\n",
       "  'Title': 'Thales Thermography Triage (3T) - Pilot Project',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Fever',\n",
       "  'Interventions': 'Device: Thermography|Device: Tympanic Thermometer|Device: Forehead Thermometer|Device: 62 Max + Infra-red thermometer',\n",
       "  'Outcome Measures': 'To determine the diagnostic accuracy of HTD for the measurement of fever, using an equivalence comparison with the maximum temperature recorded with two routinely used temperature measurements (tympanic and forehead), margin ±0.2°C.',\n",
       "  'Sponsor/Collaborators': 'NHS Greater Clyde and Glasgow|Thales Group',\n",
       "  'Gender': 'All',\n",
       "  'Age': '16 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 200.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Prospective',\n",
       "  'Other IDs': '287901',\n",
       "  'Start Date': 'November 1, 2020',\n",
       "  'Primary Completion Date': 'December 15, 2020',\n",
       "  'Completion Date': 'May 2021',\n",
       "  'First Posted': 'March 11, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 11, 2021',\n",
       "  'Locations': 'Queen Elizabeth University Hospital, Glasgow, United Kingdom',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04792450/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04792450'},\n",
       " {'Rank': 5627,\n",
       "  'NCT Number': 'NCT04444986',\n",
       "  'Title': 'Bioequivalence Study of Favir 200 mg Film Tablet Kocak Under Fasting Conditions',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Bioequivalence',\n",
       "  'Interventions': 'Drug: FAVIR 200 MG FT|Drug: AVIGAN 200 mg FT',\n",
       "  'Outcome Measures': 'AUC0-tlast of favipiravir|Cmax of favipiravir|AUC0-inf of favipiravir|tmax of favipiravir',\n",
       "  'Sponsor/Collaborators': 'Kocak Farma|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti',\n",
       "  'Gender': 'Male',\n",
       "  'Age': '18 Years to 40 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Phase 1',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other',\n",
       "  'Other IDs': 'NOV2020/01919',\n",
       "  'Start Date': 'June 5, 2020',\n",
       "  'Primary Completion Date': 'June 11, 2020',\n",
       "  'Completion Date': 'June 13, 2020',\n",
       "  'First Posted': 'June 24, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'November 30, 2020',\n",
       "  'Locations': 'Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Gaziantep, Turkey',\n",
       "  'Study Documents': '\"Study Protocol, Statistical Analysis Plan, and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/86/NCT04444986/Prot_SAP_ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04444986'},\n",
       " {'Rank': 5643,\n",
       "  'NCT Number': 'NCT04041453',\n",
       "  'Title': 'Albendazole Plus High Dose Ivermectin for Trichuriasis in Pediatric Patients',\n",
       "  'Acronym': 'HI4T',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Trichuris Infection|Helminthiasis',\n",
       "  'Interventions': 'Drug: Ivermectin|Drug: Albendazole',\n",
       "  'Outcome Measures': 'Cure Rate|Egg Change Rate|Beta Tubulin Resistance',\n",
       "  'Sponsor/Collaborators': 'Alejandro Krolewiecki|Brock University|Universidad Nacional del Centro de la Provincia de Buenos Aires|Universidad Nacional Autonoma de Honduras|Universidad Nacional de Salta',\n",
       "  'Gender': 'All',\n",
       "  'Age': '2 Years to 14 Years \\xa0 (Child)',\n",
       "  'Phases': 'Phase 2',\n",
       "  'Enrollment': 176.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '01-2019',\n",
       "  'Start Date': 'October 9, 2019',\n",
       "  'Primary Completion Date': 'March 7, 2020',\n",
       "  'Completion Date': 'March 7, 2020',\n",
       "  'First Posted': 'August 1, 2019',\n",
       "  'Results First Posted': 'July 29, 2020',\n",
       "  'Last Update Posted': 'July 29, 2020',\n",
       "  'Locations': 'IIET, Oran, Salta, Argentina|Universidad Autónoma de Honduras, Tegucigalpa, Honduras',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/53/NCT04041453/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04041453'},\n",
       " {'Rank': 5649,\n",
       "  'NCT Number': 'NCT04696107',\n",
       "  'Title': 'Effectiveness of Coping Strategies on the Control of Chronic Non-Cancer Pain and Quality of Life (CNCP_CopQol)',\n",
       "  'Acronym': 'CNCP_CopQol',\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Chronic Pain|Musculoskeletal Diseases|Quality of Life|Pain Measurement',\n",
       "  'Interventions': 'Behavioral: Psychoeducative intervention',\n",
       "  'Outcome Measures': 'Change from Baseline Pain perception|Change from Baseline Quality of life|Gender.|Age.|Weight.|Height.|Body Mass Index (BMI).|% of patients with more than one type of pain in addition to mCNCP|Pain evolution time.|Changes from Baseline analgesic pharmacological treatment defined by the WHO therapeutic scale at 6 months.|Changes from Baseline amount of analgesic pharmacological treatment at 6 months.|Rate of smoking consumption.|Incidence of physical exercise practice.|Rate of alcohol consumption.|% of patients with other concomitant chronic pathologies.|% of patients with family history of chronic pain.|Educational level.|Habitual residence.|Marital status.|Incidence of caregivers among participants.|Employment situation.|Changes from Baseline Emotional Coping Strategies by the Reduced Chronic Pain Coping Questionnaire at 6 months.|The rate of adherence to treatment.|Incidence of causes of non-adherence to treatment.|Changes from Baseline Sleep Quality (Oviedo Questionnaire) at 6 months.|Changes from Baseline Global Family Unit Operation (Family Apgar Test) at 6 months|Changes in the frequentation of Medical Services during the study per patient.',\n",
       "  'Sponsor/Collaborators': 'Hospital San Juan de Dios del Aljarafe de Sevilla|University of Seville|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 144.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'HSJDA-20.1',\n",
       "  'Start Date': 'April 1, 2021',\n",
       "  'Primary Completion Date': 'February 28, 2022',\n",
       "  'Completion Date': 'December 31, 2022',\n",
       "  'First Posted': 'January 6, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 6, 2021',\n",
       "  'Locations': 'Hospital San Juan de Dios del Aljarafe, Bormujos, Sevilla, Spain',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/07/NCT04696107/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04696107'},\n",
       " {'Rank': 5659,\n",
       "  'NCT Number': 'NCT03518216',\n",
       "  'Title': 'Neural Mechanisms of Treatment Response to ADAPT',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Functional Abdominal Pain Syndrome|Anxiety',\n",
       "  'Interventions': 'Behavioral: ADAPT',\n",
       "  'Outcome Measures': \"Functional Connectivity of Amygdala with the Prefrontal Cortex|Regional Brain Activation in Areas Associated with Cognitive, Affective, and Visceral Afferent Aspects of Pain|Neuroimaging data linked to pain and anxiety outcomes|Pain Intensity/Unpleasantness via Visual Analog Scale|State Anxiety|Screen for Child Anxiety Related Disorders|Functional Disability Inventory|Rome IV Diagnosis Checklist|MRI Safety and Screening|Self-Efficacy Pain Scale- Child Version|Affective Reactivity Index- Self Report|Pain Catastrophizing Scale for Children|Children's Depression Inventory 2|NIH Promis Pain Interference|Peterson Pubertal Development Scale|Edinburgh Handedness Inventory|Fullness Rating Scale|Child Pain History|Depression Anxiety Stress Scales|Pain Catastrophizing Scale|Screen for Child Anxiety Related Disorders- Parent Report|Functional Disability Inventory- Parent Report|Self-Efficacy Chronic Pain Scale- Parent Version|Medication use|Affective Reactivity Index- Parent- Report|Adverse Childhood Events|COVID-19 Exposure and Family Impact Survey|Child COVID-19 Related Distress|Child COVID-19 Related Distress Coping\",\n",
       "  'Sponsor/Collaborators': 'Michigan State University|National Center for Complementary and Integrative Health (NCCIH)|Spectrum Health Hospitals',\n",
       "  'Gender': 'All',\n",
       "  'Age': '11 Years to 16 Years \\xa0 (Child)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 93.0,\n",
       "  'Funded Bys': 'Other|NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '2017-4545|K23AT009458',\n",
       "  'Start Date': 'July 3, 2018',\n",
       "  'Primary Completion Date': 'August 2022',\n",
       "  'Completion Date': 'August 2022',\n",
       "  'First Posted': 'May 8, 2018',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 9, 2021',\n",
       "  'Locations': 'Michigan State University, Grand Rapids, Michigan, United States',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/16/NCT03518216/Prot_SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03518216'},\n",
       " {'Rank': 5666,\n",
       "  'NCT Number': 'NCT03343483',\n",
       "  'Title': 'The Helping Older People Engage Project: Improving Social Well-Being in Later Life',\n",
       "  'Acronym': 'HOPE',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Loneliness|Quality of Life',\n",
       "  'Interventions': 'Behavioral: Volunteering|Behavioral: Life Review',\n",
       "  'Outcome Measures': 'Loneliness|Health-related Quality of Life|Belonging|Meaning and Purpose|Satisfaction with Social Roles and Activities|Social Isolation',\n",
       "  'Sponsor/Collaborators': 'University of Rochester|National Institute on Aging (NIA)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '60 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 300.0,\n",
       "  'Funded Bys': 'Other|NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'R01AG054457',\n",
       "  'Start Date': 'January 1, 2018',\n",
       "  'Primary Completion Date': 'February 28, 2023',\n",
       "  'Completion Date': 'February 28, 2023',\n",
       "  'First Posted': 'November 17, 2017',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 10, 2021',\n",
       "  'Locations': 'University of Rochester, Rochester, New York, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03343483/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03343483'},\n",
       " {'Rank': 5668,\n",
       "  'NCT Number': 'NCT04406194',\n",
       "  'Title': 'Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions',\n",
       "  'Acronym': 'Favipiravir',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Bioequivalence',\n",
       "  'Interventions': 'Drug: FAVICOVIR 200 mg Film Tablet|Drug: AVIGAN 200 mg Film Tablets',\n",
       "  'Outcome Measures': 'AUC0-tlast of Favipiravir|Cmax of Favipiravir|AUC0-inf of Favipiravir|Tmax of Favipiravir',\n",
       "  'Sponsor/Collaborators': 'Atabay Kimya Sanayi Ticaret A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti',\n",
       "  'Gender': 'Male',\n",
       "  'Age': '20 Years to 40 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Phase 1',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other',\n",
       "  'Other IDs': 'NOV2020/1917',\n",
       "  'Start Date': 'May 14, 2020',\n",
       "  'Primary Completion Date': 'May 22, 2020',\n",
       "  'Completion Date': 'June 19, 2020',\n",
       "  'First Posted': 'May 28, 2020',\n",
       "  'Results First Posted': 'August 12, 2020',\n",
       "  'Last Update Posted': 'August 14, 2020',\n",
       "  'Locations': 'Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04406194/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/94/NCT04406194/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04406194'},\n",
       " {'Rank': 5669,\n",
       "  'NCT Number': 'NCT04400682',\n",
       "  'Title': 'Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions',\n",
       "  'Acronym': 'Favipiravir',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Bioequivalence',\n",
       "  'Interventions': 'Drug: FAVIRA 200 MG Film Tablet|Drug: AVIGAN 200 MG Film Tablets',\n",
       "  'Outcome Measures': 'AUC0-tlast|Favipiravir Cmax|AUC0-inf of Favipiravir|Tmax of Favipiravir',\n",
       "  'Sponsor/Collaborators': 'Novelfarma Ilaç San. ve Tic. Ltd. Sti.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti',\n",
       "  'Gender': 'Male',\n",
       "  'Age': '20 Years to 40 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Phase 1',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other',\n",
       "  'Other IDs': 'NOV2020/1923|FARGE 367',\n",
       "  'Start Date': 'May 28, 2020',\n",
       "  'Primary Completion Date': 'June 5, 2020',\n",
       "  'Completion Date': 'June 18, 2020',\n",
       "  'First Posted': 'May 22, 2020',\n",
       "  'Results First Posted': 'August 11, 2020',\n",
       "  'Last Update Posted': 'August 11, 2020',\n",
       "  'Locations': 'Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04400682/Prot_SAP_000.pdf|\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/82/NCT04400682/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04400682'},\n",
       " {'Rank': 5704,\n",
       "  'NCT Number': 'NCT04480255',\n",
       "  'Title': 'NICU2HOME+: Supporting Illinois Families',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Premature Birth|NICU|Premature|Infant',\n",
       "  'Interventions': 'Other: Group 1: Standard of Care|Other: Group 2: NICU2HOME+ app',\n",
       "  'Outcome Measures': 'Mobile Application Outcome 1|Mobile Application Outcome 2|State-Trait Anxiety Inventory (STAI)|Parenting Sense of Competence Scale (PSOC)|Edinburgh Postnatal Depression Scale (EPDS)|Press Ganey Questionnaire (PG)|Healthcare encounters (HE)|Readmission rate (RR)|User Version of the Mobile Application Rating Scale (uMARS)|Perinatal PTSD Questionnaire - Modified (PPQ-M)|COVID-19 Impact Scale|Perceived Stress Scale (PSS)|MOS- Social Support Scale (MOS)|Health Behavior (HB)|CDC- Hear Her Campaign',\n",
       "  'Sponsor/Collaborators': 'Craig Garfield|Blue Cross Blue Shield|Northwestern University',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 600.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care',\n",
       "  'Other IDs': 'STU00212196',\n",
       "  'Start Date': 'August 3, 2020',\n",
       "  'Primary Completion Date': 'December 2021',\n",
       "  'Completion Date': 'June 2022',\n",
       "  'First Posted': 'July 21, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'January 19, 2021',\n",
       "  'Locations': 'Northwest Community Hospital, Arlington Heights, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Centra Dupage Hospital, Winfield, Illinois, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/55/NCT04480255/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04480255'},\n",
       " {'Rank': 5718,\n",
       "  'NCT Number': 'NCT04386876',\n",
       "  'Title': 'Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions',\n",
       "  'Acronym': 'Orvical',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Bioequivalence',\n",
       "  'Interventions': 'Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet|Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet',\n",
       "  'Outcome Measures': 'Primary PK End Points',\n",
       "  'Sponsor/Collaborators': 'World Medicine ILAC SAN. ve TIC. A.S.|Novagenix Bioanalytical Drug R&D Center|Farmagen Ar-Ge Biyot. Ltd. Sti',\n",
       "  'Gender': 'Male',\n",
       "  'Age': '20 Years to 40 Years \\xa0 (Adult)',\n",
       "  'Phases': 'Phase 1',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Industry|Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other',\n",
       "  'Other IDs': 'NOV2020/01911|FARGE365',\n",
       "  'Start Date': 'April 30, 2020',\n",
       "  'Primary Completion Date': 'May 22, 2020',\n",
       "  'Completion Date': 'June 11, 2020',\n",
       "  'First Posted': 'May 13, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 31, 2020',\n",
       "  'Locations': 'Novagenix Drug R&D Center, Akyurt, Ankara, Turkey|Farmagen Ar-Ge Biyot. Ltd. Sti., Sahinbey, Gaziantep, Turkey',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04386876/ICF_000.pdf|\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/76/NCT04386876/Prot_SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04386876'},\n",
       " {'Rank': 5720,\n",
       "  'NCT Number': 'NCT04813068',\n",
       "  'Title': \"Lung Cancer Patients' Attitudes to a Second Course of Radiotherapy\",\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Not yet recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Lung Cancer|Recurrence',\n",
       "  'Interventions': 'Other: Semi-structured interview',\n",
       "  'Outcome Measures': 'Feelings and concerns re: second radiotherapy course|Choice of treatment in recurrent setting|Attitude to side effects in context of possible outcomes|Toxicity from previous radiotherapy|Attitude to surveillance scans',\n",
       "  'Sponsor/Collaborators': 'NHS Greater Glasgow and Clyde|University of Glasgow|The Beatson Cancer Charity',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': nan,\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Observational',\n",
       "  'Study Designs': 'Observational Model: Cohort|Time Perspective: Retrospective',\n",
       "  'Other IDs': 'GN20ON632',\n",
       "  'Start Date': 'March 2021',\n",
       "  'Primary Completion Date': 'December 2021',\n",
       "  'Completion Date': 'June 2022',\n",
       "  'First Posted': 'March 24, 2021',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'March 24, 2021',\n",
       "  'Locations': nan,\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/68/NCT04813068/Prot_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04813068'},\n",
       " {'Rank': 5723,\n",
       "  'NCT Number': 'NCT04449744',\n",
       "  'Title': 'Evaluating Adaptive Dispenser Initiation Protocols for MySafeRx During Post-detox Buprenorphine Treatment- a Pilot Study',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Opioid-use Disorder',\n",
       "  'Interventions': 'Other: MySafeRx Inspire Plus|Other: MySafeRx Inspire Flex',\n",
       "  'Outcome Measures': 'Acceptability of Medication Dispenser|Biochemically-Confirmed Illicit Opioid Use|Outpatient Buprenorphine Medication Adherence|Outpatient Buprenorphine Treatment Engagement/ Retention',\n",
       "  'Sponsor/Collaborators': 'University of South Florida|Cambridge Health Alliance',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years to 65 Years \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 30.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'PRO00038163 - Pilot|R01CE003039',\n",
       "  'Start Date': 'July 13, 2020',\n",
       "  'Primary Completion Date': 'January 31, 2021',\n",
       "  'Completion Date': 'March 1, 2021',\n",
       "  'First Posted': 'June 29, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 17, 2020',\n",
       "  'Locations': 'ACTS Adult Addiction Receiving Facility (AARF), Tampa, Florida, United States',\n",
       "  'Study Documents': '\"Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/44/NCT04449744/ICF_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04449744'},\n",
       " {'Rank': 5728,\n",
       "  'NCT Number': 'NCT01435018',\n",
       "  'Title': 'Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'HIV-1 Infection',\n",
       "  'Interventions': 'Drug: Etoposide (ET)|Drug: Bleomycin and Vincristine (BV)|Drug: Paclitaxel (PTX)|Drug: Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)',\n",
       "  'Outcome Measures': \"Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of Progression-Free Survival by Week 48 for BV+ART vs. PTX+ART|Cumulative Rate of Death by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of Death by Week 48 for BV+ART vs. PTX+ART|Cumulative Rate of IERC-confirmed KS Progression by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of IERC-confirmed KS Progression by Week 48 for BV+ART vs. PTX+ART|Cumulative Rate of AIDS-defining Event by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of AIDS-defining Event by Week 48 for BV+ART vs. PTX+ART|Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of HIV-1 RNA Virologic Failure by Week 48 for BV+ART vs. PTX+ART|Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART|Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART|Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of KS Progression, Death, or AIDS Defining Event by Week 48 for BV+ART vs. PTX+ART|Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of KS Progression, Death, AIDS Defining Event, or Virologic Failure by Week 48 for BV+ART vs. PTX+ART|Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of KS Progression, Death, AIDS Defining Event, Virologic Failure, or KS-IRIS by Week 48 for BV+ART vs. PTX+ART|Cumulative Rate of Change in KS Treatment by Week 48 for ET+ART vs. PTX+ART|Cumulative Rate of Change in KS Treatment by Week 48 for BV+ART vs. PTX+ART|Cumulative Rate of Death for ET+ART vs. PTX+ART|Cumulative Rate of Death for BV+ART vs PTX+ART|Time to IERC-confirmed KS Progression or Death for ET+ART vs. PTX+ART|Time to IERC-confirmed KS Progression or Death for BV+ART vs. PTX+ART|Number of Participants With Objective Response for ET+ART vs. PTX+ART|Number of Participants With Objective Response for BV+ART vs. PTX+ART|Duration of Objective Response for ET+ART vs. PTX+ART|Duration of Objective Response for BV+ART vs. PTX+ART|Number of Participants With Symptomatic Peripheral Neuropathy (SPN)|Number of Participants With Peripheral Neuropathy (PN)|Number of Participants With Treatment-related Toxicities and Adverse Events (AEs)|Changes in CD4+ Lymphocyte Cell Count for ET+ART vs. PTX+ART|Changes in CD4+ Lymphocyte Cell Count for BV+ART vs. PTX+ART|Self-reported Adherence to ART Therapy|Presence of Oral KS|Salivary KSHV|Quality of Life Measures|Immunohistochemical Evaluations of Viral and Cellular Gene Expression.|Plasma KS-associated Herpesvirus (KSHV)|Peripheral Blood Mononuclear Cell (PBMC) KSHV|RNA Levels for KSHV Genes|Cellular and Humoral Markers of Immune Function and Activation|Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 2|Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 3|Number of Participants With IERC-Confirmed KS Disease Progression, Dose-Limiting Toxicity, Death, AIDS-Defining Events, Virologic Failure and Objective Response in Step 4\",\n",
       "  'Sponsor/Collaborators': 'AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|National Cancer Institute (NCI)|National Institute of Dental and Craniofacial Research (NIDCR)|AIDS Malignancy Consortium',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Phase 3',\n",
       "  'Enrollment': 334.0,\n",
       "  'Funded Bys': 'Other|NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': 'ACTG A5263/AMC 066|1U01AI068636|U01CA121947',\n",
       "  'Start Date': 'October 1, 2013',\n",
       "  'Primary Completion Date': 'March 13, 2018',\n",
       "  'Completion Date': 'August 29, 2019',\n",
       "  'First Posted': 'September 15, 2011',\n",
       "  'Results First Posted': 'April 8, 2019',\n",
       "  'Last Update Posted': 'November 23, 2020',\n",
       "  'Locations': 'Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil|Moi University International Clnical Trials Unit, Eldoret, Kenya|KMRI / Walter Reed Project Clinical Research Center, Kericho, Kenya|Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460), Kisumu, Kenya|Univ. of Malawi, John Hopkins Project, Blantyre, Malawi|Malawi CRS (12001), Lilongwe, Malawi|Family Clinical Research Unit (FAM-CUR) CRS (8950), Cape Town, West Cape, South Africa|Durban Adult HIV CRS (11201), Durban, South Africa|University of Witwatersrand, Johannesburg, South Africa|Uganda Cancer Institute ACTG CRS, Kampala, Uganda|UZ-Parirenyatwa CRS (30313), Harare, Zimbabwe',\n",
       "  'Study Documents': '\"Study Protocol and Informed Consent Form\", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01435018/Prot_ICF_000.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01435018/SAP_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT01435018'},\n",
       " {'Rank': 5738,\n",
       "  'NCT Number': 'NCT03483935',\n",
       "  'Title': 'Microwave Therapy for Treatment of Precancerous Actinic Keratoses',\n",
       "  'Acronym': 'MTAK',\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Actinic Keratoses|Precancerous Skin Lesion',\n",
       "  'Interventions': 'Other: Microwave treatment',\n",
       "  'Outcome Measures': 'Resolution of AK Lesions Following Microwave Treatment|Complete Resolution of AKs Following Microwave Treatment|Partial Resolution of AKs Following Microwave Treatment|Level of Pain Experienced During Treatment|Duration of Pain Post Treatment|Change in Ki67 Staining Determined Immunohistochemically by the Use of Specific Antibodies on Fixed Material|Change in Hematoxylin and Eosin Stain|Change in Apoptotic Cells Determined Using the ApopTag Peroxidase Detection Kit|Change in Gene Activity Determined by ApopTag Peroxidase',\n",
       "  'Sponsor/Collaborators': 'University of Dundee|Emblation Limited',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 18.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment',\n",
       "  'Other IDs': '2016DS12',\n",
       "  'Start Date': 'March 7, 2018',\n",
       "  'Primary Completion Date': 'February 28, 2019',\n",
       "  'Completion Date': 'February 28, 2019',\n",
       "  'First Posted': 'March 30, 2018',\n",
       "  'Results First Posted': 'February 23, 2021',\n",
       "  'Last Update Posted': 'February 23, 2021',\n",
       "  'Locations': 'NHS Tayside, Dundee, United Kingdom',\n",
       "  'Study Documents': '\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03483935/Prot_001.pdf|\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03483935/SAP_002.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03483935'},\n",
       " {'Rank': 5744,\n",
       "  'NCT Number': 'NCT03102034',\n",
       "  'Title': 'Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age',\n",
       "  'Acronym': nan,\n",
       "  'Status': 'Completed',\n",
       "  'Study Results': 'Has Results',\n",
       "  'Conditions': 'Respiratory Syncytial Virus Infections',\n",
       "  'Interventions': 'Biological: D46/NS2/N/ΔM2-2-HindIII|Biological: Placebo',\n",
       "  'Outcome Measures': 'Number of Participants With Solicited Adverse Events (AEs) by Grade|Number of Participants With Unsolicited AEs by Grade|Number of Participants With Serious Adverse Events (SAEs)|Number of Participants Infected With RSV Vaccine Virus|Peak Titer of Vaccine Virus Shed|Duration of Vaccine Virus Shedding in Nasal Washes|Number of Participants With a Greater Than or Equal to 4-fold Rise in Serum RSV-neutralizing Antibody Titer|Serum Antibody Responses to RSV F Glycoprotein as Assessed by Enzyme-linked Immunosorbent Assay (ELISA)|Number of Participants Who Had Symptomatic, Medically Attended Respiratory and Febrile Illness, Among Those Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season|Magnitude of Serum RSV-neutralizing Antibody Responses in the Vaccine and Placebo Recipients Who Experienced Natural Infection With wt RSV During the Subsequent RSV Season.|Number of Participants With B Cell Responses to Vaccine|Frequency of Mucosal Antibody Responses to Vaccine',\n",
       "  'Sponsor/Collaborators': 'National Institute of Allergy and Infectious Diseases (NIAID)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '6 Months to 24 Months \\xa0 (Child)',\n",
       "  'Phases': 'Phase 1',\n",
       "  'Enrollment': 32.0,\n",
       "  'Funded Bys': 'NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention',\n",
       "  'Other IDs': 'IMPAACT 2013|30074',\n",
       "  'Start Date': 'April 6, 2017',\n",
       "  'Primary Completion Date': 'May 25, 2018',\n",
       "  'Completion Date': 'May 25, 2018',\n",
       "  'First Posted': 'April 5, 2017',\n",
       "  'Results First Posted': 'June 14, 2019',\n",
       "  'Last Update Posted': 'December 30, 2020',\n",
       "  'Locations': \"Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Johns Hopkins University Center for Immunization Research, Baltimore, Maryland, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States\",\n",
       "  'Study Documents': '\"Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03102034/SAP_000.pdf|\"Study Protocol\", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03102034/Prot_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03102034'},\n",
       " {'Rank': 5766,\n",
       "  'NCT Number': 'NCT04429061',\n",
       "  'Title': 'Reaching 90 90 90 in Adolescents in Zambia: Using All Our SKILLZ',\n",
       "  'Acronym': 'SKILLZ',\n",
       "  'Status': 'Recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'HIV Infections|Pregnancy Related|STI|Mental Health Wellness 1',\n",
       "  'Interventions': 'Behavioral: SKILLZ-Girl Enhanced football curriculum',\n",
       "  'Outcome Measures': 'Number of participants undergoing HIV testing within 24 months|Number of participants accessing SRH related prevention services within 24 months|The percentage of HIV infected participants being virally suppressed at 12 months|The percentage of HIV infected participants retained in care at 3 months|The percentage of HIV infected participants retained in care at 6 months|The percentage of HIV infected participants retained in care at 12 months|Conduct a process evaluation to describe how the intervention worked|Average short-term costs for the program implementation based on net-costs for the intervention.|Fidelity monitoring or adherence to the program as measured by the number of coaching sessions conducted per plan.|Identify barriers that prevent intervention participation',\n",
       "  'Sponsor/Collaborators': 'University of Alabama at Birmingham|University of California, San Francisco|Centre for Infectious Disease Research in Zambia|Grassroot Soccer (GRS)|Washington University School of Medicine',\n",
       "  'Gender': 'Female',\n",
       "  'Age': '16 Years and older \\xa0 (Child, Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 3200.0,\n",
       "  'Funded Bys': 'Other',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care',\n",
       "  'Other IDs': 'IRB-300002251',\n",
       "  'Start Date': 'March 1, 2020',\n",
       "  'Primary Completion Date': 'March 30, 2023',\n",
       "  'Completion Date': 'June 30, 2023',\n",
       "  'First Posted': 'June 11, 2020',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'June 11, 2020',\n",
       "  'Locations': 'Centre of Infectious Disease Research Zambia, Lusaka, Zambia',\n",
       "  'Study Documents': '\"Study Protocol and Statistical Analysis Plan\", https://ClinicalTrials.gov/ProvidedDocs/61/NCT04429061/Prot_SAP_000.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT04429061'},\n",
       " {'Rank': 5771,\n",
       "  'NCT Number': 'NCT03392883',\n",
       "  'Title': 'Scaling Up Science-based Mental Health Interventions in Latin America',\n",
       "  'Acronym': 'DIADA',\n",
       "  'Status': 'Active, not recruiting',\n",
       "  'Study Results': 'No Results Available',\n",
       "  'Conditions': 'Depression|Problematic Alcohol Use',\n",
       "  'Interventions': 'Behavioral: Laddr',\n",
       "  'Outcome Measures': 'The Integrated Measure of Implementation Context and Outcomes as a Change Over Time in Low and Middle Income Countries Consumer Instrument|The Integrated Measure of Implementation Context and Outcomes as a Change Over Time in Low and Middle Income Countries Provider Instrument|The Integrated Measure of Implementation Context and Outcomes as a Change Over Time in Low and Middle Income Countries Organizational Staff Instrument|The Program Sustainability Assessment Tool (PSAT) Providers|The Program Sustainability Assessment Tool (PSAT) Administrative Staff|Patient Health Questionnaire (PHQ-8)|Alcohol Timeline Follow-back (Alcohol TLFB) (only for pilot participants)|12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS)|EuroQOL Five Dimensions Questionnaire (EQ-5D) (only for pilot participants)|General Anxiety Disorder screener (GAD-7)|EuroQol Visual Analogue Scale (EQ-VAS) (only for pilot participants)|The Quick Drinking Screen (QDS) (for full implementation study only)',\n",
       "  'Sponsor/Collaborators': 'Dartmouth-Hitchcock Medical Center|Pontificia Universidad Javeriana|National Institute of Mental Health (NIMH)',\n",
       "  'Gender': 'All',\n",
       "  'Age': '18 Years and older \\xa0 (Adult, Older Adult)',\n",
       "  'Phases': 'Not Applicable',\n",
       "  'Enrollment': 3091.0,\n",
       "  'Funded Bys': 'Other|NIH',\n",
       "  'Study Type': 'Interventional',\n",
       "  'Study Designs': 'Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research',\n",
       "  'Other IDs': '1U19MH109988 D18019|1U19MH109988',\n",
       "  'Start Date': 'February 13, 2018',\n",
       "  'Primary Completion Date': 'April 2021',\n",
       "  'Completion Date': 'April 2021',\n",
       "  'First Posted': 'January 8, 2018',\n",
       "  'Results First Posted': nan,\n",
       "  'Last Update Posted': 'December 19, 2020',\n",
       "  'Locations': 'Salud de Tundama, Duitama, Boyaca, Colombia|Empresa Social del Estado Hospital Regional de Duitama- Santa Rosa de Viterbo Branch, Santa Rosa de Viterbo, Boyaca, Colombia|ESE Hospital San Antonio de Guatavita, Guatavita, Cundinamarca, Colombia|Hospital Mario Gaitán Yanguas, Soacha, Cundinamarca, Colombia|Empresa Social del Estado Hospital Nelson Restrepo Martinez, Guayabal, Tolima, Colombia|Javesalud, Bogotá, Colombia',\n",
       "  'Study Documents': '\"Informed Consent Form: Patient Informed Consent form\", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03392883/ICF_000.pdf|\"Informed Consent Form: Staff Informed Consent form\", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03392883/ICF_001.pdf',\n",
       "  'URL': 'https://ClinicalTrials.gov/show/NCT03392883'}]"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## Convert dataframe to dictionary as a preparation to create the embedding (vectorised data). \n",
    "## The data is stored in key-value format\n",
    "df_CT_cancer.to_dict('records')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Patient ID</th>\n",
       "      <th>Sex</th>\n",
       "      <th>Age</th>\n",
       "      <th>Baseline Score on House–Brackmann scale</th>\n",
       "      <th>Time between onset of symptoms and start of treatment</th>\n",
       "      <th>Treatment Group</th>\n",
       "      <th>Received Prednisolone</th>\n",
       "      <th>Received Acyclovir</th>\n",
       "      <th>3-Month Score on House–Brackmann scale</th>\n",
       "      <th>Full Recovery in 3 Months</th>\n",
       "      <th>9-Month Score on House–Brackmann scale</th>\n",
       "      <th>Full Recovery in 9 Months</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Female</td>\n",
       "      <td>77</td>\n",
       "      <td>6</td>\n",
       "      <td>Within 24 hr</td>\n",
       "      <td>Prednisolone–Placebo</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "      <td>2</td>\n",
       "      <td>No</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Female</td>\n",
       "      <td>61</td>\n",
       "      <td>6</td>\n",
       "      <td>Within 24 hr</td>\n",
       "      <td>Prednisolone–Placebo</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>1</td>\n",
       "      <td>Yes</td>\n",
       "      <td>1</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Female</td>\n",
       "      <td>46</td>\n",
       "      <td>4</td>\n",
       "      <td>&gt;24 to ≤48 hr</td>\n",
       "      <td>Prednisolone–Placebo</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>1</td>\n",
       "      <td>Yes</td>\n",
       "      <td>1</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Female</td>\n",
       "      <td>46</td>\n",
       "      <td>3</td>\n",
       "      <td>Within 24 hr</td>\n",
       "      <td>Prednisolone–Placebo</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>1</td>\n",
       "      <td>Yes</td>\n",
       "      <td>1</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Female</td>\n",
       "      <td>42</td>\n",
       "      <td>3</td>\n",
       "      <td>&gt;24 to ≤48 hr</td>\n",
       "      <td>Prednisolone–Placebo</td>\n",
       "      <td>Yes</td>\n",
       "      <td>No</td>\n",
       "      <td>1</td>\n",
       "      <td>Yes</td>\n",
       "      <td>1</td>\n",
       "      <td>Yes</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Patient ID     Sex  Age  Baseline Score on House–Brackmann scale  \\\n",
       "0           1  Female   77                                        6   \n",
       "1           2  Female   61                                        6   \n",
       "2           3  Female   46                                        4   \n",
       "3           4  Female   46                                        3   \n",
       "4           5  Female   42                                        3   \n",
       "\n",
       "  Time between onset of symptoms and start of treatment       Treatment Group  \\\n",
       "0                                       Within 24 hr     Prednisolone–Placebo   \n",
       "1                                       Within 24 hr     Prednisolone–Placebo   \n",
       "2                                      >24 to ≤48 hr     Prednisolone–Placebo   \n",
       "3                                       Within 24 hr     Prednisolone–Placebo   \n",
       "4                                      >24 to ≤48 hr     Prednisolone–Placebo   \n",
       "\n",
       "  Received Prednisolone Received Acyclovir  \\\n",
       "0                   Yes                 No   \n",
       "1                   Yes                 No   \n",
       "2                   Yes                 No   \n",
       "3                   Yes                 No   \n",
       "4                   Yes                 No   \n",
       "\n",
       "   3-Month Score on House–Brackmann scale Full Recovery in 3 Months  \\\n",
       "0                                       2                        No   \n",
       "1                                       1                       Yes   \n",
       "2                                       1                       Yes   \n",
       "3                                       1                       Yes   \n",
       "4                                       1                       Yes   \n",
       "\n",
       "   9-Month Score on House–Brackmann scale Full Recovery in 9 Months  \n",
       "0                                       2                        No  \n",
       "1                                       1                       Yes  \n",
       "2                                       1                       Yes  \n",
       "3                                       1                       Yes  \n",
       "4                                       1                       Yes  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## load the eligibility criteria for clinical trial data set from file to dataframe for analysis\n",
    "df_PatintEC = pd.read_csv('./data/Bells_Palsy_Clinical_Trial.csv')\n",
    "df_PatintEC.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Patient ID</th>\n",
       "      <th>Age</th>\n",
       "      <th>Baseline Score on House–Brackmann scale</th>\n",
       "      <th>3-Month Score on House–Brackmann scale</th>\n",
       "      <th>9-Month Score on House–Brackmann scale</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>count</th>\n",
       "      <td>494.000000</td>\n",
       "      <td>494.000000</td>\n",
       "      <td>494.000000</td>\n",
       "      <td>494.000000</td>\n",
       "      <td>494.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>mean</th>\n",
       "      <td>247.500000</td>\n",
       "      <td>44.868421</td>\n",
       "      <td>3.680162</td>\n",
       "      <td>1.340081</td>\n",
       "      <td>1.143725</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>std</th>\n",
       "      <td>142.749781</td>\n",
       "      <td>14.550357</td>\n",
       "      <td>1.131752</td>\n",
       "      <td>0.609037</td>\n",
       "      <td>0.461050</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>min</th>\n",
       "      <td>1.000000</td>\n",
       "      <td>16.000000</td>\n",
       "      <td>2.000000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25%</th>\n",
       "      <td>124.250000</td>\n",
       "      <td>34.000000</td>\n",
       "      <td>3.000000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50%</th>\n",
       "      <td>247.500000</td>\n",
       "      <td>44.000000</td>\n",
       "      <td>4.000000</td>\n",
       "      <td>1.000000</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75%</th>\n",
       "      <td>370.750000</td>\n",
       "      <td>55.000000</td>\n",
       "      <td>4.000000</td>\n",
       "      <td>2.000000</td>\n",
       "      <td>1.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>max</th>\n",
       "      <td>494.000000</td>\n",
       "      <td>90.000000</td>\n",
       "      <td>6.000000</td>\n",
       "      <td>4.000000</td>\n",
       "      <td>4.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "       Patient ID         Age  Baseline Score on House–Brackmann scale  \\\n",
       "count  494.000000  494.000000                               494.000000   \n",
       "mean   247.500000   44.868421                                 3.680162   \n",
       "std    142.749781   14.550357                                 1.131752   \n",
       "min      1.000000   16.000000                                 2.000000   \n",
       "25%    124.250000   34.000000                                 3.000000   \n",
       "50%    247.500000   44.000000                                 4.000000   \n",
       "75%    370.750000   55.000000                                 4.000000   \n",
       "max    494.000000   90.000000                                 6.000000   \n",
       "\n",
       "       3-Month Score on House–Brackmann scale  \\\n",
       "count                              494.000000   \n",
       "mean                                 1.340081   \n",
       "std                                  0.609037   \n",
       "min                                  1.000000   \n",
       "25%                                  1.000000   \n",
       "50%                                  1.000000   \n",
       "75%                                  2.000000   \n",
       "max                                  4.000000   \n",
       "\n",
       "       9-Month Score on House–Brackmann scale  \n",
       "count                              494.000000  \n",
       "mean                                 1.143725  \n",
       "std                                  0.461050  \n",
       "min                                  1.000000  \n",
       "25%                                  1.000000  \n",
       "50%                                  1.000000  \n",
       "75%                                  1.000000  \n",
       "max                                  4.000000  "
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_PatintEC.describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'Patient ID': 1,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 77,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 2,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 61,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 3,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 4,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 5,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 6,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 7,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 8,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 28,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 9,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 10,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 11,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 12,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 18,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 13,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 30,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 14,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 15,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 16,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 32,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 17,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 18,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 19,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 20,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 21,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 32,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 22,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 23,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 32,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 24,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 61,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 25,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 63,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 26,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 64,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 27,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 28,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 68,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 29,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 30,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 31,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 32,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 33,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 34,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 68,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 35,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 24,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 36,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 37,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 69,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 38,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 69,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 39,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 68,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 40,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 39,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 41,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 42,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 43,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 44,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 45,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 46,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 23,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 47,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 19,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 48,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 61,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 49,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 27,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 50,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 72,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 51,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 52,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 18,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 53,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 67,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 54,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 55,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 66,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 56,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 62,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 57,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 32,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 58,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 59,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 61,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 60,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 70,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 61,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 20,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 62,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 63,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 64,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 65,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 66,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 67,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 76,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 68,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 69,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 86,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 70,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 67,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 71,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 31,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 72,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 27,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 73,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 74,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 75,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 76,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 70,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 77,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 78,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 79,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 80,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 24,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 81,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 82,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 28,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 83,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 30,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 84,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 85,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 86,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 24,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 87,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 88,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 89,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 90,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 25,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 91,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 92,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 93,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 30,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 94,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 95,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 96,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 97,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 98,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 99,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 72,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 100,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 63,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 101,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 59,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 102,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 103,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 104,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 105,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 106,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 107,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 108,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 109,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 110,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 111,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 112,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 113,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 26,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 114,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 31,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 115,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 116,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 117,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 118,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 61,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 119,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 120,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 26,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 121,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 122,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 123,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Prednisolone–Placebo',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 124,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 125,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 25,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 126,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 127,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 128,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 62,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 129,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 130,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 62,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 131,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 31,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 132,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 133,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 134,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 135,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 136,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 137,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 138,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 139,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 140,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 141,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 57,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 142,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 143,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 144,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 145,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 67,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 146,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 30,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 147,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 39,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 148,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 149,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 150,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 151,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 20,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 152,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 153,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 16,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 154,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 155,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 156,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 157,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 26,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 158,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 159,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 160,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 31,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 161,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 162,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 163,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 164,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 165,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 166,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 26,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 167,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 168,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 169,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 62,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 170,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 171,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 66,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 172,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 173,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 22,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 174,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 175,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 176,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 39,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 177,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 178,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 23,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 179,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 82,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 180,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 63,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 181,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 28,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 182,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 183,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 31,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 184,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 185,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 186,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 187,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 66,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 188,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 189,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 190,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 191,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 192,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 193,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 21,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 194,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 59,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 195,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 64,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 196,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 28,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 197,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 198,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 199,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 200,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 201,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 202,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 63,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 203,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 204,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 68,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 205,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 206,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 19,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 207,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 208,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 27,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 209,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 64,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 210,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 211,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 212,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 213,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 214,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 31,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 215,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 216,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 217,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 218,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 219,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 69,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 220,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 221,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 222,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 223,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 30,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 224,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 225,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 28,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 226,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 67,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 227,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 228,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 62,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 229,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 230,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 231,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 17,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 232,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 59,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 233,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 234,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 235,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 236,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 27,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 237,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 57,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 238,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 239,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 240,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 64,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 241,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 68,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 242,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 243,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 32,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 244,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 245,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 54,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 246,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 247,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 69,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 248,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 249,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 250,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 26,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Prednisolone',\n",
       "  'Received Prednisolone': 'Yes',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 251,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 22,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 252,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 63,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 253,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 18,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 254,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 19,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 255,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 256,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 27,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 257,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 258,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 25,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 259,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 260,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 261,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 262,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Unknown',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 263,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 57,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 264,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 26,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 265,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 54,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 266,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 267,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 268,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 269,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 54,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 270,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 271,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 57,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 272,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 273,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 59,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 274,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 275,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 276,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 30,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 277,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 278,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 22,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 279,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 20,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 280,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 21,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 281,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 282,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 283,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 284,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 285,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 26,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 286,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 287,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 288,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 289,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 26,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 290,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 68,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 291,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 292,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 293,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 294,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 24,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 295,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 296,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 297,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 298,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 299,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 300,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 301,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 65,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 302,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 303,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 77,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 304,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 305,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 306,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 307,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 308,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 31,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 309,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 310,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 311,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 312,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 28,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 313,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 74,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 4,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 4,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 314,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 315,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 316,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 72,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 4,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 4,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 317,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 318,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 54,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 319,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 320,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 83,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 321,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 322,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 323,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 324,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 325,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 39,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 326,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 327,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 328,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 66,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 329,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 330,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 331,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 80,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 332,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 84,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 333,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 334,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 335,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 336,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 337,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 32,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 338,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 339,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 340,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 341,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 64,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 342,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 343,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 344,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 30,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 345,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 28,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 346,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 75,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 347,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 348,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 349,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 350,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 25,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 351,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 352,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 76,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 353,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 354,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 17,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 355,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 356,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 357,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 358,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 359,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 32,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 360,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 361,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 362,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 21,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 363,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 364,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 365,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 366,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 367,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 368,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 369,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 16,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 370,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 371,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 372,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 35,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Acyclovir–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'Yes',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 373,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 59,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 374,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 375,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 65,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 376,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 377,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 378,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 379,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 380,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 381,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 25,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 382,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 383,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 384,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 385,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 386,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 387,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 83,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 388,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 389,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 390,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 391,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 19,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 392,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 24,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 393,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 20,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 394,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 395,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 27,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 396,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 397,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 54,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 398,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 399,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 54,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 400,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 19,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 401,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 402,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 403,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 73,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 404,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 405,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 406,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 407,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 408,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 409,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 58,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 410,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 20,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 411,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 412,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 16,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 413,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 414,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 415,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 70,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 416,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 417,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 418,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 79,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 419,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 30,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 420,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 421,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 422,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>48 to ≤72 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 423,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 424,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 47,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 425,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 27,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 426,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 427,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 428,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 49,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 429,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 31,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 430,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 431,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 432,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 433,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 25,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 434,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 435,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 71,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 436,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 437,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 73,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 438,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 23,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 439,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 66,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 440,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 66,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 441,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 442,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 68,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 443,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 28,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 444,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 46,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 445,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 89,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 446,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 447,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 448,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 449,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 52,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 450,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 65,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 451,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 452,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 453,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 43,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 454,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 455,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 456,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 51,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 457,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 48,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 458,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 38,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 459,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 55,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 460,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 461,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 39,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 462,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 63,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 463,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 36,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 464,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 54,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 465,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 25,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 466,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 42,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 467,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 62,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 3,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 468,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 469,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 61,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 470,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 90,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 471,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 472,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 44,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 473,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 474,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 50,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 475,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 41,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 476,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 32,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 477,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 24,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 478,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 54,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 479,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 22,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 480,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 20,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 481,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 29,\n",
       "  'Baseline Score on House–Brackmann scale': 2,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 482,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 45,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 483,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 484,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 77,\n",
       "  'Baseline Score on House–Brackmann scale': 6,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 4,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 4,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 485,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 486,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 53,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 487,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 60,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 488,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 489,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 490,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 40,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 2,\n",
       "  'Full Recovery in 9 Months': 'No'},\n",
       " {'Patient ID': 491,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 37,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 492,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 56,\n",
       "  'Baseline Score on House–Brackmann scale': 3,\n",
       "  'Time between onset of symptoms and start of treatment': '>24 to ≤48 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 493,\n",
       "  'Sex': 'Male',\n",
       "  'Age': 33,\n",
       "  'Baseline Score on House–Brackmann scale': 4,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 3 Months': 'Yes',\n",
       "  '9-Month Score on House–Brackmann scale': 1,\n",
       "  'Full Recovery in 9 Months': 'Yes'},\n",
       " {'Patient ID': 494,\n",
       "  'Sex': 'Female',\n",
       "  'Age': 34,\n",
       "  'Baseline Score on House–Brackmann scale': 5,\n",
       "  'Time between onset of symptoms and start of treatment': 'Within 24 hr',\n",
       "  'Treatment Group': 'Placebo–Placebo',\n",
       "  'Received Prednisolone': 'No',\n",
       "  'Received Acyclovir': 'No',\n",
       "  '3-Month Score on House–Brackmann scale': 4,\n",
       "  'Full Recovery in 3 Months': 'No',\n",
       "  '9-Month Score on House–Brackmann scale': 4,\n",
       "  'Full Recovery in 9 Months': 'No'}]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## Convert dataframe to dictionary as a preparation to create the embedding (vectorised data). \n",
    "## The data is stored in key-value format\n",
    "df_PatintEC.to_dict('records')"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
